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Abstract 
The adrenocorticotropic hormone (ACTH) receptor, also known as the 
melanocortin 2 receptor (MC2R) is primarily expressed in the adrenal gland and binds 
to ACTH to activate a signalling cascade that leads to steroidogenesis.  The 
characterisation of the melanocortin 2 receptor has previously been hindered by the 
failure of cell surface expression in heterologous cells.  Unlike other melanocortin 
receptors, MC2R surface expression requires an accessory protein called 
melanocortin 2 receptor accessory protein (MRAP).  MRAP has been shown to 
facilitate trafficking of MC2R from the endoplasmic reticulum to the plasma membrane 
and it also has a role in MC2R signalling. 
Naturally occurring MC2R mutations occur in Familial Glucocorticoid 
Deficiency (FGD) type 1.  The functional defect remains uncertain for the majority, 
mainly due to the difficulties in characterisation which has been limited in Y6 cells 
(mouse derived adrenal cells which are free of MCRs) because of poor transfection 
efficiency.  The first two results chapter of this thesis focus on the molecular biology of 
FGD mutations and the genotype-phenotype relationship of the disease.  The 
functional defects of these mutations have been analysed in transfectable 
heterologuous cells stably expressing MRAP.  The majority of the missense mutations 
are trafficking-defective, and yet all appear to interact with MRAP, but some mutations 
are trafficking-competent and fail to signal.   
Clinical details including the age of presentation; presenting plasma ACTH and 
cortisol; height and weight were examined in FGD type 1 and 2 (mutation of MC2R or 
MRAP respectively) to determine whether there is a genotype-phenotype correlation.  
Within FGD type 1, there was no clear clinical distinction between the functional 
defects in vitro and in vivo data.  However, there were phenotypic differences between 
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FGD type 1 and 2, with FGD 2 appearing to be more severe with a younger age and a 
lower height SDS at presentation.     
The final part of this thesis focuses on MC2R dimerisation and signalling of the 
receptor. Co-immunoprecipitation studies showed that MC2R homodimerisation is 
constitutive.  This interaction was not enhanced in the presence of MRAP or ACTH.  
No effect on signalling was observed.  When a signalling mutant (R128C) and a ligand 
binding mutant (D103N) were co-transfected with MRAP and stimulated with ACTH, 
signalling was not restored, suggesting no cross talk between the two receptors.   
In the final discussion the implication of these findings are considered with 
respect to their relevance to disease and novel therapeutic strategies.   
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1.1 The Adrenal Gland 
 The adrenal gland is an important endocrine organ which produces hormones 
including glucocorticoids, mineralocorticoids, sex steroids and catecholamines which 
are essential to life.  The physiological increase in production of glucocorticoid is vital 
during stress and acute illness which is under the regulation of the hypothalamic-
pituitary-adrenal axis (HPA).  
1.1.1 The Adrenal morphology 
The human adrenal cortex consists of three concentric zones which are 
morphologically and functionally distinct.  The outermost is the zona glomerulosa 
which produces aldosterone, followed by the zona fasciculata which produces 
glucocorticoid (cortisol in humans and primates and corticosterone in rodents) and 
then the zona reticularis which produces adrenal androgens.  ACTH is the principal 
regulator of cortisol production by the zona fasciculata, but it has secondary 
importance in aldosterone and adrenal androgen production.  
1.1.2 The adrenal steroidogenic pathway  
The common rate limiting step in steroid biosynthesis is the uptake of 
cholesterol from cellular stores to the inner membrane of the mitochondrial matrix; this 
is regulated by StAR (steroidogenic acute regulatory) protein.  Once inside the 
mitochondria, the cholesterol side chain is cleaved to form pregnenolone by 
cholesterol desmolase (CYP11A1, P450scc).  Pregnenolone is the common precursor 
for all other steroids and is metabolised to mineralcorticoids, glucocorticoids or sex 
hormones by several other enzymes (see Figure 1.1).   
Chapter 1- Introduction 
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Dihydrotestosterone
Testosterone
Androstenedione
DHEA
Cortisone
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Aromatase (CYP19)
StAR,
Cholesterol 
Desmolase
(CYP11A1)
Pathways of steroid biosynthesis
 
Figure 1.1: The steroidogenic pathway for the synthesis of mineralocorticoids 
(aldosterone), glucocorticoids (cortisol) and sex hormones (testosterone, 
dihydrotesterone and oestrogens).  The enzymatic activities catalysing each 
bioconversion are highlighted in colours.  Figure adapted from Endotext (Nimkarn & 
New 2008).   
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1.2 Hypothalmic-Pituitary-Adrenal (HPA) axis 
Adrenocorticotrophic hormone (ACTH) is released by corticotroph cells in the 
anterior pituitary where it is cleaved from the larger peptide pro-opiomelanocortin 
(POMC).  ACTH release is stimulated by corticotrophin-releasing hormone (CRH) 
secreted by the hypothalamus.  CRH acts on specific pituitary receptors and exerts 
trophic and releasing actions on corticotroph cells.  The circadian release of ACTH will 
stimulate the production of cortisol in the adrenal gland, which is regulated by a 
negative feedback action at the pituitary.  Production of other adrenal cortex 
hormones (such as androgens) does not exert this regulatory feedback.  Figure 1.2 
illustrates the regulation of the hypothalamic-pituitary-adrenal axis. 
ACTH 
External stimuli and stress
Pituitary
Cortisol
Mineralcorticoids
Androgens
Endogenous rhythms
Hypothalmus
Adrenal
 
Figure 1.2: General scheme of regulation of the pituitary-adrenal axis.  CRH, 
corticotrophin-releasing hormone; ACTH, adrenocorticotrophic hormone. 
Chapter 1- Introduction 
      
21 
 
1.2.1 Pro-opiomelanocortin 
Pro-opiomelanocortin (POMC) is a polypeptide precursor that undergoes 
extensive, tissue specific post-translation modification to generate a range of smaller, 
biologically active peptides (Bertagna 1994).  These include ACTH and the  α-, β-, and 
γ-melanocyte-stimulating hormone, collectively known as melanocortins.  The POMC 
gene is primarily expressed in the pituitary gland, but has also been detected in 
numerous non-pituitary tissues, including hypothalamus, testes, ovary, placenta, 
duodenum, liver, kidney, lung, thymus and lymphocytes (Smith & Funder 1988).   
Both ACTH and α-melanocyte-stimulating hormone (α-MSH) were first purified 
and sequenced from the pituitaries of other species.  The two peptides shared the first 
13 amino acids, but the importance of this was not realised until the isolation of 
corticotrophin-like intermediate peptide (CLIP) (Scott et al. 1974), the peptide that 
comprises the C-terminal of ACTH.  With the identification of the high molecular 
weight forms of immunoreactive ACTH (Orth et al. 1973; Mains & Eipper 1976) it was 
then realised that  ACTH and α-MSH were derived from the same molecule.   
The existence of a common precursor to a number of pituitary hormones was 
uncovered with the discovery of another pituitary peptide, β-endorphin which shares 
the same sequence as the C-terminal of β-lipotrophin (β-LPH) (Chretien et al. 1976; 
Bradbury et al. 1976).  This is yet another pituitary hormone released under the same 
conditions as ACTH.  It was later recognised that ACTH and endorphin were derived 
from the same protein (Eipper & Mains 1978).  The true structural relationship 
between ACTH and endorphin was revealed when the cDNA encoding POMC was 
subsequently cloned from both bovine intermediate lobe (Nakanishi et al. 1979) and 
from the mouse pituitary cell line AtT-20 (Roberts et al. 1979).   
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1.2.2 Structure of the POMC gene 
The structure of the POMC gene has been characterised in humans 
(Takahashi et al. 1981; Cochet et al. 1982b) and other species and is well conserved.  
It is located on the short arm of chromosome 2 at 2p23.3 and spans over 8kb.  The 
POMC gene consists of three exons separated by two large introns (Takahashi et al. 
1981; Cochet et al. 1982a).  As illustrated in Figure 1.3, the first exon contains no 
coding sequence and the second exon codes for the N-terminal part of the coding 
sequence for the POMC peptide.  The third exon encodes most of the mature protein.   
Signal peptide
γ-MSH α-MSH CLIP              γ-LPH         β-Endorphin
Arg -Lys Arg -Arg Lys-Arg Lys-Arg Lys-Lys  Lys-Arg Lys-Lys
N-terminal fragment         ACTH(1-39) β-LPH
(1-13 )       (18-39)  
Exon 1 Exon 2 Exon 3
_____ ______ ______Intron 1 Intron 2
 
Figure 1.3.: Structure of the POMC gene and protein.  The locations of the various 
peptides together with the dibasic amino acid residue cleavage sites are shown.  
Adapted from Journal of Neuroendocrinology (Bicknell 2008).  MSH, melanocyte-
stimulating hormone; CLIP, corticotrophin-like intermediate lobe peptide; LPH, 
lipotropin.   
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1.2.3 POMC derived peptides 
The discovery of the structure and biosynthesis of POMC led to the understanding 
that a number of bioactive peptides were derived from this large precursor molecule 
(Eipper & Mains 1980).  POMC can be cleaved enzymatically into the following 
peptides: 
1. Adrenocorticotropic hormone (ACTH) and β-lipotrophin (β-LPH) in the anterior 
pituitary 
2. Corticotrophin-like intermediate lobe peptide (CLIP), γ- lipotrophin (γ-LPH),α-
melanocortin stimulating hormone (α-MSH) and β –endorphin in the 
intermediate lobe 
3. γ-melanocortin stimulating hormone (γ – MSH) 
POMC is expressed in both the anterior and intermediate lobes of the pituitary (the 
intermediate lobe is absent in the human).  In the anterior lobe, POMC is produced in 
corticotrophs (approximately 1% of the total protein) and in the intermediate lobe, it is 
produced in melanotrophs. (Bicknell 2008).  In rodent pituitaries, the exclusive 
presence of prohormone convertase, PC2 in the melanotrophs of the intermediate 
lobe (not present in humans) is responsible for the specific conversion of ACTH to α-
MSH and CLIP.  This is in contrast with corticotrophs of the anterior lobe, which do not 
contain PC2, and will therefore only produce ACTH (Vieau et al. 1994).   
As already described, prohormone convertase enzymes PC1 and PC2 process 
POMC directly at sites of dibasic residues (Lys-Lys or Lys-Arg) (Benjannet et al. 
1991).  This process generates ACTH, the N-pro-opiomelanocortin, joining peptide, 
and beta-lipotropin.  ACTH can be further processed to generate α-MSH and CLIP, 
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whereas β-LPH can be processed to generate γ-LPH and β-endorphin (Benjannet et 
al. 1991).  Figure 1.4 illustrates the cleavage of  POMC related peptides.   
Pro-opiomelanocortin (POMC)
Pro-ACTH β-lipotropin (LPH)
N-POC JP ACTH
γ3-MSH α-MSH CLIP
γ-LPH γ-EP
PC 1
PC 2
 
Figure 1.4: Processing of pro-opiomelanocortin and its derivatives.  The cleavage of 
POMC into smaller fragments by prohormone convertases PC 1 and 2.  N-POC, N-
proopiomelanocortin; JP, joining peptide; EP, endorphin; CLIP, corticotrophin-like 
intermediate peptide.  Adapted from JBC (Zhou et al. 1993).   
 
1.2.3.1  Adrenocorticotropic hormone 
The adrenocorticotropic hormone, ACTH, is released from corticotrophs in the 
anterior pituitary.  In the human pituitary POMC is enzymatically processed to pro-
ACTH, which is then cleaved to give ACTH.  This process is accomplished by PC1 
located within the mature dense core granules (Benjannet et al. 1991).   
ACTH is a 39 amino acid (aa) peptide, which has a molecular weight of 4.5kDa 
and is highly specific for the melanocortin 2 receptor (MC2R) in the adrenal gland.  
The N terminal 12 amino acids are highly conserved between species, thus reflecting 
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the importance of this region for biological activity.  ACTH is part of the melanocortin 
family of peptides because it contains the melanotropic His-Phe-Arg-Trp structural 
component at position 6-9.   
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-
Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe 
Figure 1.5: ACTH sequence in three letter code.   
 
ACTH SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF 
α- MSH SYSMEHFRWGKPV 
β-MSH AEKKDEGPYRMEHFRWGSPPKD 
γ-MSH YVMGHFRWDRFG 
  
Table 1.1: Summary of single letter peptide sequences of ACTH and other MSHs.   
 
The amino acid sequence of ACTH is 39 residues long with a serine at the 
amino-terminal and phenylalanine at the carboxyl terminal in all mammalian species 
studied.  The sequences of the NH2–terminal [1-24] and the COOH-terminal [34-39] 
are identical, whereas some differences are observed between position 25 and 34, 
suggesting that the first 24 aa contain the biologically important part of the molecule.   
This has been confirmed by the observation that the synthetic 
nonadecapeptide corresponding to the first 19 residues of ACTH exhibited all the 
biological activity of ACTH (Ramachandran & Choh 1967).  Further studies suggest 
that residues 15-18 containing the positive charge Lys-Lys-Arg-Arg (Figure 1.5) could 
play an important role in the binding of the hormone to its receptor, whereas the NH2 –
terminal, in particular residue 4-10, forms the “active core” of the molecule for 
steriodogenesis (Ramachandran 1973).   
1.2.3.2  α – Melanocyte stimulating hormone  
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α –MSH consists of ACTH 1-13 and is derived from ACTH (sequence shown 
in table 1.1).  ACTH is cleaved with PC2 in the melanotroph cells in the intermediate 
lobe of the pituitary in species such as rat and mouse.  The N-terminal serine residue 
of α-MSH is N-acetylated in many species and undergoes amidation at the C-terminal 
valine.  The adult human pituitary does not have this distinct intermediate lobe and 
therefore this is not a source of α-MSH in humans.  However, α-MSH produced in the 
skin or hypothalamus may access the circulation, but it is not clear if α-MSH is in the 
circulation normally (Kortlandt et al. 1986; Croughs et al. 1991).   
1.2.3.3  γ – Melanocyte stimulating hormone 
 γ-MSH is a proteolytic cleavage product of the N-terminal fragment of POMC, 
which has a much more limited spectrum of biological activities than does ACTH or α 
–MSH.  It selectively stimulates MC3R, being approx 100X more potent at MC3R than 
the MC4R.  
1.2.3.4  Other derivative peptides 
Corticotropin-like Intermediate Lobe Peptide (CLIP) is produced as the residue 
after the cleavage of α-MSH.  CLIP, which is cleaved from ACTH 18-39 not thought to 
circulate in humans and does not have a bioactive role.   
β–lipotropin lies at the C-terminus of POMC and is cleaved into γ-lipotropin 
and β-endorphin.  In the human anterior pituitary, the cleavage is limited.  In the 
circulation there is much more β-lipotropin than β-endorphin, which is present at very 
low levels (Stewart et al. 1994).   
β–endorphin is a 31 amino acid peptide containing the sequence for 
metencephalin as the first 5 amino acids at its N terminus.  It has been demonstrated 
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to play a role in certain behavioural patterns, in obesity, diabetes and psychiatric 
diseases (Dalayeun et al. 1993).   
 
1.2.4 ACTH action 
Circulating ACTH binds with high affinity receptors located on the surface of 
adrenocortical cells.  ACTH binds to the melanocortin-2 receptor (MC2R) in the 
adrenal gland (Catalano et al. 1986; Clark 2000).  This results in an increase in 
intracellular cAMP levels (Haynes 1958), which in turn activates the steroidogenic 
pathway (see section 1.1.2).  Activation of the MC2R by ACTH leads to uptake of 
cholesterol into the cell, activation of the enzymes which mediate conversion of 
cholesterol esters to free cholesterol and the translocation of cholesterol into 
mitochondria.  Furthermore, ACTH also upregulates the expression of mitochondrial 
enzymes converting cholesterol to corticosterone (Ney et al. 1967; Garren et al. 1971; 
Gill 1972; Mukai et al. 1998).   
There are several key genes known to be regulated by ACTH stimulation of 
cAMP in the adrenal (listed in table 1.2).  These target genes include steroidogenic 
acute regulatory (StAR) protein, which is involved in mitochondrial cholesterol import, 
steroidogenic enzymes involved in conversion of cholesterol into steroid, and the 
MC2R gene itself.  The steroidogenic pathway has already been illustrated in Figure 
1.1.   
Gene name Alternative or common name 
CYP11A1 P450 side chain cleavage enzyme 
CYP17 17α- Hydroxylase 
CYP21 21 Hydroxylase 
CYP11B1 11β-Hydroxylase 
CYP11B2 Aldosterone synthase 
MC2R ACTH receptor 
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StAR   
c-FOS  
c-JUN  
JUN-B  
c-MYC   
  
Table1.2: Key genes regulated by ACTH stimulation of cAMP in the adrenal gland. (Clark 
2000) 
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1.3 Primary adrenal insufficiency 
It has now been more than 150 years since Thomas Addison first described 
the clinical features of adrenal failure (Addison T 1868).  It is well known that this 
clinical syndrome could be caused by a diversity of diseases, which have in common 
the impaired secretion of glucocorticoids, mineralocorticoids and androgens.  The 
principal symptoms are fatigue, reduced appetite, weight loss and many patients 
experience salt craving and dizziness.  The most obvious clinical sign is 
hyperpigmentation owing to the high level of circulating ACTH.   
The presentation of disease varies significantly between individuals.  Many 
patients have symptoms for many years prior to diagnosis and others develop adrenal 
crisis more acutely.  Untreated disease could be fatal, and correctly managed patients 
have been reported to live near-normal lives (Mason et al. 1968).  However, a 
retrospective population-based study performed in Sweden over 14 years, had shown 
that the relative risk of death is more than 2-fold greater in patients with adrenal 
insufficiency (Bergthorsdottir et al. 2006).  The higher rate of death was attributed to 
cardiovascular, malignant and infectious diseases.  
Biochemical features include electrolyte disturbances (hyponatraemia and 
hyperkalaemia), serum cortisol is typically below the reference range, and ACTH is 
grossly elevated (Arlt & Allolio 2003).  Low serum aldosterone levels and elevated 
renin activity and low dehydroepiandrosterone sulphate levels usually accompany the 
diagnosis.   
The various aetiologies of primary adrenal insufficiency can be categorised 
into adrenal dysgenesis/ hypoplasia, adrenal destruction and impaired 
steroidogenesis (Ten et al. 2001).       Adrenal dysgenesis due to MC2R mutations is 
the focus of this thesis.                
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1.3.1 Familial Glucocorticoid Deficiency 
Familial glucocorticoid deficiency (FGD), also known as hereditary 
unresponsiveness to ACTH was first recognised half a century ago (Shepard et al. 
1959).  Inactivating MC2R mutations in Familial Glucocorticoid Deficiency (FGD) were 
first described over 15 years ago  (Clark et al. 1993; Tsigos et al. 1993).  This is a rare 
autosomal recessive disease which is characterised by isolated glucocorticoid 
deficiency and ACTH resistance (OMIM 202200).  Inactivating mutations of the G-
protein coupled receptor, MC2R are found in 25% of FGD kindred, known as FGD 
type 1  (Clark et al. 1993; Tsigos et al. 1993; Weber et al. 1995; Clark et al. 2005).  
FGD type 2 is due to mutations of the MRAP gene and accounts for 20% cases and 
FGD type 3 is due to STAR mutation which accounts for 5% (Metherell et al. 2009).  
The cause of the remaining ~50% of cases is yet to be found.  
In general, many cases present in the neonatal period, when persistent or 
severe hypoglycaemia prompts further investigation.  If diagnosis is not recognised at 
an early age, patients usually present over the next few years with failure to thrive, 
collapse, recurrent infective and hypoglycaemic episodes with skin pigmentation and 
even coma.  Long term neurological sequelae of FGD could vary from learning 
difficulties to spastic quadriplegia, which are likely to be due to the numerous 
episodes of severe hypoglycaemic attacks during childhood (Modan-Moses et al. 
2006).  The adrenal pathology of affected individuals reveals the absence of 
fasciculata or reticularis cells together with disorganisation of glomerulosa cells 
(Shepard et al. 1959; Migeon et al. 1968; Kelch et al. 1972; Clark et al. 2005).   
The diagnosis is confirmed with a low plasma cortisol in the presence of 
elevated ACTH (above 1000pg/ml [normal range <80pg/ml]) (Clark & Weber 1998).  
One distinguishing feature which separates this disease from other forms of primary 
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adrenal deficiency, is the preservation of the renin-angiotensin-aldosterone system 
(RAS), and these patients have normal electrolytes.  It has been recognised that 
minor transient impairment of the RAS is seen in some patients at the time of 
presentation.  This may reflect volume depletion at this time and therefore 
reassessment of the renin and aldosterone levels after stabilization may be valuable.  
A recent report suggested that a partial mineralocorticoid deficient state exists in 
those patients with a more “severe genotype” (Lin et al. 2007).  The physiological 
explanation of this observation is unclear.  In contrast, subsequent study of FGD 
patients with homozygous nonsense and frameshift mutations predicting a 
significantly truncated protein hence severely disrupting MC2R function, did not have 
mineralocorticoid deficiency (Chan et al. 2009b). 
 
1.3.2 Familial Glucocorticoid Deficiency Type 1 
Since the cloning of the MC2R in 1992 by Mountjoy, numerous homozygous or 
compound heterozygous mutations of MC2R have been identified worldwide (Clark et 
al. 2005).  Interestingly, the majority of these were missense mutations, and nonsense 
mutations were usually compounded with a missense mutation on the opposing allele.  
Homozygous nonsense and frameshift mutations are extremely rare (Chan et al. 
2009b).  The expected outcome would be a significantly truncated protein severely 
disrupting the function of MC2R (Tsigos et al. 1995), which could lead to the 
possibility of reduced survival in utero, or that it could present as a very different 
phenotype (Clark et al. 2009).   
In FGD type 1, mutations of the MC2R are widespread and scattered throughout the 
coding region of the gene (Figure 1.6).  
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Figure 1.6: Schematic diagram of the MC2R showing the positions of all known 
mutations found in FGD type 1.  Adapted from Trends in Endocrinology and Metabolism 
(Clark et al. 2005).   
 
1.3.3 Familial Glucocorticoid deficiency type 2 
Originally, the many patients who did not have mutations within the coding 
exon of the MC2R gene were classified as having FGD type 2.  Genetic studies using 
homozygosity mapping revealed a potential locus for FGD on chromosome 21, and 
this was subsequently identified as the MRAP gene (this is discussed in section 1.7).   
Several mutations in MRAP have been described in FGD type 2.  These 
mutations appear to cluster around the first coding exon (exon 3), particularly at the 
splice donor site.  The same mutations occur in unrelated families, suggesting that 
this is a common region for mutation.   
Mutations in the ACTH receptor (MC2R) associated with Familial Glucocorticoid Deficiency Type 1
(Green boxes – nonsense mutations; Red boxes – missense mutations; Blue boxes – probable functionally neutral polymorphisms)
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The majority of MRAP mutations are homozygous nonsense mutations, which 
probably result in the complete absence of the truncated protein, in contrast with 
MC2R mutations.  To date, only two full length missense MRAP mutations have been 
identified, V26A and Y59D.  Functional analysis demonstrates impairment of MC2R 
function with late age of onset of disease (Hughes et al. 2009).   
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1.4 G-protein coupled receptors (GPCRs) 
The clinical focus of the thesis is the defective function of MC2R in FGD type1.  
MC2R belongs to a family of seven transmembrane domains G-protein-coupled 
receptor and is the smallest member of the melanocortin family subgroup.    
 
1.4.1 General features of GPCRs 
GPCRs also known as seven transmembrane domain receptors, are the 
largest group of integral membrane proteins.  These proteins function to act as a link 
between extracellular signals and intracellular processes.  There are over 890 GPCRs 
in the human genome of which approximately 450 are predicted to be receptors for a 
vast range of endogenous ligands (Devi 2001; Takeda et al. 2002) including biogenic 
amines, peptides, glycoproteins, lipids, nucleotides, ions and proteases.  GPCRs have 
been named based on their ability to recruit and regulate the activity of intracellular 
heterotrimeric G proteins.   
Important studies over the last decade have led to the resolution of four GPCR 
structures.  The first structure to be crystallized was the rhodopsin receptor in 2000 
(Palczewski et al. 2000), it was not until eight years later that the model for opsin (the 
ligand-free form of GPCR rhodopsin) was achieved (Park et al. 2008; Scheerer et al. 
2008).  In 2007 the first structure of a ligand-activated GPCR, β2–adrenergic receptor, 
was crystallised (Cherezov et al. 2007).  This was closely followed by the β1 
adrenergic receptor (Rasmussen et al. 2007)  and the adenosine receptor (Warne et 
al. 2008) the following year.   
GPCRs do not share any overall sequence homology (Probst et al. 1992; 
Kolakowski, Jr. 1994).  The presence of seven transmembrane-spanning α-helical 
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segments (Figure 1.7) connected by alternating intracellular and extracellular loops, 
with the amino terminus located on the extracellular side and the carboxyl terminus on 
the intracellular side is the only common structural feature in all GPCRs.  These 
helices are thought to be organised sequentially in an anti-clockwise fashion 
traversing the phospholipid bilayer 7 times.   
1
2 3
4
5
6
7
A
 
5
N
C
B
 
Figure 1.7: Schematic structure of a seven helical GPCR.  A: Aerial view of the GPCR 
with the helices transversing the lipid membrane in an anti-clockwise manner.  B: 
Showing the transmembrane domains connected by intra- and extracellular loops.   
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1.4.2 GPCR classification 
There are three major subfamilies where significant sequence homology is 
found (Gether 2000).  These include the receptor related to the rhodopsin and the β2 
adrenergic receptor (family A), the receptors related to the glucagon receptor (family 
B), and the receptors related to the metabotropic neurotransmitter receptors (family 
C).  The yeast pheromone receptors make up two minor unrelated subfamilies, family 
D (STE2 receptors) and family E (STE3 receptors).  Table 1.3 summaries the three 
major subfamilies.   
The subfamily of rhodopsin/ β2 adrenergic receptor-like receptor (family A) is 
by far the largest and the most studied.  Melanocortin receptors and MC2R, which are 
the main focus of this thesis belong in this group.  Family A is phylogenetically 
subdivided further into six major subgroups.  The overall homology among all type A 
receptors is low, and the only residue that is conserved among all family A receptors 
is the arginine in the Asp-Arg-Tyr (DRY) motif at the cytoplasmic side of 
transmembrane domain (TM3) (Bourne et al. 1991; Kolakowski, Jr. 1994; Gether 
2000).   
Family A: Rhodopsin / β2 adrenergic receptor-like 
Biogenic amine receptors (adrenergic, serotonin, dopamine, muscarinic, histamine) 
 
CCK, endothelin, tachykinin, neuropeptide Y, TRH, neurotensin, bombesin and growth 
hormone secretagogues receptors 
 
Adenosine, cannabinoid, melanocortin and olfactory receptors 
 
Chemokine, FSH, LH, TSH, opioid, oxytocin, vasopressin, plus others 
 
Melatonin receptors and other non-classified 
 
Invertebrate opsins and bradykinin receptors 
 
Family B: Glucagon, vasoactive intestinal polypeptide (VIP) receptors, calcitonin-like 
receptors 
Calcitonin, CGRP, CRF receptors 
 
PTH and PTHrP receptors 
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Glucagon, glucagon-like peptide, GiP, GHRH, PACAP, VIP and secretin receptors 
 
Family C: Metabotropic neurotransmitter/ calcium receptors 
Metabotropic glutamate receptors 
 
Metabotropic GABA receptors 
 
Calcium receptors 
 
Vomeronasal pheromone receptors 
 
Taste receptors 
 
Table 1.3: Table of the three major subfamilies division in GPCR and some of the major 
subgroups.  Adapted from Endocrine Reviews  (Gether 2000). 
 
1.4.3 The GPCR signalling pathway 
1.4.3.1  Heterotrimeric G proteins  
Transmembrane GPCRs activate G-proteins, guanine-nucleotide exchange 
factors, on the inner surface of the cell membrane and continue the signal 
transduction initiated by exogenous stimuli (Kolakowski, Jr. 1994; Hoon et al. 1999).  
The G-proteins are heterotrimeric and are composed of three subunits, namely the α-, 
β and γ subunits.  The activated receptor induces a conformational change in the 
associated G protein α-subunit leading to the release of GDP (guanosine 
diphosphate) followed by binding of GTP (guanosine triphosphate) (Bourne et al. 
1991).  In the inactive state, the α-subunit of the G-protein is bound to GDP. The 
complex formation between the active receptor state and the G protein is followed by 
the release of GDP from α-subunit of the G protein, subsequently, allowing for a GTP 
molecule to bind.  This allows the α- and βγ-subunits to dissociate which then results 
in the activated form of G protein (Figure 1.8).  The active GTP-bound α-subunit is 
sometimes referred to as Gα(GTP)  and the βγ-subunit as Gβγ.  These mobile subunits 
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influence cell functions and the consequent production of second messangers (eg. 
cAMP or inositol-1,4,5-triphospate [IP3 ] or to alter ion channel functions) (Hamm 
1998; Wieland & Chen 1999).  Within moments, the GTP on Gα(GTP)  is hydrolysed to 
GDP by GTPase on the Gα and this allows for the α- and βγ-subunits to re-unite to 
form inactive G-protein complexes again.   
There are a number of different Gα genes, the four main subfamilies of Gα-
protein, shown in Table 1.4 (Sierra et al. 2000), GPCRs appear to show selectivity for 
coupling  to these respective G-protein families.   
Subclass Functions
Gs activate adenylyl cyclase, regulate Ca 2+ channels
Gi inhibit adenylyl cyclase, regulate K+ and Ca 2+ channels, 
activate cGMP phosphodiesterase
Gq activate phopholipase C
G12 regulate small GTP binding proteins  
Table 1.4: Four main subclasses of α-subunits.   
 
Numerous GPCRs signal via activation of α-subunit (Gs) which activates the 
effector molecule adenylyl cylase and subsequent signalling processes as seen in 
figure 1.8.  Melanocortin 2 receptor is one of these GPCRs which signals via adenylyl 
cyclase.   
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↑ cAMP ↓ cAMP ↑ Ca 2+
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Figure 1.8: Diagram of GPCRs interaction with heterotrimeric G proteins.  The activation 
of the receptor triggers a conformational change in the receptor, which then catalyses 
the dissociation of the G proteins and activates several downstream effectors.  Adapted 
from Nature Reviews (Dorsam & Gutkind 2007).   
 
1.4.3.2  Adenylyl Cyclases 
Adenylyl cyclase (AC) is the effector enzyme responsible for converting 
adenosine triphosphate (ATP) to adenosine 3, 5-monophosphate (cAMP).  It is a 
ubiquitous second messenger that mediates various cellular responses by activation 
of cAMP-dependent protein kinase (Tesmer et al. 2002).  There are nine isoforms of 
adenylyl cylcase which have been identified (ACI to ACIX).  They all share several 
Chapter 1- Introduction 
      
40 
 
features including activation by the α-subunit of the heterotrimeric G protein Gs, 
activation by the diterpene forskolin and inhibition by a class of adenosine analogues 
known as P-site inhibitors (Tesmer et al. 2002).  This is process is illustrated in Figure 
1.9.   
 
1.4.3.3  Adenosine 3, 5-monophosphate (cAMP) 
cAMP is recognised as a versatile regulatory agent that acts to control the rate 
of a number cellular processes (Robison & Sutherland 1970).  It is used as a second 
messenger widely throughout the animal kingdom, and has a principal role in 
mediating the effects of a great variety of hormones (Robison et al. 1968; Butcher et 
al. 1968).   
As mentioned before, the formation of cAMP from ATP is catalyzed by 
adenylyl cyclase.  cAMP is one of the most important second messengers involved as 
a modulator of physiological processes (Rall & Sutherland 1958; Sutherland & 
Robison 1966), and is involved in regulating the neuronal, endocrine, cardiovascular 
systems along with other functions and actions.   
The level of cAMP in cells is influenced by the relative specific 
phosphodiesterase, which catalyzes the hydrolysis of cAMP to 5’-AMP (Butcher & 
Sutherland 1962).  Cyclic nucleotide phosphodiesterases (PDEs) function in 
conjunction with adenylyl cyclases to regulate the amplitude and duration of cell 
signalling mediated via cAMP.  Therefore, PDEs serve to regulate a range of 
biological responses to the first messengers such as light, hormones or 
neurotransmitters, making this step a potential therapeutic target.   
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1.4.3.4  cAMP-dependent protein kinase 
cAMP-dependent protein kinase (PKA), a serine/threonine kinase, is the 
mediator of cAMP signalling in mammals (Scott 1991).  Activation of a GPCR and 
subsequently an adenylate cyclase as described in section 1.4.3.2, leads to the 
production of cAMP.  The cAMP-dependent kinase is activated by binding of cAMP.  
The PKA holoenzyme is composed of the genetically distinct catalytic (C) and the 
regulatory (R) subunits, which bind cAMP (Figure 1.9).  These form the tetrameric 
holoenzyme R2C2 that dissociates in the presence of cAMP into R2(cAMP)4 dimer 
and two free catalytically active C subunits (McKnight et al. 1988).  These catalytic 
subunits, released after conformational changes in the regulatory subunit following 
cAMP binding, will then phosphorylate cytoplasmic and nuclear target proteins.  
Cross-talk with other intracellular signalling pathways such as the MAPK (mitogen-
activated protein kinase) pathway has been shown (Naor et al. 2000).  In the nucleus, 
PKA catalytic subunits phosphorylate the cAMP-responsive element-binding protein 
(CREB), resulting in activation of transcription of cAMP-responsive element (CRE)-
containing genes (Schenk & Snaar-Jagalska 1999).   
Chapter 1- Introduction 
      
42 
 
R R
R R
CC C C
PKA inactive PKA active
cAMP
cAMP
cAMP
cAMP
cAMP
MAPK
crosstalk
AC AC Plasma membrane
ATP cAMP
Gs
Phosphorylation of CREB which 
binds to CRE to regulate gene 
transcription
PDE
Intracellular
 
Figure 1.9: Cartoon summarising the activation of cAMP and protein kinases.  cAMP 
activates protein kinase A (PKA).  The catalytic subunit of PKA enters the nucleus and 
phosphorylates CREB which then binds to CRE containing genes and transcription.  
PDE, phosphodiesterases; AC, adenylyl cyclase; MAPK, mitogen activated protein 
kinase.   
 
1.4.4 GPCR dimerisation 
Many types of GPCRs are known to exist predominately as both homodimers 
and heterodimers, rather than as monomers (Bouvier 2001; George et al. 2002).  
Recent studies also suggest that the existence of this oligomeric assembly could have 
functional roles for receptor pharmacology, signalling and regulation (Terrillon & 
Bouvier 2004; Milligan 2004; Prinster et al. 2005).  Even though their existence is 
widely accepted, the functional importance had been met with some scepticism.   
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It has been shown that the essential step for the biosynthesis and expression 
of proteins along the secretory pathway is the ability to exit from the ER (Petaja-Repo 
et al. 2000).  Only correctly folded receptors can escape the ER quality control 
system, whereas the incorrectly folded proteins are retained and degraded (Petaja-
Repo et al. 2001).  Previous studies have shown that GPCRs like the metabotropic γ-
aminobutyric acid b receptor (GABAB) requires heterodimerisation of GABAB1 and 
GABAB2 subunits in order for correct transport to the plasma membrane, as, when 
expressed alone, GABAB1 is retained intracellularly (Marshall et al. 1999; Margeta-
Mitrovic et al. 2000).   
Using newer methods such as cellular fractionation and fluorescence or 
bioluminescence resonance energy transfer studies (FRET and BRET respectively) 
there is increasing evidence that GPCR dimerisation occurs in the ER (Issafras et al. 
2002; Overton & Blumer 2002; Terrillon et al. 2003).  Other supporting evidence for 
GPCR dimerisation occurring early in the secretory pathway is seen with mutant 
receptors behaving as dominant-negatives in the presence of the wild type receptors 
and preventing any cell surface expression.  These observations were made with the 
truncated mutations of the vasopressin receptor V2R (Zhu & Wess 1998), rhodopsin 
mutants (Colley et al. 1995) and GnRH receptors (Grosse et al. 1997) among others.  
There is conflicting data as to whether receptor activation can promote or 
inhibit dimerisation.  Some studies suggest that ligand binding is able to promote 
dimer formation (Rodriguez-Frade et al. 1999; Angers et al. 2000; Horvat et al. 2001) 
or inhibition of its formation (Gines et al. 2000; Cheng & Miller 2001), whereas many 
others believe that homodimerisation and heterodimerisation are constutitive 
processes which are not affected by ligand binding (Overton & Blumer 2000; Issafras 
et al. 2002; Ayoub et al. 2002; Terrillon et al. 2003; Guo et al. 2003; Stanasila et al. 
2003).  It is possible that different receptors behave differently or it may be that the 
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differences in findings could be due to the interpretation difficulties linked to the 
techniques used, such as FRET and BRET (Terrillon & Bouvier 2004).  These 
techniques depend on the relative distance and orientation between the donor and 
acceptor fluorophores, and, if there is a change in energy transfer after ligand 
stimulation, this can suggest either that there is change in the dimerisation process or, 
alternatively, a change in the conformation of the existing dimers.   
The studies on GABAB imply the first evidence that GPCR dimerisation may 
have a crucial role in signal transduction.  GABAB1 binds γ-aminobutyric acid (GABA) 
at the cell surface, but it is only functional when co-expressed with GABAB2 (Margeta-
Mitrovic et al. 2000; Galvez et al. 2001).  This was explained by a transactivation 
model in which GABAB1 binds to GABA while GABAB2 activates a G protein for 
signalling (Galvez et al. 2001).  Signalling as a result of heterodimerisation has also 
been suggested in other receptors, for example the chemokine CCR5/CCR2 (Mellado 
et al. 2001), somatostatin receptors SST2a/SST3 (Pfeiffer et al. 2001) and taste 
receptors (Nelson et al. 2001).   
Indeed, the artificial over-expression system in heterologus cells would not be 
of any biological relevance unless these receptors are expressed in the same cells in 
vivo. In vivo studies with mouse cardiomyocytes, shows that blockade of either AT1 
receptor or the β2-adrenergic receptor with selective antagonists inhibits the signalling 
of both receptors simultaneously (Barki-Harrington et al. 2003).  Suggesting in a 
physiological model that two GPCRs could heterodimerise.   
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1.4.5 Ligand-Binding domains of Class A GPCRs 
Class A GPCR binding sites to endogenous “small molecule” ligands are well 
characterised for the retinal photochromophore in rhodopsin and for catecholamines 
in the adrenergic receptors and others (Savarese & Fraser 1992; Kobilka 1992; Ji et 
al. 1998).  The binding sites for these classical neurotransmitters such as epinephrine, 
dopaimine, serotonin etc are thought to be contained in a binding crevice which is 
formed by the transmembrane helices (Gether 2000).  For example, the binding site 
for β2 adrenergic receptor agonists and antagonists is found in TM 3, 5 and 6.  By 
spectroscopic analysis of the fluorescent antagonist carazolol to β2 adrenergic 
receptor, there was evidence that the binding crevice is deeply buried in the receptor 
molecule (Tota & Strader 1990).  Interestingly, the most important interaction is 
thought to be a salt bridge between the charged amine of adrenergic ligands and the 
carboxylated side chain of Asp113 located at TM3 (Strader et al. 1991).   
For the majority of Class A receptors, such as angiotensin (AT1 and AT2) 
(Hjorth et al. 1994; Heerding et al. 1997), chemokines (Leong et al. 1994), 
vasopressin (Cotte et al. 1998), gonadotropin-releasing hormone receptors (GnRH) 
(Davidson et al. 1997) and others, there is evidence that the major interactions 
between ligand and receptor are in the amino terminus and predicted extracellular 
loop regions.  It has also been reported that in the case of high affinity binding of 
glycoprotein hormones, for example luteinizing hormone (LH) and follicle stimulating 
hormone (FSH), to their receptors, binding initially occurs at the extracellular domain, 
and is followed by a conformational change at the amino-terminal part of the hormone 
which will lead to secondary contacts with the extracellular loop regions of the 
membrane-associated part of the receptor for activation (Ji et al. 1998).   
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1.5 The Melanocortin receptor family 
The natural melanocortins α-, β-, and γ-MSH and ACTH bind to melanocortin 
receptors (MCR), which are expressed on the cell surface and belong to the 
superfamily of GPCRs (Mountjoy et al. 1992; Cone et al. 1996).  Five melanocortin 
receptors have been cloned (Mountjoy et al. 1992; Chhajlani et al. 1993; Gantz et al. 
1993a).  They have a sequence homology of 39 to 61% to one another at the amino 
acid level and bind to the natural melanocortin peptides with differential affinity (Table 
1.5).  MC2R is selective for ACTH, α-MSH is the preferred, though not exclusive 
agonist for MC5R whereas MC3R is the least selective receptor of the family (Brzoska 
et al. 2008).   
 
Receptor Ligand specificity Site of expression Action 
MC1R α-MSH > ACTH > γ-MSH 
Skin, melanocyes, 
macrophage 
Skin and hair pigmentation 
MC2R ACTH  
Adrenal cortex, 
adipose tissue 
Steroidogensis 
MC3R γ-MSH > ACTH > α-MSH 
Brain, placenta, 
pancreas, stomach 
Energy homeostasis 
MC4R α-MSH > ACTH > γ-MSH Brain, spinal cord 
Control of appetite, energy  
homostasis, erectile function 
MC5R α-MSH > ACTH > γ-MSH 
Exocrine glands, 
lymphocytes 
Regulation of excorine function,  
immunoregulatory function  
 
Table 1.5: Melanocortin receptors, ligand specificity, site of expression and action. 
 
1.5.1 Cloning of the Melanocortin receptors 
MC1R was the first melanocortin receptor to be identified by PCR using 
primers designed to the highly conserved TM3 and TM6 domains of GPCRs with 
cDNA from a human melanoma specimen (Mountjoy et al. 1992).  The sequence of 
this PCR product indicated a novel 372 nucleotide product with GPCR characteristics 
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(Mountjoy et al. 1992; Chhajlani et al. 1993).  This novel product was then used as a 
probe to perform Northern hybridization to screen for its expression in several tissues 
such as brain, adrenal gland, testis, WM 266-4 melanoma cells and others.  A specific 
RNA band was exclusively seen in the melanoma cell line sample.   A melanoma cell 
cDNA library was then screened using this novel DNA fragment that resulted in the 
isolation of a cDNA clone, which encodes a 317 amino acid protein which was 
subsequently found to bind MSH peptide, now known as MC1R.   
The human MC2R gene was cloned in parallel with the human MC1R by 
Mountjoy in 1992.  Its identity was based on homology with the MC1R and its specific 
site of expression in the adrenal cortex.  Soon after, the other three members of the 
melanocortin family (MC3, 4 and 5R) were cloned using degenerate oligonucleotides 
based on the conserved amino acid sequences of the MC1R and MC2R (Gantz et al. 
1993a; Gantz et al. 1993b; Gantz et al. 1994). 
 
1.5.2 Melanocortin 1 receptor 
The MC1R is the principal melanocortin receptor in the skin where it regulates 
pigmentation (Haskell-Luevano et al. 1994) with high affinity to α-MSH.  It is also 
present in the mucosal cells of the human gastrointestinal tract (Colombo et al. 2002), 
and various cell types of the immune system including human monocytes (Bhardwaj 
et al. 1997; Cooper et al. 2005), lymphocytes, and neutrophils(Catania et al. 1996).  
Due to the wide distribution of the receptor, it has been shown to be involved in a 
number of biological functions including pigmentation, anti-pyretic and anti-
inflammatory actions (Catania et al. 1996; Bhardwaj et al. 1997).   
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Mutations of MC1R have profound effects on pigmentation.  MC1R is highly 
polymorhphic in humans (Schaffer & Bolognia 2001).  Certain allelic variants of the 
gene in humans are associated with red hair and pale skin (Valverde et al. 1995).   
 
1.5.3 Melanocortin 2 receptor 
MC2R is the primary ACTH receptor which is responsible for steriodogensis in 
the adrenal cortex.  Mutation in the MC2R may result in familial glucocorticoid 
deficiency characterised by the resistance to ACTH.  MC2R is also expressed in 
adipose tissue in mice and minimal in humans (Wikberg 1999).  Although ACTH is 
lipolytic in mice, it is not so in humans, and the function of MC2R in human adipose 
tissue is presently unclear (Gantz & Fong 2003).  See section 1.6 for MC2R for more 
detailed discussion of MC2R function.   
 
1.5.4 Melanocortin 3 receptor 
MC3R is expressed in many areas of the CNS and in several peripheral 
tissues including the gastrointestinal tract and placenta (Chhajlani 1996).  MC3R is 
expressed predominately in the hypothalamic nuclei (Gantz et al. 1993a) and is 
known to regulate food intake and energy homeostasis.  MC3R-null mice have a loss 
of lean body mass and an increase in subcutaneous fat while maintaining a relatively 
normal body weight (Chen et al. 2000).  Among the MCR subtypes, γ-MSH has its 
greatest affinity at MC3R, an observation which is assumed to be physiological 
importance (Gantz & Fong 2003).   
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1.5.5 Melanocortin 4 receptor 
MC4R is expressed in the CNS, mainly in the hypothalamus (Gantz et al. 
1993a).  Its principal role is in food intake regulation (Butler et al. 2001). Inactivating 
mutations of MC4 cause obesity both in mice and humans (Farooqi et al. 2001; 
Mergen et al. 2001).  MC4R negatively regulates appetite and food intake in response 
to agonist thought to be α-MSH, and conversely its inverse agonist/ antagonist AgRP 
provides an orexigenic signal (Huszar et al. 1997; Breit et al. 2006).   
 
1.5.6 Melanocortin 5 receptor 
MC5R is expressed in numerous peripheral tissues including the adrenals, 
adipocytes, skin and many others (Chhajlani 1996).  It is thought to have a role in 
exocrine function especially sebaceous gland secretion, as evidenced by MC5R 
knockout mice having decreased sebaceous lipid production (Chen et al. 1997).  It 
may also have a role in tear secretion by the lacrimal gland (Entwistle et al. 1990) and 
in immune regulation (Taylor & Namba 2001).   
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1.6 Melanocortin 2 receptor 
This is the smallest of all G protein coupled receptors (GPCR) consisting of 
297aa and is primarily expressed in the adrenal cortex (Mountjoy et al. 1992; Naville 
et al. 1994; Cammas et al. 1997).  It is highly specific for ACTH and unlike other 
melanocortin receptors, it does not have affinity for other melanocortins (α, β and γ-
MSH).  
 
1.6.1 Structure of MC2R gene 
The human MC2R gene is located in chromosome 18p11.2- and consists of 
two exons; 49 bp of the 5’ untranslated region of the MC2R is located in exon 1 and is 
18 kb upstream of exon 2 (Naville et al. 1994).  Exon 2 contains 128 bp of 5’ 
untranslated sequence and the full length coding sequence.  The short first exon lies 
downstream of a promoter which includes an initiator element and several 
steroidogenic factor-1 (SF-1) sites (Naville et al. 1994).   
 
1.6.2 Expression of the MC2R 
Using in situ hybridization, the MC2R mRNA has been shown to be expressed 
in all three zones of the human adrenal.  The highest expression level was found in 
the zona glomerulosa and fasciculata (Figure 1.10) (Mountjoy et al. 1992; Xia & 
Wikberg 1996; Thomas et al. 2003).   Other extra-adrenal tissue expression in 
humans has been shown in the ovary (Chhajlani et al. 1993), skin (Slominski et al. 
1996) and vascular endothelial cells (Hatakeyama et al. 2000).  It has also been found 
to be present in adipose tissue (Boston & Cone 1996), pituitary (Morris et al. 2003), 
sympathetic ganglia (Nankova et al. 2003) and skin (Slominski et al. 1996). 
Chapter 1- Introduction 
      
51 
 
 
Figure 1.10: MC2R expression in adrenal cortex. In situ localisation of MC2R in rat 
adrenal sections in zona glomerulosa (ZG) and fasciculata (ZF).   A and B: MC2R 
localised with anti-MC2R antibody (H70, Santa Cruz).  C and D: controls, no antibody 
used.  M=medulla.  Courtesy of Leonardo Guasti.   
 
1.6.3 Melanocortin 2 receptor signalling pathway 
The mechanism of GPCR signalling has already been discussed in section 
1.4.3.  Briefly, the MC2R is known to signal via the adenylyl cyclase – cAMP signalling 
cascade.  The first step is for Gsα dissociation from the receptor-ligand complex, 
which leads to adenylyl cyclase activation.  This catalyses the production of cAMP 
which then in turn leads to cAMP dependent protein kinase A (PKA) activation and 
hence cAMP response element binding protein (CREB) phosphorylation.  The 
cascade will eventually leads to the induction of the enzymes for steroidogenesis, and 
ultimately cortisol release.  The schematic illustration in Figure 1.11, outlines the 
cAMP signalling cascade and the essential features of the mechanism of action of 
ACTH.   
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Figure 1.11: The essential features of ACTH action in stimulating steroidogenesis in 
adrenal cells.  ACTH binds and activates the MC2R at the cell surface, resulting in the 
activation of the heterotrimeric G protein by exchange of GDP for GTP and dissociation 
of the α-subunit from the βγ-subunits.  Gsα then stimulates membrane-associated 
adenylate cyclase to produce cAMP, which in turn activates PKA in the cytosol.  The 
catalytic subunits of PKA dissociate and phosphorylate target factors, which include 
the cAMP response element binding protein (CREB).  CREB act as a transcription factor 
that increases the expression of steroidogenic acute regulatory protein (StAR) which 
stimulates cholesterol uptake into the mitochondria.  The transcription, translation and 
activation of StAR are regulated by PKA in response to trophic hormone.  The 
cholesterol uptake will induce the transcription of the steroidogenic enzymes CYP11A 
(P450 scc), CYP17 (17α-hydroxylase), CYP21 (21-hydroxylase), and CYP11B1 (11β-
hydroxylase), which ultimately results in an increased rate of cortisol synthesis.   
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1.6.4 MC2R knockout 
The specific role of MC2R in adrenal gland development, steroidogenesis and 
carbohydrate metabolism was tested with an inactivation mutation of the MC2R gene 
by Chida (2007).  They found that MC2R knockout (MC2R-KO) in mice led to three-
quarter neonatal lethality, possibly from the result of hypoglycaemia.  MC2R-KO mice 
developed hypoglycaemia during fasting which suggests that they have defective 
mechanisms in maintaining gluconeogenesis.  Neonatal hypoglycaemia in MC2R-KO 
mice might be secondary to the low level of circulating corticosterone (the main form 
of glucocorticoid in mice and other species) and epinephrine.   
Adult MC2R-KO mice had significant adrenal hypoplasia when compared to 
the wild type siblings (Chida et al. 2007).  The surviving adult MC2R-KO mice 
displayed marked atrophy of the adrenal glands with markedly atrophied zona 
fasciculata.  The zona glomerulosa and the adrenal medulla remained fairly intact.  
The authors suggest that MC2R is not required for proper development of zona 
glomerulosa but is required for the zona fasciculata.  There were also deficiencies in 
hormone production, in that not only was the corticosterone level undetectable, but 
aldosterone and catecholamine levels were also significantly reduced.   
The model of MC2R-KO mice is different from the human phenotype of 
famililal glucocorticoid deficiency type 1 (FGD).  In contrast to the human, these mice 
have low aldosterone levels and unaltered body length.  This disparity was explained 
by the fact that it is very rare for FGD patients to have a homozygous nonsense 
mutation, as most of them have one or two missense alleles instead.   
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1.6.5 Expression of MC2R in heterologous cells 
There have been significant difficulties in the functional expression of MC2R in 
a system that is free of any endogenous MCR expression (Naville et al. 1996b; Noon 
et al. 2002; Rached et al. 2005).  Transfected plasmids encoding the MC2R can be 
transcribed and translated, however, the receptor, fails to exit the endoplasmic 
reticulum.  Several groups have been unsuccessful in the functional expression of 
MC2R in HEK 293 or CHO cells.  There is convincing evidence of functional 
expression of MC2R in the Cloudman M3 melanoma cell line (Naville et al. 1996b).  
There is also evidence of functional expression seen with African green monkey 
kidney cell line, Cos-7 cells (Weber et al. 1993), but these results were confounded by 
the presence of other endogenous melanocortin receptors. 
Two cell lines which can provide reasonable expression of the MC2R with no 
other interfering melanocortin receptors are the Y6 and OS3 cell lines.  These two 
mutant cell lines were derived from the ACTH-responsive Y1 mouse adrenocortical 
cell line (Schimmer et al. 1995).  Y1 cells endogenously respond to ACTH with an 
increased adenylyl cyclase activity.  Y6 and OS3 mutants fail to express the gene 
encoding MC2R (Schimmer et al. 1995).  Studies using these cell lines enabled the 
functional characterisation of the MC2R using radioligand binding assays as well as 
cAMP assays (Elias et al. 1999).  Therefore, this observation that human MC2R could 
be expressed in cells with endogenous melanocortin receptors led to the speculation 
that a cofactor for expression is needed which was present in these cell lines.   
 
1.6.6 MC2R desensitisation and internalisation 
Desensitisation of the MC2R in the Y1 adrenocortical cell line has been 
previously investigated (Baig et al. 2001).  It is well established that the MC2R is 
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coupled to a Gαs subunit and that activation of adenylate cyclase is a major primary 
signalling event (Clark et al. 2003).  Like other GPCRs, after the initial ligand receptor 
interaction and signalling, the endogenously expressed MC2R in Y1 cells is 
desensitised.  Baig has shown that approximately 60% of MC2R signalling is 
desensitised within 30 min of ACTH stimulation.  The desensitisation process persists 
for several hours.  Interestingly, other factors such as forskolin do not desensitise 
MC2R.   
cAMP-dependent protein kinase (PKA) is activated after ACTH stimulation via 
binding of cAMP to the PKA regulatory subunits (as described in section 1.4.3.4).  
When PKA is blocked, using the PKA inhibitor H89 there is a complete loss of 
desensitisation.  Further supportive evidence indicating that PKA plays an important 
role in desensitisation is seen with site-directed mutagenesis of the single consensus 
PKA phosphorylation site in the third cytoplasmic loop at serine 208.  This mutant 
receptor has the same cell surface expression as the wild-type MC2R, however, it 
displayed almost complete loss of desensitisation for the entire 120 min study period 
(Baig et al. 2001).   
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1.7 Melanocortin 2 receptor accessory protein (MRAP) 
The observation that human MC2R could be expressed only in cells with 
endogenous melanocortin receptors led to speculation that a cofactor for expression 
was required. This hypothesis was proven correct when MRAP (melanocortin 2 
receptor accessory protein) was identified in 2005 (Metherell et al. 2005) in an effort to 
find another causative gene for FGD (Familial glucocorticoid deficiency).  Genetic 
studies using homozygosity mapping revealed a potential locus for disease on 
chromosome 21q22.1.  Sequence analysis of this gene in the index family showed the 
presence of a splice site mutation that was highly likely to lead to a defective protein.  
Similar defective MRAP mutations were shown in other cases (Metherell et al. 2005).    
MRAP was originally identified as FALP (fat tissue specific low molecular 
weight protein) a small protein of unknown function containing a single hydrophobic 
transmembrane domain protein which is upregulated during differentiation of the 
mouse pre-adipocyte cell line 3T3-L1 into adipocytes (Xu et al. 2002).  Interestingly, 
MC2R is also upregulated in this cell line during differentiation (Noon et al. 2002).  
MRAP mRNA is found highly expressed in the adrenal, as well as lymph nodes, brain, 
testis, breast and adipose tissue (Xu et al. 2002; Metherell et al. 2005) as seen in 
Figure 1.12.   
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Figure 1.12: Tissue distribution studied by Metherell et al. demonstrates that MRAP 
expression extends beyond the adrenal gland (Metherell et al. 2005).  MC2R expression 
is shown in blue, MRAPα in yellow and MRAPβ in green. 
 
The human MRAP gene consists of 6 exons.  Exons 5 and 6 are alternatively 
spliced to encode MRAPα or MRAPβ.  MRAPα is 172 amino acids in length, and 
predicted to have a molecular mass of 19kDa.  MRAPβ is 102 residues and is 
approximately 14kDa.  MRAPα is encoded by exons 1-5 and MRAPβ by exons 1-4 
and 6.  The MRAP gene structure and its alternative splicing have been illustrated in 
Figure 1.13. 
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Figure 1.13: Diagram of MRAP gene, transcription and translation.  Alternative splicing 
leads to the inclusion of exon 5 or 6 to generate the MRAPα and MRAPβ isoforms 
respectively.  The N-terminus (yellow), transmembrane domain (blue) and C-terminus 
(black) of the MRAP protein is shown.   
 
MRAP joins a group of single transmembrane domain proteins that supports 
expression of GPCRs.  These include the small single transmembrane domain 
receptor activity modifying proteins (RAMPs), which support the expression of the 
calcitonin and calcitonin-like receptor (McLatchie et al. 1998; Morfis et al. 2003); the 
dopamine receptor interacting protein (DRiP78) which is required for the trafficking of 
the D1 dopamine receptor (Bermak et al. 2001); and the RTP proteins, which traffic 
olfactory receptors (Saito et al. 2004).  Despite similar protein structures and 
functional parallels, there is no sequence conservation and no indication that they 
function by a common mechanism.   
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The identification of MRAP provided a molecular explanation for the previous 
difficulties in expression of MC2R.  MRAP interacts with MC2R and facilitates cell 
surface expression and produces a functional ACTH responsive receptor when 
transfected in non-adrenal cell lines.  On confocal imaging MRAP co-localises with 
MC2R at both the endoplasmic reticulum and at the plasma membrane (Metherell et 
al. 2005).   
The mouse adrenocortical cell line, Y1 endogenously expresses both MC2R 
and MRAP, and is responsive to ACTH.  When MRAP is knocked down in Y1 using 
RNA interference, the response to ACTH was significantly reduced (Cooray et al. 
2008).  When human MRAP was re-transfected into the knockdown Y1 cells, the 
MC2R function was restored.   
MRAP has been shown to exist as an antiparallel homodimer where one copy 
of MRAP has a “C-terminus out” and the other has “N-terminus out” orientation 
(Sebag & Hinkle 2007).  The MRAP dimer structure was also suggested by Cooray 
(2008) when a significantly higher molecular weight band was seen on gel 
electrophoresis using Y1 adrenocortical cells after transfection of hMRAP.  This was 
confirmed with mass spectroscopic analysis.   
The interaction site between MRAP and MC2R has recently been identified 
(Webb et al. 2009).  The tyrosine rich N-terminus of MRAP is required for trafficking 
MC2R to the cell surface and the MRAP transmembrane domain is sufficient for the 
MRAP/MC2R interaction.  Whilst the C-terminus of MRAP is not required for MC2R 
interaction or trafficking of the receptor, it may be important in the regulatory role of 
cell surface expression (Roy et al. 2007; Webb et al. 2009).   
Previous studies have shown that MRAP interacts with MC2R and has a role 
in the trafficking of the receptor which facilitates cell surface expression (Metherell et 
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al. 2005; Roy et al. 2007; Cooray et al. 2008).  MRAP allows the MC2R to be 
glycosylated and localise to the plasma membrane; in the absence of MRAP, MC2R is 
nonglycosylated and is degraded in the ER (Sebag & Hinkle 2007).  However, 
contrary findings of Roy et al. (2007), showed that N-terminus myc tagged MC2R 
localised on the cell surface in the absence of MRAP in HEK293-FRT cells, whilst 
MRAP is required for the GFP-MC2R cell surface expression.  They suggest that 
MRAP enhanced MC2R expression at the cell surface but MRAP is not necessary for 
MC2R cell surface localisation.  It is possible that the observed discrepancy in result 
may be due to the differences in MC2R constructs and it is possible that the cell line 
used may express endogenous MRAP.   
There is evidence that MRAP is required for ACTH binding and MC2R 
signalling.  Following knockdown of MRAP mRNA with siRNA, there was a marked 
reduction of signalling in response to ACTH in Y1 cells (Cooray et al. 2008).  There is 
published data suggesting the MRAP amino acids 18-21 (LDYI) are essential for 
MC2R cAMP signalling and binding to ACTH (Hinkle & Sebag 2009; Sebag & Hinkle 
2009b).  This finding was revealed in the characterisation of MRAP2, an MRAP 
homologue which lacks the critical LDYI domain.  In their hands, MC2R had a marked 
reduction in ACTH binding and in cAMP production when co-expressed with MRAP2 
and stimulated with ACTH compared with MRAP.  They therefore concluded that the 
LDYI region in MRAP is required for ACTH binding to MC2R.  This is somewhat 
conflicting to the finding from Chan et al (Chan et al. 2009c) who showed that MRAP 
and MRAP2 independently assist MC2R signalling.  There was also the interesting 
observation that the disruption of the single MRAP2 glycosylation site leads to failure 
of cAMP signalling in MC2R after ACTH stimulation.  The exact functional mechanism 
of MRAP in MC2R signalling therefore remains unclear.   
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1.8 Hypothesis and Aims: 
The overall aim of this thesis is to study the molecular mechanisms 
responsible for ACTH insensitivity in FGD and to investigate MC2R dimerisation in the 
presence of MRAP.  This thesis exploits the availability of MRAP, using it as a tool for 
the detailed investigation of MC2R for the first time.     
The first aim of this thesis was to identify the molecular defects in all naturally 
occurring mutations found in FGD and analyse the genotype-phenotype relationship.  
In other melanocortin receptors such as MC4R, some of the defective mutations are 
known to have defective trafficking and are therefore non-responsive to agonist (Ho & 
MacKenzie 1999).  The hypothesis is that mutations in the MC2R cause loss of 
function in many cases because of interference with trafficking and folding of the 
receptor rather than ligand binding in itself.  To test this hypothesis, the functional 
consequences of the missense mutations in the trafficking of the receptors or 
signalling were tested in stably expressing MRAP cell lines and potential loss of 
interaction with MRAP was tested by co-immunoprecipitation.   
Secondly, the functional data of the different MC2R genotypes were compared 
with the phenotype data and judged for their severity.  Correlations between FGD type 
1 and 2 were also made to compare any phenotypic differences. 
 The final aim of this thesis was to investigate the homodimerisation and 
heterodimerisation of the MC2R using co-immunoprecipitation.  The functional 
consequences of dimerisation were also assessed in vitro.  
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2.1  Equipment, reagents and plasticware 
The details of laboratory equipment are listed in the Appendix 8.1.  General 
laboratory chemicals, tissue culture reagents and antibodies stated (listed in Appendix 
8.2) were purchased from Sigma-Aldrich (Poole, Dorset, UK) and general plasticware 
from VWR, UK unless otherwise stated.  General solutions and buffers were prepared 
in deionised water and autoclaved or filtered where necessary.   
 
2.2   Cell culture protocols and stable cell lines 
         All cell culture procedures were performed under sterile conditions in a laminar 
airflow hood.  Cells were incubated in a humidified atmosphere of 5% CO2, 95% air 
(LEEC Ltd. Research Incubator, Nottingham, UK).  The cell lines used in this study 
were HEK 293T (human embryonic kidney cells) and CHO (Chinese hamster ovary 
cells).  The medium was changed every 2-3 days.  When cells became 90-100% 
confluent they were passaged and placed in new tissue culture flasks or plated out for 
experiments.   
2.2.1  Cell culture maintenance 
 CHO cells were grown in 50% Dulbecco’s Modified Eagles Medium with L-
glutamate (DMEM) (GIBCO,UK) and 50% Ham’s F12 (GIBCO, UK) media 
supplemented with 10% foetal bovine serum (Sigma-Aldrich, UK), 1% penicillin 
/streptomycin (Invitrogen Ltd, UK).   
 HEK 293T cells were grown in the presence of DMEM media with 10% foetal 
bovine serum (FBS) and 1% penicillin/streptomycin. 
           The media was pre-warmed to 37ºC before use.  Passage numbers were 
recorded on each flask. 
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2.2.2 Passaging cells 
Materials 
Phosphate buffer solution (PBS) - 7.5mM Na2HPO4, 2.5mM NaH2 PO4 and 150 mM 
NaCl (Sigma-Aldrich, UK) 
Trypsin (2.5g porcine trypsin/EDTA) 
DMEM/ Ham’s F12 (1:1) or DMEM medium as stated above 
Method 
         Cells were serially passaged in 75cm2 tissue culture dishes or plates (Greiner, 
Gloucestershire, UK) in a 37oC, 5% CO2 incubator.  When cells reached 90% 
confluence, they were split in a 1:5 to 1:10 ratio.  Cell passage numbers were noted at 
all times.  The medium was first aspirated and cells washed in PBS before incubation 
with 3mls of trypsin/EDTA, to destroy adherence.  Fresh medium was then added to 
the cell suspensions and these were transferred to a new tissue culture dish. 
2.2.3  Cell storage 
            Cells were grown to confluence to be stored in liquid nitrogen.  After cells were 
trypsinised, equal volumes of fresh medium were then added and centrifuged at 
1000Xg for 5 min.  The pellets were then resuspended in FBS containing 10% (v/v) 
dimethyl sulphoxide (DMSO) [Sigma-Aldrich, UK].  700μl was transferred to 
cryotubes.  The cryotubes were wrapped in multiple layers of paper and bubble wrap 
to allow slow cooling in a -70oC freezer overnight.  Within 48-72hours, the cryotubes 
were transferred to liquid nitrogen for long term storage. 
2.2.4  Cell counting 
Materials 
Neuberg Haemocytometer 
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Method 
          Cells were counted in a Neuberg Haemocytomer to determine cell 
concentration.  25μl of cell suspension (after trypsinisation) was added to 25μl trypan 
blue and 150μl medium.  50μl of this mixture was then applied to the cytometer by 
pipetting into the counting area.  A 10X lens was focused on the grid lines of the 
1mm2 area and clear cells visible in the region (dead cells take up the trypan blue and 
are hence blue coloured) were counted. 
Cell concentration was determined as the average of 4 corners counted (n). 
Cell concentration (cells/ml) = n X dilutional factor (200/25) X 10 000  
 
2.2.5  Transfection into mammalian cell lines 
Lipid based transfection of mammalian cells was performed using LipofectamineTM 
2000 (Invitrogen Ltd, UK) according to the manufacturer’s instructions.   
Materials  
LipofectamineTM 2000 (Invitrogen Ltd,UK) 
Cell culture medium 
Opti-MEM® I reduced serum medium (Invitrogen Ltd, UK) 
 
Methods 
Cells were grown in tissue culture plates and were at 60-80% confluence before 
transfection.  The amount of DNA and lipofectamine used was as suggested by the 
manufacturer (Invitrogen).   
Culture vessel DNA transfection per well (ng) Lipofectamine (μl/well) 
24 wells 200 1 
12 wells  800 2 
6 wells 2000 5 
10 cm
2
 plate 4000 20 
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Table 2.1: Table of transfection regent and DNA used for specific tissue culture vessel.   
 
         In two separate tubes DNA was added to a suitable volume of Opti-MEM® I 
reduced serum medium, gently mixed and incubated at room temperature for 5 min.    
In another centrifuge tube the appropriate amount of lipofectamine was added to Opti-
MEM and left to stand for 5 min.  Thereafter, the two mixtures were combined and left 
for 25min at room temperature for complex formation.  The mixture was then gently 
pipetted onto the cell culture flask and incubated at 37°C in a CO2 incubator for 24 to 
48 hrs.   
           The transfection efficiency was assessed by transfection of cells under the 
same condition with a pEGFP-N1 (Clontech) empty vector.  The percentage of cells 
expressing GFP was determined by epi-fluorescence using a Nikon Eclipse TS100 
inverted microscope, equipped with a Nikon C-SHG and T1-FM epi-fluorescence 
module through a FITC filter (Ex 465-495, Dm 505, Bar 155/555) [Nikon Instruments 
Europe B.V., Netherlands).  The transfection efficiency achieved in HEK 293T cells 
was 90% and 60% for CHO cells.   
 
2.2.5  Stable cell line generation 
          The first step for the generation of a G418 resistant stable cell line was to 
determine the concentration G418 leading to cell death of the non-transfected cells, 
over 10 day period.  This was determined using an antibiotic titration curve.  
 
2.2.5.1  Antibiotic Titration Curves 
Materials 
Geneticin (G418) (Sigma-Aldrich, UK) 
CHO Cell medium or HEK 293 cell medium 
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Methods 
         Cells were plated in their standard medium to achieve 25% confluence in 24 well 
plates.  Wells were treated in triplicate with varying amounts of G418 antibiotic: 0, 
200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800 μg/ml in medium.  Cells were then 
incubated for 10-14 days with the medium and antibiotic refreshed every 3 days.  The 
plates were inspected daily for signs of toxicity and the presence of viable cells.  The 
lowest concentration of G418 that began to give notable cell death at approximately 7-
10 days and killed all cells within 2 weeks was identified and this concentration was 
then used to select cells containing MRAP α or β pcDNA3.1 plasmid after transfection.   
 
2.2.5.2  Creating stable cell lines expressing MRAPα and MRAPβ 
          Cells were grown in 100cm2 tissue culture plates until 60% confluence was 
achieved.  Constructs made from pcDNA3.1(+) vectors containing either MRAP α, 
MRAP β or empty vector were transfected individually into both CHO and HEK293 
cells.  12 μg DNA was transfected in each plate of cells.  Cells were transfected for 24 
hours before they were split into a 1:5 and 1:10 ratio.  New medium with an 
appropriate dose of fresh G418 was added the following day.    Untransfected cells 
were treated with G418 and used as a negative control.  Once the cells in the 
negative control were all killed off, the selection was considered to be complete and 
the cells were grown in media with G418 until distinct colonies were visible (14-21 
days).  The selection medium was changed every 3 days during this process.  
Individual colonies were isolated by the dilutional method (see section 2.2.5.3).  All 
subsequent tissue culture was performed in medium containing antibiotic at the same 
concentration as in the selection process.   
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2.2.5.3  Isolation of colonies after antibiotic selection  
          Monoclonal stable cells were selected by the dilutional method.  Cells were 
diluted to 4 cells/ 1000μl and 200 μl of diluted cells with antibiotic medium were plated 
into 96 well plates.  Cells were incubated at 37°C and visually inspected daily.  Wells 
with more than one colony were discarded.  Wells with one colony only were selected 
and grown into a bigger population, as potential stable cell lines. 
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2.3  Nucleic acid extraction, purification, amplification and 
modification 
2.3.1 Extraction of RNA from cells 
This extraction technique is based on selective binding of RNA to a silica gel 
based membrane, hence enabling wash steps to remove contaminants such as DNA 
and protein.   
Materials 
RNaseZAP® 
QIAGEN RNeasy® mini kit 
RNAse free water 
Phosphate buffered solution (PBS) 
 
Method 
Equipment and work surfaces were treated with RNaseZAP® to minimise the 
degradation of extracted RNA by RNases.  Cell were grown to 80% confluence in 6 
well plates, washed twice in PBS and then harvested by cell scraping in 1.5ml ice cold 
PBS.  Cells were then pelleted by a 2minute centrifugation at 300xg at 4oC and the 
supernatant discarded.  The rest of the protocol is as per manufacturer’s instruction 
for QIAGEN RNeasy® Mini Kit.  Briefly, the cell pellet was then resuspended and 
homogenised in 350μl buffer RLT lysis buffer for lysing pelleted cells.  One volume of 
70% ethanol was added to the homogenized lysate, and mixed well by pipetting.  Up 
to 700μl of the sample was transferred to an RNeasy spin column which was placed 
over a 2ml collection tube and spun for 15sec at 13 000 rpm.  The flow through was 
discarded, 700μl buffer RW1 (containing a guanidine salt, for washing the membrane 
bound RNA) was added to RNeasy spin column it was then spun at 13 000 rpm for 
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another 15secs.  Flow through was discarded, 500μl buffer RPE (wash buffer) was 
added to RNeasy spin column.  This was spun and flow-through discarded.  Another 
500μl buffer RPE was added to RNeasy spin column, then spun and flow-through was 
discarded.  Finally RNeasy spin column was placed in a new 1.5ml collection tube, 
30-50μl RNase-free water was added directly to the spin column membrane.  This 
was then spun at 13 000 rpm for another one minute in order to elute RNA.   
The RNA collected was quantified using the Nanodrop ND 1000 spectrophotometer.   
 
2.3.2 DNAse treatment of RNA 
Materials 
DNase I - 6.4 µg/ml , 18.6 unit/ µg  (Promega) 
RNase inhibitor -  40units/µl (Promega) 
M-MLV RT 5X buffer (Promega) 
70% ethanol 
RNase free water 
 
Method 
To ensure that the RNA was not contaminated with genomic DNA, all RNA 
extracted underwent DNase treatment.  2 µg RNA was treated with 1µl DNase, 1 µl 
RNase inhibitor and 4 µl buffer (5X) M-MLV RT was reconstituted in total volume of 20 
µl with water.  The mixture was left at 37°C for 15 min.  
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2.3.3 Phenol extraction of nucleic acids  
To remove proteins from nucleic acid, for example following enzymatic treatments, an 
equal volume of phenol equilibrated to pH 8.0 was added to the solution which was 
then vortexed well and centrifuged at 13 000 rpm for 2min.  The contaminating 
protein, lipids and carbohydrates are preferentially soluable in the non-aqueous 
phenol whilst the nucleic acid remains in the aqueous upper phase.  The separated 
upper aqueous phase was removed by pipetting to a clean tube.   
 
2.3.4 Precipitation of nucleic acids 
The precipitation of nucleic acid (50μl) was performed by adding 1/10 volume 
(5μl) of 3M Na acetate, 2.5 volume (125μl) absolute ethanol and 2μl glycogen.  The 
mixture was mixed and incubated at -70ºC for a minimum of 15 min and a maximum 
of overnight to precipitate nucleic acids.  Precipitated products were centrifuged at 13 
000 rpm for 10 min.  The RNA pellet can then be visualised at the bottom of the 
microcentrifuge tube.  The supernatant was carefully removed by pipetting.  The pellet 
was washed with 70% ethanol and centrifuged again for further 10 min at 13 000 rpm.  
After removal of all ethanol, the pellet was air-dried and resuspended in 10 μl water.   
 
2.3.5   Determination of Nucleic acid concentration and purity 
         The concentration and purity of DNA or RNA was determined using the 
NanoDrop (ND-100) spectrophotometer (Labtech International, UK) in accordance 
with the manufacturer’s instructions.   
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         The optical density (OD) absorbance reading at 260nm was used to determine 
the concentration of the DNA or RNA, OD 260/ OD 280 ratios were used to determine 
the purity of the sample.  Pure DNA and RNA have ratios of 1.8 and 2.0 respectively.  
Ratios less than 1.8 indicate that the sample may be contaminated with protein 
whereas ratios greater than 2.0 may mean that the sample is contaminated with 
chemicals.   
 
2.3.6 cDNA synthesis from mRNA using reverse transcriptase 
Materials 
RNA  
Random primer (0.5μg/μl) , Promega 
M-MLV RT buffer (5X), Promega 
Dithiothreitol (DTT) 
dNTP 10mM (equal volume of dATP, dCTP, dGTP, dTTP) 
Reverse transcriptase (Promega) 
RNAse® ribonuclease inhibitor (Promega) 
 
Method 
2μg RNA was added with 1μl random primer master mix to make the final 
volume to 12μl.  The mixture was heated to 70°C for 10 min to break any secondary 
structure of RNA.  This was immediately placed on ice for a few minutes to anneal the 
random primers.  The reverse transcriptase reaction was typically made up to a total 
volume of 20μl as follows: 
1 µl into freezer was removed and stored at -20ºC (a negative RT sample).  
Chapter 2 – Materials and Methods 
      
73 
 
To the remaining 11 µl was added:  RT buffer (5X) : 4 µl 
                                             0.1M DTT : 2µl  (dithiothreitol)  
                                          10mM dNTP: 1µl     
Reverse Transcriptase: 1 µl  (MMLV- RT) 
                            RNAse inhibitor: 1 µl 
 
The reaction was mixed gently, spun briefly and incubated at 37ºC for 1 hour.  
Samples were stored at -20ºC.   
 
2.3.7 Designing oligonucleotides 
The general principles for designing oligos are that: 
1. The optimal primer length is 18-25 base pairs (bp).   
2. The G/C content should be designed to be 40-60% 
3. Primers used in RT-PCR should be intron-spanning to ensure the PCR reaction 
amplifies only cDNA and do not have contaminated genomic DNA. 
Forward and reverse primers should anneal at approximately the same 
temperature.  52-58 ºC generally produces the best results- a rough calculation for 
the melting temperature, Tm of oligonucleotides can be made using is the following 
formula: 
Tm (ºC) = (number of C/ G bases) X 4 + (number of A /T bases) X2 
In practice however most primer sequences were designed using Primer 3 
software with DNA sequences of interest from NCBI or ENSEMBL databases.   
For site directed mutagenesis (SDM) two complementary oligonucleotides 
containing the desired mutation, flanked by unmodified nucleotide sequence were 
designed and synthesised.  12-17 bases are incorporated on either side of the 
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mutated nucleotide, giving a primer length of 25-35 bp (Figure 2.1).  The primers used 
for SDM are shown in Appendix 8.3. 
Normal sequence:   ....TCTCCCTGCTTGGCTCCATCTTCAG.....  
G116V   ....TCTCCCTGCTTGTCTCCATCTTCAG....   
Figure 2.1: Example of oligonucleotide design for site directed mutagenesis.  Normal 
MC2R sequence at the region of interest is shown.  To perform SDM, the glycine is 
exchanged for valine by the exchange of GGC for GTC.   
 
 
2.3.8 Polymerase Chain Reaction (PCR) 
PCR is a technique used to amplify the gene of interest.  PCR consists of a 
series of 20-40 cycles of repeated primer extensions using a thermostable DNA 
polymerase.  The basic principle involves an initiation step when DNA is denatured at 
95ºC.  This is followed by annealing of sequence-specific oligonucleotide primers at 
reaction temperature is usually about 3-5 ºC below the Tm of the primers used.  This 
temperature is usually in the ranges of 50-65 ºC for 20-40 seconds.  Following 
annealing the extention reaction takes place at 72ºC with synthesis of DNA occurring 
at a rate of approximately 1-2kb/min.   
PCR reaction is typically carried out in a total volume of 25μl as follows: 
Materials 
Template    0.5μl 
Sense primer (10 μM)   0.5μl 
Anti Sense primer (10 μM)  0.5μl 
10X buffer    2.5μl 
Taq DNA polymerase (5 U/μl) 0.25μl 
dNTPs (10mM)   0.5μl 
ddH2O     20.25μl 
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Total volume     25μl 
 
Method  
PCR automated cycling was typically carried out in the following condition shown 
below.  
1. initial template denaturation              94°C for 5 min  ------1 cycle 
2. Subsequent denaturation                  94°C for 30 secs 
primer annealing                               55°C for 30 secs 
primer extension                               72°C for 60 secs-----25 cycles 
3. extension of incomplete products     72°C for 7 min   ------1 cycle 
 
2.3.9  Agarose gel electrophoresis 
Materials: 
Agarose (electrophoresis grade) 
Ethidium Bromide (10mg/ml) 
Loading dye solution (40% w/v surose, 0.25% w/v bromophenol blue or Orange G, 
DEPC water) 
10X TAE (40mM Tris-acetate, 2 mM disodium ethylenediaminetetraactete 
(Na2EDTA), pH 8.3)  National Diagnostics 
DNA markers (GeneRuler TM DNA ladder Mix, 0.5mg DNA/ml, Fermentas) 
Method: 
         All PCR products were run on 1-2% agarose gels in 1X TAE buffer and 
visualised alongside DNA markers with ethidium bromide staining.  The PCR 
reaction was mixed with loading dye at a 1:5 ratio prior to loading into the wells of 
the agarose gel.  In the laboratory gel tank, the electrophoresis was carried out at 
120 V for 30 min or until clear separation of bands was achieved.  Ethidium bromide  ----1 cycle 
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intercalated into DNA will fluoresce under UV light at 340 nm, allowing visualisation 
of the DNA.  An Uvitec transluminator was used to visualise the bands, and capture 
a digital image of the gel.   
 
2.3.10  Extraction of DNA from agarose gels 
Materials: 
The QIAquick Gel extraction kit, QIAGEN 
         The exact composition of the buffers used is unavailable but the principle of 
QIAquick is based on binding properties of DNA to a silica membrane in the 
presence of high salt buffer.  This allows washes with high salt buffers to remove 
impurities and contaminants, and elution of DNA from the membrane is then 
accomplished under low salt condition.   
Method: 
           The DNA fragment of interest was visualised under UV light, and excised 
with a sharp clean blade.  The gel slice was weighed in a microcentrifuge tube and 
the volume was estimated, assuming 100mg = 100 μl.  3 x volume of buffer QG 
(binding and solubilisation buffer) was added to 1 volume of gel.  The samples were 
incubated at 50ºC, vortexing intermittently until complete gel solubilisation was 
achieved.  The sample was applied to the QIAquick column and centrifuged for 1 
min at 13 000 rpm.  The flow-through was collected and discarded.  The column 
was washed with 750 μl of buffer PE and centrifuged at 13 000 rpm for a further 
minute.  The column was placed in a clean microcentrifuge tube and allowed to dry 
at room temperature for 1 min.  30 – 50 μl water was added to the membrane to 
elute DNA sample by centrifugation at 13 000 rpm for 1 min.  The DNA was stored 
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at -20 ºC. 
 
2.3.11   DNA sequencing 
           Sequencing of PCR products or clones was performed to ensure that they 
were specific.  Sequencing was performed by the Genome Centre (Bart’s and the 
London School of Medicine and Dentistry, Queen Mary University of London) using 
BigDye 3.1 chemistry (Applied Biosystems, UK), which is based on the Sanger 
dideoy-mediated chain termination method.  Analysis of sequence chromatograms 
was carried out using BioEdit (Hall, 1999).  
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2.4    Cloning and plasmid preparation 
2.4.1  Basic steps of subcloning 
           Subcloning is a basic molecular biology procedure which involves the 
introduction of DNA sequences typically into bacterial plasmid vectors.  Inserts of 
interest could be cut out from parental vectors or could be generated by PCR, from 
the relevant tissue cDNA.  Figure 2.2 outlines the principal steps involved in 
subcloning.   
Parent vector Destination vector
Digest vectors with restriction enzymes 
Insert released from parent vector
Insert could also be 
generated from PCR
Gel purification for inert and vector
Ligation of insert  into vector
Transformation and culture onto LB agar plate
Plasmid DNA purification  
Figure 2.2: Cartoon diagram illustrating the basic steps of subcloning.   
 
 
 ---25 cycles 
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2.4.2  MRAP α and β plasmid constructs 
        Two sets of primers to human MRAP α and β were designed with EcoR-I and 
Hind-III restriction sites in place.  These restriction sites were incorporated into the 
primer sequences to allow direct cloning into the mammalian vector pcDNA3.1 (+) 
(Invitrogen, Carlsbad, CA) in the correct orientation.  MRAP α and β share the same 
sequence for the first 200 bp, and therefore the same forward primer was used.   
The forward primer was designed with a Hind-III (underlined) restriction site at the 5’ 
end: 
MRAP αβ forward primer:   
    5’ GCA AAG CTT ATG GCC AAC GGG ACC AAC  3’ 
The reverse primers were designed with a EcoR-I (underlined) restriction site at the 
5’ end:  
MRAP α reverse primer:  
    5’ TAC GAA TTC TCA GCT CTG CAA TTG AGA 3’ 
MRAP β reverse primer: 
    5’ TAC GAA TTC TCA GGC CGC CCC TTC CTC 3’ 
RT-PCR was performed as previously described (section 2.3.8) using human 
adrenal cDNA as a template (made from adrenal cortex total RNA, bought from 
Ambion).  The PCR product was cloned into the mammalian expression vector 
(pcDNA3.1).   
Previously cloned by another investigator in the lab, human MRAP α in pGEM®T-
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easy (Promega, UK) was digested with EcoR-I and Not-I, which are common 
restriction sites to both pGEM T-easy and pcDNA3.1(+) vectors.  This can be seen 
in the vector maps (Appendix 8.4).   
 
2.4.3  Restriction digest 
         Restriction endonuclease digestion is part of the cloning strategy, to linearise 
vectors and to verify the presence and orientation of a given insert in a particular 
vector.  Enzymes were obtained from New England Biolabs (NEB) or Promega, UK.  
A typical reaction is shown below.   
Materials 
DNA   1μg 
10X buffer  5μl 
Restriction enzyme 1μl (2-10 units) 
ddH2O   x μl 
total volume reaction 50μl 
 
         Typically the digest was performed at 37 ºC for 2 hours.  The program NEB 
CUTTER V2.0 was used to select the most suitable restriction sites in the desired 
vector.  Double digests were performed in a similar manner in a two step procedure; 
the reaction buffers were selected using information available from manufacturers.   
 
2.4.4  Ligations 
The inserts were incorporated into the plasmid vectors by ligation using T4 DNA 
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ligase and reactions were set up as following: 
T4 DNA Ligase (1-3U/μl; Promega)              1μl 
T4 DNA ligase buffer 10X                        1μl 
(300mM Tris buffer [pH 7.8 at 25ºC], 100mM MgCl2, 100mM DTT and 10mM ATP) 
Vector                                      1μl 
Insert                                      xμl 
ddH2O  to a final volume of 12μl             yμl 
Method 
          The digested vector was gel cleaned as described in section 2.3.10, prior to 
ligation.  Ligation reactions were left overnight at 4ºC. The ratio of insert/vector DNA 
was calculated according to following equation: 
     ng of vector x kb size of insert     x  molar ratio of insert    = ng of insert 
           kb size of vector                                               vector 
 
Optimal molar ratios of insert/vector were 3: to 5:1 
 
2.4.5  Preparation of ampicillin antibiotic plates 
Materials 
Luria Bertani (LB) Agar 9g LB, 8g Agar in 400ml ddH2O 
Ampicillin              final concentration 100μg/ml 
Petri dishes 
 
Method 
         400ml LB agar was freshly prepared and autoclaved.  The broth was left to 
stand at room temperature and was allowed to cool to approximately 37oC.  
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100μg/ml ampicillin was then added and the broth mixed.  Approximately 15-20ml 
broth was then poured into 10cm Petri dishes under a Bunsen burner flame.  The 
plates were then to dried in a 37ºC cabinet and stored at 4oC in a sealed bag for up 
to 1 month.   
 
2.4.6  Transformation of competent bacteria 
Materials 
LB agar plates with 100μg/ml ampicillin  
S.O.C medium (Invitrogen Ltd, UK) or LB broth 
JM 109 E-coli competent cells (Promega, UK) 
DNA sample 
 
Method 
          A 15ml round bottomed polypropylene culture tube was chilled on ice.  100μl 
of JM 109 competent cells, thawed on ice, were pipetted into the 15ml tube.  50ng of 
DNA was added to JM 109 cells and placed on ice for 10 minutes.  The cells were 
heat shocked at 42°C for 45-50 seconds and returned to the ice for another 2min 
before 900 μl SOC medium was added.  The tube was incubated at 37°C for 60min 
with shaking at 225 rpm.   
          The cells were then centrifuged for 5 min at 2000 rpm and the supernatant 
discarded.  The cells were then plated onto an LB ampicillin agar plate and 
incubated overnight at 37°C.  The vector pGEM®-3Z (Promega, UK) was 
transformed as a control plasmid to assess the transformation efficiency of the cells.   
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2.4.7  Bacterial culture 
Materials 
LB broth (9g per 400ml ddH2O) 
Ampicillin (final concentration 100 μg/ml) 
 
Method 
         Each bacterial colony was selected from the LB agar plate with a sterile pipette 
tip and transferred to 5ml of sterile LB broth containing ampicillin.  The transfer of 
the colony to culture has to be sterile and performed under a burning flame.  The 
cultures were incubated overnight at 37ºC in a shaking incubator at 225rpm.   
 
2.4.8  Glycerol stock 
        500 μl of cultured transformed bacterial cells were pipetted into a sterile 
centrifuge tube containing 500μl sterile glycerol (Sigma-Aldrich, UK).  The mixture 
was vortexed well and stored at -70°C.  
 
2.4.9  Plasmid DNA purification 
        The principle of the QIAprep procedure is based on the alkaline lysis method of 
isolation of low molecular weight (plasmid) DNA from bacterial cells.  QIAprep 
columns use a silica membrane for selective adsorption of DNA in the presence of 
high salt buffer.  The DNA is eluted in low-salt buffer or water.  The exact 
composition of the reagent is unavailable.   
Materials 
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QIAprep miniprep kit, QIAGEN 
 
Method 
         Plasmid DNA was purified according to manufacturer’s instruction.  The 5ml 
bacterial culture was centrifuged in a 15ml Falcon tube for 15min at 3000 rpm, at 
4ºC.  After removing the media, the pellet was suspended in 250μl of ice cold Buffer 
P1 (cell suspension solution) and transferred to a 1.5 ml microcentrifuge tube.  Then 
250μl P2 (cell lysis solution) was added and mixed gently.  350μl N3 (neutralization 
solution) was added and mixed gently. 
        The microcentrifuge tube was spun at 13000 rpm for 10minutes.  The 
supernatant was applied to a QIAprep spin column and centrifuged at a maximum 
speed for 30-60seconds.  The flow through was discarded and the column washed 
with 500μl PB solution and then 750μl buffer PE.  The DNA was then eluted in 30-50 
μl ddH2O  and collected in a clean microcentrifuge tube, which was centrifuged for 2 
min at 13 000 rpm.   
 
2.4.10  Site directed mutagenesis 
          DNA mutations, for example to change amino acids in a protein, were created 
by deleting or inserting single or multiple nucleotides.   
Materials 
 
Clontech Advantage® HD Polymerase Mix  (2.5 unit/μl) 
 
Advantage® 5X reaction Buffer (containing 5mM MgCl2) 
 
Dpn-I restriction enzyme 20, 000 units/ml 
 
dNTP mix 10mM   
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Competent JM109  E.coli cells (Promega, UK) 
 
Primer design 
         Two complementary oligonucleotides containing the desired mutation, flanked 
by unmodified nucleotide sequence were synthesised (see Appendix 8.3 for primers 
sequences).  Primers were between 25-35 bases in length.  The desired mutation 
should be in the middle of the primer with ~12-17 bases of correct sequence on both 
sides.   
The sample reaction was prepared as follows: 
 
DNA template     50ng 
Reaction Buffer 5X               10μl 
Oligonucleotide primer 1   125ng 
Oligonucleotide primer 2   125ng 
dNTPs      1μl 
Advantage® HD Polymerase Mix  0.4μl  
ddH2O      xμl 
 
Total volume      50μl 
 
Methods 
           The reaction mixture was subjected to thermal cycling based on the following 
cycling parameters.  Segment 1 was 1 cycle at 95ºC for 30 seconds, followed by 
segment 2 which had 12 cycles of 95ºC for 30 seconds, 55ºC for 1 minute, 68ºC for 
6.5 minutes (1 min/kb of plasmid).  Finally, segment 3 was 1 cycle of at 68°C for 7 
minutes.  This reaction mixture then contained new mutated plasmid containing 
staggered nicks, as well as the original native plasmid.  The mixture was transferred 
to ice for 2 minutes, to ensure that it was below 37ºC, and then 1μl Dpn-I restriction 
endonuclease was added, and the mixture mixed by pipetting, and centrifuged 15 
secs, at 6000X g.  This was then incubated at 37ºC for 60 minutes to digest the 
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parental (nonmutated) DNA leaving only the mutated plasmid product.  5μl of the 
treated DNA was then used for standard bacterial transformation (described in 
section 2.4.6).  The transformed plasmid was then purified (see section 2.4.9) and 
the presence of the desired mutation confirmed by direct sequencing (see section 
2.3.11).      
 
 
  ---1 cycle 
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2.5   Protein analysis and protein-protein interaction 
2.5.1  Protein extraction 
To detect mutant MC2R protein in transfected cells and for co-
immunoprecipitation assays, total protein was extracted from confluent cells, grown in 
75 cm2 plates.   
Materials 
n-Dodecyl-β-D-maltoside  - Sigma-Aldrich, UK 
Protease inhibitor cocktail (Roche, cOmplete) [chymotrypsin 1.5μg/ml, thermolysin 
0.8μg/ml, papain 1mg/ml, pronase 1.5Mg/ml, pancreatic extract 15μg/ml, trypsin 
0.2μg/ml, one table dissolved in 50 ml PBS]  
PBS pH 7.4  
Sample buffer (see section 2.5.2) 
 
Method 
Cell lysis buffer was prepared from chilled PBS + 0.1% n-Dodecyl-β-D-
maltoside + protease inhibitor cocktail, a fresh buffer for each cell lysate preparation.  
Cells in 75cm2 tissue culture dish were washed in cold PBS three times and aspirated.  
Cells were then frozen at -70ºC for at least 15 min to assist with cell lysis.  500-800μl 
ice-cold cell lysis buffer was then added to the dish.  Cells were scraped and collected 
in a 1.5ml microcentrifuge tube, followed by dispersion with a syringe and G23 needle.  
Cells were incubated on ice for 30min.  The lysed cells were then centrifuged at 13 
000 rpm at 40C for 30minutes.  Supernatant was collected and stored at -70°C until 
required.   
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2.5.2  Preparation of buffers 
2X Sample buffers (SDS reducing buffer)   
Distilled water       2.8ml 
0.5M Tris-HCl, ph 6.8  1ml 
Glycerol   2ml 
10% (w/v) SDS  1.6ml 
2-β-mercaptoethanol  0.4ml 
0.05% Bromophenol blue 2μl 
Alloquot into 1.5 ml centrifuge tubes and freeze -20°C.    
 
Washing buffer 
PBS tablet   5 tablets + 1L water 
Tween-20 (Sigma-Aldrich) 0.5ml 
Mixed together and stored at room temperature 
 
5X Transfer buffer 
For 400ml mixed in ddH2O 
Tris base    6g 
Glycine   28.8g 
 
Dissolved the mixture and stored at room temperature 
Add 20% methanol and dilute in water immediately prior to use.   
 
 
Blocking buffer 
 
5% (w/v) reduced fat milk powder  (Marvel) 
Washing Buffer 
 
 
2.5.3  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The specific composition of the Invitrogen running buffers or Bis- Tri Gels were 
not available.   
Materials  
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Protein ladders – Prestained protein marker, broad range (6-175 kDa) – New England 
Biolabs, UK or rainbow molecular weight markers (10-250 kDa) – Amersham, UK 
MES (2-[N-Morpholino]ethanesulfonic acid) or  
MOPS (3-[N-morpholino]propanesulfonic acid)  SDS Running buffer (20X)- Invitrogen 
NuPAGE® 
MOPS/SDS is for proteins greater than 200 kDa to 14 kDa or MES/SDS for proteins 
between 25 to 60 kDa.   
10-12% Bis-Tri Gel – Invitrogen NuPAGE® 1.00mm X 10-12 wells 
XCell SureLock® Mini-Cell – Invitrogen, UK 
 
Method 
The protein samples were mixed with an equal amount of 2X loading buffer in 
a 1.5ml centrifuge tube.  SDS is an ionic detergent which coats the protein 
proportional to their molecular weight and the resultant negative charge allows the 
proteins to separate on a gel based on their size.  The samples were heated at 95ºC 
for 5min, to denature the protein complexes, centrifuged briefly and loaded into pre-
cast 12% gels (when blotting for MRAP-Flag).  In some cases denaturing was 
performed at room temperature for 30 min, specifically to improve resolution of 
GPCRs on gels.  Samples were run alongside protein markers to enable an 
approximation of the molecular weight of identified proteins.  Using a XCell 
SureLock® Mini-Cell, proteins were separated by SDS-PAGe at 120 V, until the dye 
front reached the bottom of the gel.  MES/SDS buffer was used for MRAP blotting and 
MOPS/SDS buffer was used for GPCR blotting.   
 
2.5.4  Protein transfer 
Materials 
Washing buffer (see section 2.5.2) 
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Hybond-P TM hydrophobic polyvinylidene Difluoride (PVDF) membrane – Amersham, 
UK 
Extra thick blotting paper- Bio-Rad Laboratories, CA, USA 
Transfer buffer (see section 2.5.2) 
Trans-Blot SD Semi Dry Transfer Cell – Bio-Rad Laboratories Ltd, UK 
Ponceau S stain (0.2% (w/v) Ponceau S + 1% Acetic acid) 
 
Method 
After running the gel, protein transfer was effectively achieved using a semi 
dry-transfer technique.  Two sheets of Bio-Rad thick blotting paper were soaked in 
transfer buffer.  A piece of PVDF membrane, cut to size was soaked in water.  A 
Trans-Blot SD Semi Dry Transfer Cell was used for protein transfer according to the 
manufacturer’s instructions.  The semi-dry blotter was run for approximately 30 min at 
15V with a current of 0.4 A per gel.  After transfer the membrane was removed and 
the transfer of proteins was determined using Ponceau S stain.   
 
2.5.5  Immunoblotting 
Materials  
Blocking buffer (see section 2.5.2) 
Monoclonal anti-Flag M2 antibody produced in mouse (Sigma-Aldrich, UK)           
Monocloncal anti-HA antibody produced in mouse (Sigma-Aldrich, UK) 
Rabbit Anti-GAPDH polyclonal antibody (Santa Cruz Biotechnology Inc, Germany)         
IRDye 800CW goat anti-mouse antibody, 800CW goat anti-rabbit or 680CW goat anti-
mouse  (LICOR, bioscience)                    
LICOR Odyssey reader -a fluorescence-based detection method for western blotting 
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Method 
The transferred membrane was incubated with blocking buffer over night at 
4ºC or at least 2hrs at room temperature, with gentle agitation.  The membrane was 
incubated with primary antibodies for 1.5 – 24 hours (mouse anti-Flag mouse or 
mouse anti-HA or rabbit anti-GAPDH antibody) at 1:1000.  The membrane was 
washed thoroughly with washing buffer and then incubated with the appropriate 
secondary antibodies for 1 hour (for example, 800Hz mouse 1:10000), in the dark in a 
blacked out box.  The membrane was then washed thoroughly with washing buffer 
and was ready for scanning with the LICOR Odyssey reader.   
 
2.5.6  Re-probing Western blots 
To determine the total protein loaded in each lane, blots required further 
probing with rabbit polyclonal GAPDH antibody.  The probed membrane was washed 
in washing buffer for 30 min with gentle agitation.  This was follow by immunoblotting 
with GAPDH antibody as described in section 2.5.5.   
 
 
2.5.7  Co-immunoprecipitation 
Materials 
Cell lysis buffer (see section 2.5.1) 
Monoclonal anti-HA agarose conjugate, Clone HA-7 (Sigma-Aldrich, UK) 
Anti-Flag M2 Affinity gel (Sigma-Aldrich, UK) 
Monoclonal anti-Flag M2 antibody produced in mouse (Sigma-Aldrich, UK)           
Monocloncal anti-HA antibody produced in mouse (Sigma-Aldrich, UK) 
Sample buffer (see section 2.5.2) 
Washing buffer (see section 2.5.2) 
 
Chapter 2 – Materials and Methods 
      
92 
 
Method 
The agarose was washed 3 X in 1ml PBS and after each wash the agarose 
was centrifuged at 4 000 rpm for 1 min.  The PBS was discarded carefully leaving the 
agarose intact.  500μl of cell lysate previously prepared (as described in 2.5.1) was 
added to 30μl agarose beads in a microcentrifuge tube and placed on a rolling rotor 
overnight at 4ºC.  The following day, the agarose was washed 5 X in 1ml PBS.  With 
the last two washes lasting for 20 – 30 min.  On the last wash approximately 10μl 
supernatant was left after removing the PBS from the agarose.  40μl sample buffer 
was added and to the sample and boiled for 3 min.  The samples were then 
centrifuged at 13 000 rpm for 1 min.  The supernatant was then ready for 
immunoblotting as described in section 2.5.3.   
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2.6  Functional studies 
2.6.1  Cell surface assay 
Materials 
For transfection (refer to section 2.2.5) 
200ng plasmid 
2µl lipofectamine per well (in 24 well plate) 
For cell surface assay 
Triton 0.025% (Sigma-Aldrich, UK, Triton X-100) diluted in PBS 
Monoclonal Anti-HA (mouse IgG1 isotype) (Sigma-Aldrich, UK) 
LI-COR® Bioscience Blocking Buffer 
LI-COR® Bioscience IRDye®800CW Conjugated Goat Anti-Mouse IgG   
PBS (PBS tablets, Sigma-Aldrich, UK) 
3.7% paraformaldehyde (PFA) (BDH,UK)  
 
Method 
         After cells were transfected for 24-48hrs in 24 well plates, all medium was 
discarded, and the cells were washed with PBS for 5 min twice.  The cells were fixed 
with 200 μl 3.7% PFA for 10min and then washed for 5 min twice with PBS.  To 
permeabilise cells, 200 μl 0.025% triton was added for 10 minutes.  Again cells were 
washed twice in PBS.  The plates were then blocked for 1 hour with LI-COR® 
blocking buffer at room temperature, followed by incubation with 200μl mouse anti-HA 
(1:1000) antibody diluted in blocking buffer for one hour.  After two further washes 
with PBS, cells were then incubated with 200μl of the secondary antibody 
IRDye®800CW (1:1000) diluted in blocking buffer.  This step was performed at room 
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temperature but in darkness (plates were foiled).  Again they were washed with PBS 
(2X) and then the plates were scanned using LI-COR® Odyssey plate reader.   
The quantification of cell surface expression of the receptors was calculated by 
the ratio of the signal from unpermeabilised and permeabilised cells.  The theory is 
outlined in figure 2.3.   
Cell expression ratio = Unpermeabilised reading – background reading 
      Permeabilised reading – background reading 
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Figure 2.3:  Cartoon illustration of cell surface assay.  Cell surface expression was 
quantified by cell surface assay and assyed using a LICOR Odyssey plate reader.  Cell 
surface expression was normalised for transfection efficiency by determining the ratio 
of the unpermeabilised to the permeabilised signal.   
 
2.6.2  Luciferase Assay 
Genetic reporter systems are widely used to study eukaryotic gene expression 
and cellular physiology.  Applications include the study of receptor activity, 
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transcription factors, intracellular signalling, mRNA processing and protein folding.  
Dual reporters are commonly used to improve experimental accuracy.  Promega’s 
Dual-Luciferase Reporter Assay System assays the activities of firefly (Photinus 
pyralis) and Renilla (Renilla reiformis, also known as sea pansy) luciferases which are 
measured sequentially from a single sample.   
After stimulation of a Gs linked 7 transmembrane receptor, intracellular 
signalling leads to cAMP production and the subsequent phosphorylation of the 
transcription factor CREB (cAMP response binding protein).  Phosphorylated CREB in 
turn upregulates the transcriptional activity gene promoters containing cAMP 
response elements (CRE).  By using a construct containing a luciferase gene under 
the control of a promoter containing a CRE, the subsequent luciferase activity 
produced gives a direct indication of the amount of cAMP produced by the stimulus.  
The transfected renilla plasmid is constitutively active and the renilla activity serves as 
a control for transfection efficiency for each sample.   
Cell extractions were carried out with 150μl Passive lysis buffer.  The 
luciferase assay was performed by adding 80μl of the dissolved luciferase substrate to 
the cell lysate.  Luciferase in cell lysate catalyzes the chemiluminescent reaction, 
which emits light (560nm) constantly for several minute, the emitted light is measured 
with a luminometer, Lumistar Omega (BMG Labtech, Germany).  After recording the 
luciferase activity, 80μl of the Stop and Glo reagent was added, which simultaneously 
quenched the luminescence from the firefly luciferase and activated the luminescence 
from the renilla luciferase, which was then quantified.  Because of the different 
substrate requirements of the two types of luciferase, it was possible to distinguish 
between the different bioluminescent reactions.   
Materials 
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For transfection in 6 well plates 
pRL-CMV Renilla luciferase plasmid (Promega, UK)  - 100ng/well 
α GSU-846 luciferase plasmid – 1000ng/well 
DNA plasmid of interest – 1000ng/well 
For luciferase assay 
Luciferase assay buffer 
Luciferase assay substrate  
Stop & Glo® buffer (Promega) 
Stop & Glo® substrate (Promega) 
Passive Lysis Buffer (5X) (Promega) 
Luciferase assay reagent was prepared by resuspending the lyophilized Luciferase 
assay substrate in 10ml Luciferase assay buffer.  This was stored at -70ºC.  Stop & 
Glo substract was added to Stop & Glo buffer and stored -70ºC.   
Method 
Cells were co-transfected with αGSU-846 luciferase and pRL-CMV Renilla luciferase 
plasmid along with MC2R or mutant MC2Rs.  After 24-48hours of transient 
transfection, cells were washed with PBS.  Stimulations were carried out using ACTH 
(10-7M) for 7 hours. The medium was removed and the cells were washed in PBS 
before harvesting with 150μl/well lysis buffer.  The samples were collected in a 
centrifuge tube and centrifuged at 13 000 rpm for 10 min.  25 μl samples were plated 
in opaque black 96 well plates.  Using the Lumistar Omega with the appropriate 
setting, 80μl luciferase and 80μl Stop and Glow reagent were used for each sample. 
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2.7  Confocal microscopy 
The key feature of confocal microscopy is its ability to produce in-focus images 
of thick specimens, a process known as optical sectioning. It produces images of the 
cells in a single plane.   
Materials 
 
3.7% formaldehyde  
0.25% Triton-X-100 (Sigma-Aldrich, UK) 
PBS 
Blocking buffer - 3% BSA, 10% donkey serum in PBS 
Monoclonal mouse Anti-HA antibodies (Sigma-Aldrich, UK) 
Cy TM 3-conjugated AffiniPure Donkey anti-mouse antibody (1:100) – Jackson 
ImmunoResearch  
4’, 6-diamidino-2-phenylindole (DAPI) 
Fluorescent mounting media 
 
Method 
CHO α1 cells were seeded into 12 well plates with a sterile cover slip 
previously placed in each well bottom.  Transfection was performed for 24 hours  with 
wt and mutant MC2R constructs N terminally -3XHA tagged and empty vector.  The 
media was removed and the cells were washed 3X with PBS.  Cells were then fixed 
using 3.7% formaldehyde in PBS for 10 min.  The cells were permeabilised after 
incubation with 0.25% Triton for 10 min.   After three more washes with PBS (10 min 
per wash), the cells were incubated with blocking buffer (3% (w/v) BSA, 10% (v/v) 
donkey serum in PBS) for 1 hour.  Incubation with appropriate primary antibody (for 
example, mouse anti-HA, polyclonal rabbit anti-Calnexin antibody) was performed at a 
dilution of 1:200 at room temperature for 90 min.  The cells were rinsed for 3X 10 min 
washes in PBS, followed by incubation with appropriate secondary antibody (for 
example, Cy2/Cy3-conjugated donkey secondary antibody) at a dilution of 1:100 for 1 
hour at room temperature.  Thorough washes with PBS were critical between each 
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step.  The nuclei were stained for 1 min with PBS containing 2 μg/ml DAPI (1 in 
5000).  The cover slip was then removed carefully onto a clean slide and mounted it 
with drops of fluorescent mounting media, DakoCytomation Fluorescent Mounting 
Medium (DAKO).  Fluorescence images were taken using a Zeiss LSM 510 confocal 
microscope.  The slides were stored at 4ºC in the dark.   
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3.1 Introduction 
Familial Glucocorticoid Deficiency (FGD) is a rare autosomal recessive disease which 
is characterized by isolated glucocorticoid deficiency and ACTH resistance; 
presenting features include  severe neonatal hypoglycaemia, frequent childhood 
infection and excessive skin pigmentation (Shepard et al. 1959; Franks & Nance 
1970; Clark & Weber 1998).  This is a genetically heterogeneous disorder with 
mutations in the ACTH receptor (Melanocortin 2 receptor, MC2R) accounting for 
approximately 25% of cases of FGD (Clark et al. 1993; Tsigos et al. 1993; Weber et 
al. 1995; Clark et al. 2005) and this is referred to as FGD type 1 (OMIM 202200).   
MC2R is one of five melanocortin receptors (Mountjoy et al. 1992).  It is a 297 amino 
acid seven transmembrane receptor, the smallest of all G protein-coupled receptors 
(GPCRs); it is expressed predominantly in adrenocortical cells and is highly specific 
for ACTH, which stimulates the production of glucocorticoids.  Earlier studies on 
MC2R were hampered by significant difficulties in expressing this GPCR in 
heterologous cells.  The MC2R cDNA is transcribed and translated from transfected 
expression plasmids, but the protein product fails to traffic from the endoplasmic 
reticulum (ER) (Noon et al. 2002).  The observation that human MC2R could be 
expressed in cells of adrenal origin but which lack endogenous melanocortin 
receptors (the mouse Y6 and OS3 cell lines) (Yang et al. 1997; Elias et al. 1999; 
Swords et al. 2002), has led to the hypothesis that a cofactor for expression is 
required.  Identification of the genetic cause of a second form of FGD (FGD type 2) 
led to the identification of a novel gene encoding a single transmembrane domain 
protein, named Melanocortin 2 receptor accessory protein (MRAP) which appears to 
fulfil this role.  MRAP interacts with MC2R and facilitates the trafficking of the receptor 
from ER to the cell surface (Metherell et al. 2005; Cooray et al. 2008). 
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The discovery of MRAP now provides the opportunity to characterise fully the MC2R 
in readily transfected and maintained cell lines, such as Chinese hamster ovary 
(CHO) and human embryonic kidney 293 (HEK293) cells, both of which are known not 
to endogenously express melanocortin receptor (MCR) and to be unresponsive to 
ACTH and NDP-MSH (Blondet et al. 2004; Rached et al. 2005).  This MCR-free 
system allows the complete characterization of naturally occurring mutations enabling 
the analysis of cell surface expression and signal transduction.   
Previous studies have shown that some of these mutations have impaired ligand 
binding and cAMP signalling, but the mechanisms for this defect were not 
investigated. This comprehensive analysis of MC2R mutations is the first study to 
examine the effect of the clinically identified mutations on both receptor trafficking and 
signal transduction.   
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3.2 Aims  
Naturally occurring MC2R mutations found in FGD type 1 have been known for some 
time, however the functional consequences of these mutations remains poorly 
understood.  The main aim of this chapter was to establish the molecular basis in the 
impairment of function of MC2R mutations found in FGD.  In order to achieve this goal 
the following steps have been taken.   
1. The first objective was to establish a stable cell line expressing MRAP in non-
adrenal cells (CHO and HEK293), which would gives a readily transfectable 
system that is free of other MCRs.  This allows complete characterisation of 
MC2R mutations to begin.   
2. Assessment of cell surface expression of the epitope-tagged MC2R missense 
mutations was to be determined by using cell surface assay and observing the 
localisation of these receptors using confocal microscopy.  This will determine 
the group of mutations which are either trafficking-defective or trafficking-
competent.   
3. For those receptors that reach the cell surface efficiently, receptor function will 
be characterised by ACTH binding and cAMP generation in response to 
ACTH.   
4. For the mutations which are trafficking-defective, it is possible that there could 
be interference with MRAP interaction, which could be investigated by co-
immunoprecipitation of MC2R with MRAP.   
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3.3 Materials and Methods  
All methods below have been outlined in detail in Chapter 2.  The techniques used 
and the specific antibodies for this study are briefly mentioned below. 
3.3.1 CHO and HEK293 stable cell lines expressing human MRAPα 
Human MRAPα amplified from human adrenal cDNA (Ambion) was subcloned into 
pcDNA3.1(+) vector (Invitrogen).  CHO cells were grown in DMEM/Ham’s F12 (1:1); 
HEK293 grown in DMEM, both with 10% foetal bovine serum and 
penicillin/streptomycin.  Expression of MRAPα mRNA in the selected stable cell lines 
was confirmed using RT-PCR.  In addition, the cell surface assay with wild-type 
hemagglutinin (HA) epitope tagged at the N-terminus MC2R (Wt-HA-MC2R) was 
performed to ensure cell surface expression of MC2R.   
3.3.2 Site directed mutagenesis 
Mutant MC2R expression constructs were generated by site-directed mutagenesis 
(QuickChange®II XL) using human Wt-HA-MC2R (Missouri S&T cDNA Resource 
Center) as template.  Primer sequences are specified in the appendix 8.3.  The entire 
mutant MC2R constructs were then sequenced to confirm the presence of specific 
mutations and ensure the absence of unwanted errors.   
3.3.3 Cell surface assay 
Briefly, CHO cells stably expressing MRAPα (CHOα1) were seeded in 24 well plates 
and transfected with Wt-HA-MC2R or mutated HA-MC2R.  Both permeabilised and 
unpermeabilsed plates were blocked with Odyssey® Blocking buffer (LI-COR) for 1 
hour, followed by incubation with anti-HA antibody (1:1000) for 1 hour.  Infrared-
labelled secondary goat anti-mouse antibody was then added at 1:1000 (Odyssey® 
Goat anti-mouse IR Dye @800CW) for one hour.  The plates were then analysed with 
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the LI-COR Odyssey® plate reader (800nm) after thorough washes.  The relative 
values of cell surface expression of the receptors were calculated by the ratio of 
unpermeabilised and permeabilised cells which was then normalised to wild type 
expression in each experiment.   
3.3.4  Immunoblotting and co-immunoprecipitation 
Interaction of mutated MC2R with MRAPα was assessed by co-immunoprecipitation 
(Co-IP) and immunoblotting as previously described (Metherell et al. 2005; Cooray et 
al. 2008) CHO cells were transiently transfected with MRAPα-Flag, and mutant HA-
MC2R constructs and twenty four hours after transfection, cells were lysed with 0.1% 
D-dodecyl-β-maltoside in PBS in the presence of protease inhibitors.  Anti-HA 
agarose conjugate beads (Sigma) were added to the cell lysate and incubated 
overnight, at 4°C.   The beads were collected, washed thoroughly and resuspended in 
SDS sample buffer before heating at 95ºC for 10 minutes.  The samples were then 
subjected to immunoblotting using anti-Flag (Sigma) antibodies at a dilution of 1:2000, 
followed by secondary antibody incubation (IRDye 800CW Goat Anti-Mouse IgG, LI-
COR) at 1:10000 for 1 hour and imaged with LI-COR’s Odyssey Infrared Image 
System.   
3.3.5  Confocal microscopy  
CHOα1 cells were seeded into 12 well plates containing sterile cover slips and 
transfected with either Wt-HA-MC2R, empty vector or mutated HA epitope-tagged 
MC2Rs for 24 hours.  After non-specific blocking, the cells were then incubated with 
mouse anti-HA antibody (1:200 dilution in buffer A) for 90 minutes.  This was followed 
by incubation with Cy™3-conjugated Donkey anti-mouse antibody 1:100 (Jackson 
ImmunoResearch, PA, US) for 1 hour.  For co-localization with the ER, fixed and 
permeabilised cells were incubated with rabbit anti-calnexin antibodies 1:300 (Sigma) 
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and anti-HA antibody 1:200 in blocking buffer for 90 minutes.  Secondary antibody 
incubation was performed with CyTM3 (mouse) at 1:100 and CyTM2 (rabbit) at 1:50 
(Jackson ImmunoResearch, PA, US) for 1 hour.   Nuclei were stained with PBS 
containing 2μg/ml DAPI, 4’,6-diamidino-2-phenylindole.  The cover slips were then 
carefully placed onto a clean slide and mounted with drops of fluorescent mounting 
media.  Fluorescent images were taken using a Zeiss LSM 510 confocal microscope. 
3.3.6  cAMP reporter assay 
Stable HEK293 MRAPα (HEKα7) cells grown to 70-80% confluence in 6 well plates 
were transfected with 1000ng of receptor expression plasmids along with 900ng 
αGSU-846 luciferase and 100ng pRL-CMV Renilla luciferase plasmid constructs 
(Cooray et al. 2008).  24-48 hours after transfection, cells were stimulated with ACTH 
(10-7M) for 6 hours.  Cell lysates were collected and assayed using the Dual luciferase 
reporter assay system (Promega).  Luciferase activity was measured using a 
multiplate reader (Lumistar Omega BMG Labtech), and values were normalised to the 
Renilla luciferase activity.   
3.3.7  Statistical analysis 
The data reported are the mean ± SEM of at least three independent experiments, 
performed in duplicate.  Statistical comparison was performed using unpaired two-
tailed Student’s t-test, and P values are indicated as *, P<0.05; **, P<0.01; ***, 
P<0.0001.  
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3.4   Results 
3.4.1  Establishing stably expressing MRAP cell lines 
The rationale for creating stable hMRAP cell lines is to establish a system free of 
other melanocortin receptors which has consistent hMRAP expression and have good 
transfection efficiency.  As discussed in Chapter 1, Y6 and OS3 cell lines, derived 
from the mouse Y1 adrenal cell line (Schimmer et al. 1995; Rainey et al. 2004) are the 
only cell lines which provide reasonable expression of the MC2R with no other 
interfering melanocortin receptors.  The disadvantage is that these cells transfect 
poorly.  Both CHO and HEK293 cells have been readily used in the studies of other 
GPCRs, and they have no endogenous MCRs or hMRAP (PCR shown in figure 3.3) 
(Noon et al. 2002; Rached et al. 2005).  In order to use CHO and HEK293 cells to 
study MC2R mutations, it was first necessary to introduce MRAP into them to allow 
cell surface expression and activity of the introduced receptor.  Transient transfection 
of hMRAP into these cells is possible, but will introduce transfection variability 
between experiments and is also time consuming.  Stable cell line is therefore thought 
to be a better and more efficient alternative.   
The hMRAP expression vector contained a neomycin resistant gene and cells 
containing this plamid were selected for their resistance to G418.  As a first step, a 
cytotoxicity titration curve was required to establish the minimal concentration leading 
to cell death at approximately 7-10 days.   
3.4.1.1  Antibiotic titration curve for CHO cells 
G418  dose  (μg/ml) Day on which no viable cells seen 
0 No cell death 
600 14 
Chapter 3 – MC2R mutations in FGD1 
     
107 
 
800 9 
1000 7 
 
Table 3.1: G418 cytotoxicity titration curve for CHO cells.  Cytotoxicity was noted daily 
for each antibiotic dose.  
Cells were plated out into 6 well plates and were treated with various doses of G418.  
Cytotoxicity was judged by daily microscopic inspection. The optimal cytotoxic dose of 
G418 is when complete cell death is evident between days 7 to 10.  In CHO cells, 700 
μg/ml G418 dose was chosen for stable cell selection. 
 
3.4.1.2  Antibiotic titration curve for HEK 293 cells 
G418  dose  (μg/ml) day on which no viable cells seen 
1000 No cell death 
1200 No cell death 
1400 14 
1600 12 
 
Table 3.2: G418 cytotoxicity titration curve for HEK 293 
   
Cytotoxicity was more difficult to achieve in HEK 293 cells compared to CHO cells.  A 
higher dose of antibiotic was required to attain complete cell death.  A concentration 
of 1500 μg/ml G418 was chosen for stable cell selection in HEK 293 cells.   
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The cloning of the constructs for hMRAP α cDNA in pcDNA3.1(+) have been 
described in Materials and Methods section (Chapter 2).  These constructs were 
confirmed on sequencing.   
CHO and HEK 293 were transfected with hMRAP α, as well as empty pcDNA3.1(+).  
Antibiotic selection with G418 700 μg/ml for CHO transfected cells and for HEK 293 
1500 μg/ml were used and colonies were visible after 21 days of antibiotic treatment.   
Clones of CHO hMRAP α were selected with the dilutional method (as described in 
Chapter 2.2.5.3).  After the colonies were selected, they were tested based on: 
1. To confirm the function of the stable cell line, cell surface assay was used. 
The function was tested using cell surface expression of wild type 3XHA-MC2R (N 
terminal).  A functional colony should express MC2R at the cell surface 
adequately.  This cell surface expression should be comparable to wild type cell 
lines (CHO or HEK293) transiently co-transfected with MRAP α  and HA-MC2R.   
 
2. The mRNA expression of these cells was confirmed with RT-PCR for hMRAP.   
 
 
Figure 3.1: Selection of stable MRAPα CHO cells.  Wt-HA-MC2R transiently transfected 
(in triplicate) into various potential stable cell lines (α1, 2, 4, 5 and 6).  Transient 
transfection of Wt-HA-MC2R in wild type CHOs  cotransfected with hMRAPα acts as the 
Chapter 3 – MC2R mutations in FGD1 
     
109 
 
positive control and empty vector as negative control.  Additional negative controls with 
mock transfection in wild type CHOs were also used.  As this experiment was a 
screening technique to select the best stable cell line it was only performed once.   
 
 
Figure 3.2: Selection of stable MRAPα HEK 293 cells.  Wt-HA-MC2R transiently 
transfected (in triplets) into various potential stable cell lines (α1, 2, 5, 6, 7, 8 and 12).  
Transient transfection of Wt-HA-MC2R in wild type wild type HEK 293 and cotransfected 
with hMRAPα act as the positive control and empty vector as negative control. 
 
The cell lines which demonstrated the best functionality when compared with 
transiently transfected MRAP α were selected and used for the rest of the 
experiments (Figure 3.1 and 3.2).   
 
3.4.1.3 RT-PCR confirmation of MRAP expression 
In the absence of an antibody to detect human MRAP, the expression of MRAP in 
these cell lines was confirmed by RT-PCR.    
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cDNA was made from each of the selected stable cell lines and PCR was performed 
using MRAP specific primers.  
 
 
 
 
 
 
Figure 3.3: RT-PCR showing MRAP expression.  1% agarose gel showing RT-PCR using 
primers specific for hMRAPα and hMRAPβ.  Lanes are labelled with various stable cell 
lines, CHOα1, CHOβ2(B), HEKα7 and HEKβ1. The corresponding RT +/- (reverse 
transcriptase), RT- is to demonstrate the lack of genomic DNA in each sample.  Positive 
controls are MRAPα and β vectors and negative control are wild type CHO and HEK 293.   
 
All the selected cell lines demonstrated mRNA expression for the relevant MRAP. The 
wild type CHO and HEK confirmed to have no MRAP expression.  The presence of 
human MRAP α is indicated by gel electrophoresis band at 519 bp and MRAP β at 
309 bp.  Only MRAP α cell lines were used, as MRAP α is thought to have the similar 
action to MRAP β.   
The selected stable cell lines, CHO α1 and HEK α7 were confirmed to have both 
mRNA expression and the best functionality of hMRAP α that is comparable with 
transiently transfected MRAP.     
CHO  α1 CHO β2(B) HEK  β1HEK  α7CHO  wt HEK wt hM R A P
RT + + + + + +- - - - - - α β
519bp
309bp
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3.4.2  Site directed mutagenesis of missense mutations 
Having established a heterologus MCR free system in which to study MC2R receptor 
activity it was now necessary to generate expression clones for the different MC2R 
mutants to be tested.  Wild type HA tagged MC2R was used for site directed 
mutagenesis for all naturally occurring missense mutations, except for M1K (as this is 
a non translatable protein).  A schematic diagram demonstrating the position in the 
receptor of all 24 missense mutations used in this study has previously been shown in 
Figure 1.6.  The list of the mutations is shown in Table 3.3.  The introduction of each 
mutation was confirmed by sequencing.  
 
 
Figure 3.4: Sequencing for D20N and R146H mutations.  Illustration of sequencing 
results for D20N and R146H which verifies the presence of introduced mutations.  The 
other 22 mutations were also confirmed by sequencing (sequencing data not shown).     
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D20N R128C H170L 
I44M Y129C L198P 
L55P I130N G226R 
S74I R137W A233P 
D103N H139Y C251F 
D107N R146H Y254C 
G116V T152K S256F 
S120R T159K P273H 
 
Table 3.3: List of all missense mutations in MC2R studied.   
 
3.4.3  Cell surface expression of MC2R mutations 
CHOα1, described in section 3.4.1, was chosen for its adherence properties 
and good transfection efficiency compared to HEKα7 (which also have good 
transfection efficiency, but poor adherence).  Adherence of cells is important, as this 
assay requires multiple washes.   
CHOα1 was used as a host for transient transfection of either N-terminal 
tagged HA Wt-MC2R or each of all 24 HA-MC2R missense mutations.  A cell surface 
assay was used to monitor cell surface expression of epitope-tagged MC2Rs to the 
plasma membrane by detection of fluorescent signals as described in chapter 2.  
Assays were performed in duplicate and in at least three independent experiments.  
The transfection efficiency was corrected to overall expression of receptors in 
permeabilised cells.  Each experiment was performed with wild type MC2R and 
expressed as a relative ratio to wild type, this is to correct for the variability of 
fluorescent readings between experiments.   
An occasional problem with this assay was the variability of the result between 
assays, for example for wild type MC2R, the variable readings of the unpermeabilised 
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/ permeabilised ratio (range 0.34 – 0.76; n=5) were noted.  Visual inspection of the 
emitted fluorescence from the plate, indicated that cell surface expression was 
definitely present in the wild type and was more prominent when compared with 
mutants.  The relative ratio of expression were normalised to wild type in order to 
compare between experiments.  The pitfalls of the assay were poor cell adherence 
after multiple washes, inadequate washes giving a high background reading and 
variable transfection efficiencies between experiments.  Therefore gentle but thorough 
washes were essential to perfect this technique.    
The data presented in Figure 3.5 shows that the majority of the mutations 
failed to reach the cell surface.  Eighteen out of 24 MC2R mutations demonstrated 
varying degrees of intracellular retention when compared with wild type.  These are 
subsequently referred to as the trafficking-defective mutations. S74I and T152K 
showed some degree of intracellular retention which did not reach statistical 
significance.  The trafficking defective mutations appear to be located throughout the 
receptor but those located towards the C-terminus appear to be more affected.  
Furthermore, with the exception of R128C, majority of the trafficking-competent 
mutations are located in close proximity to or within the extracellular loops.   
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Figure 3.5:  Results of cell surface assay for all 24 missense mutations.  The cell 
surface assay was used to quantify cell surface expression comparing Wt-HA-MC2R 
with all 24 MC2R missense mutations.  The quantified relative values of cell surface 
expression are shown (n=3). *,P<0.05; **, P<0.01; ***, P<0.0001,  relative to Wt-HA-MC2R.  
The majority of MC2R mutations had significant reductions in cell surface expression.  
There is only partial cell surface expression in S74I, I130N and T152K, but there is no 
significance difference when compared with wild type.   
 
To independently verify the results of the cell surface assay, confocal analysis of 
CHOα1 cells expressing HA-MC2R mutants was performed (Figure 3.6).  Wild type 
MC2R displayed efficient cell surface expression in permeabilised cells.  Similarly 
D103N and R128C showed substantial plasma membrane expression, as did the 
other mutants which reached the cell surface, (D20N, I44M, D107N and H170L-data 
shown in appendix 8.5A and 8.5B).  The trafficking-defective mutants such as R146H, 
T159K and Y254C (Figure 3.6 D, E and F) exhibited marked intracellular retention 
consistent with the results from the cell surface assay.  These mutants demonstrate 
ER retention, as exemplified by T159K which co-localises with the ER marker calnexin 
(Figure 3.6 J, K and L).  The other trafficking-defective mutants displayed similar 
findings (data not shown). The majority of these mutations lie within the 
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transmembrane domain (10/18) and second intracellular loop (5/18) (Figure 3.7 A).  
The S74I, I130N (Figure 3.7 G and H) and T152K demonstrated partial trafficking 
impairment, which did not reach a statistically significant difference on cell surface 
assay.   
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Figure 3.6: Confocal analysis of MC2R mutants in permeabilised stable CHOα1.  CHOα1 
cells were transiently transfected with A: Wt-HA-MC2R (positive control); B: D103N; C: 
R128C; D: R146H; E: T159K and F: Y254C; G: S74I and H: I130N.  I: Wt-HA-MC2R in 
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MRAP negative cells was used as the negative control.  J, K and L: T159K mutation (red) 
co-localises with ER marker, calnexin (green).  Cells were incubated with anti-HA 
antibody (red) and DNA was stained with DAPI, 4’,6-diamidino-2-phenylindole (blue).  
Representative images are shown.  The scale bar represents 10μm.   
 
The confocal analysis of MC2R mutants correlated with the results from cell surface 
assay.  In the confocal study, all trafficking-competent mutations showed convincing 
evidence of receptor expression at cell surface, such as D103N and R128C.  All the 
trafficking-defective mutations identified in Figure 3.6 failed to display convincing 
receptor plasma membrane localisation eg: I 130N, R146H, T159K and Y254C.  
Furthermore, the trafficking defective mutations eg T159K colocalised with calnexin, 
which suggests that they are localised within the ER.  The confocal images of the 
other mutations can be found in the appendix (8.5A and B). 
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Figure 3.7: Pseudostructural plot of the MC2R mapping the locations of the 18 
trafficking-defective mutations in A and the 6 trafficking-competent mutations in B.   
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The positions of the trafficking-defective and trafficking-competent mutants were 
mapped onto the MC2R.  Of the six mutants with intact trafficking function, three are 
located in the extracellular domain of MC2R (Figure 3.7 B).  Interestingly, one of the 
trafficking-competent mutation located within the 2nd  intracellular loop of the MC2R is 
the R128 substitution (R128C), which lies within the highly conserved DRY 
(Asparagine-Arginine-Tyrosine) motif, which is required for G protein coupling and 
activation (Zhu et al. 1994; Jones et al. 1995).   
 
3.4.4  Signalling function of the trafficking-competent mutants 
To determine whether there is a loss of MC2R signalling in the mutants 
expressed at the cell surface, HEKα7 cells were transfected with either Wt-HA-MC2R, 
untagged Wt-MC2R or mutant HA-MC2R and stimulated with ACTH 10 -7 M.  Cellular 
cAMP accumulation was analysed to assess receptor activity.  The stable HEK cells 
were chosen in place of the CHOα1 because of their high levels of transfection 
efficiency, protein expression and good cAMP responsiveness, but less adherence.  
Interestingly, results showed that the untagged Wt-MC2R generated 40% more cAMP 
than Wt-HA-MC2R.  Furthermore, both D20N and I44M demonstrated similar function 
when compared with Wt-HA-MC2R (Figure 3.8).  However, all other mutants (D103N, 
D107N, R128C and H170L) had significant impairment of cAMP generation, as seen 
by the decreased luciferase activity.   
Previous signalling studies on mutations such as R146H and T159K showed a lack of 
response to ACTH (Elias et al. 1999).  Data in Figure 3.5 indicate that these mutants 
fail to reach the plasma membrane and are located in the ER.  For this reason these 
mutants were not included in this study.   
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Figure 3.8:  Results of luciferase assay for all trafficking-competent mutants.  The 
luciferase assay was employed to assess the effect of MC2R mutations on cell 
signalling in response to ACTH (10
-7
M) in the HEKα7 clonal cells.  All trafficking-
competent mutants were transiently transfected. **,P<0.01; ***,P<0.0001 (compared with 
Wt-HA-MC2R).  Despite good cell surface expression, 4/6 mutants did not respond to 
stimulation by ACTH after 6 hours treatment.  
 
3.4.5  Binding studies 
Attempts were made to investigate the binding of ACTH to the trafficking-
competent but signalling-defective mutants.  It was important to dissect if the lack of 
response to ACTH was due to an ACTH binding defect or whether it was a 
downstream signalling problem.  The major obstacle in this study was the lack of cell 
adhesion after multiple washes despite modification of the cell culture plates with 
collagen treatment.  Furthermore, the failed experiments had proven to be costly, with 
the now limited production of [125 I] iodo-tyrosyl 23 (mono-iodinated ACTH at tyrosine 
23). This particular iodination was vital as iodination at tyrosine 23 will not cause 
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hindrance to ACTH binding to its receptor (Schioth et al. 1996).  The usual production 
by Amersham had been discontinued at the time of this study and therefore the 
iodinated ACTH had to be custom made to order.  After six attempts, the experiments 
were abandoned due to the high cost of the labelled production.   
Previous work by Elias (1999) had shown that D103N has impaired ACTH 
binding and that R128C is most likely involved in failure to signal.  These results 
appear to be consistent with this study.   
 
3.4.6  Co-immunoprecipitation with MRAP 
Considering the importance of MRAPα in cell surface expression and receptor 
function, we investigated whether any mutation in MC2R leads to failure of interaction 
with MRAPα.  Wild type CHO cells were transiently transfected with MRAPα-Flag and 
either Wt-HA-MC2R or mutant HA-MC2R.  Immunoprecipitation of MC2R followed by 
immunoblotting with anti-Flag antibody provides a qualitative indication of the 
interaction of Wt-MC2R and MRAPα (Figure 3.9 a).  MRAP-Flag has a predicated 
molecular weight of 24kDa and the major isoform of MRAPα is seen as a define band 
at approximately at 23kDa.  Figure 3.9b demonstrates interaction with MRAPα for 
L55P, I130N, R137W and G226R.  Interestingly, all of the MC2R mutants examined 
also interacted with MRAP, this is shown in Figure 3.10.   
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Figure 3.9: Co-immunoprecipitation studies of MC2R mutations with MRAPα.  (A): CHO 
cells transiently transfected with empty vector, MRAPα-Flag, Wt-HA-MC2R or MRAPα-
Flag + Wt-HA-MC2R were immunoblotted with anti-Flag antibody.  Cell lysates were 
immunoprecipitated with anti-HA and washed prior to SDS-PAGE and immunoblotting 
with anti-Flag antibody. The major isoforms of MRAPα were identified as shown by the 
arrow heads at 23kDa.  IP = immunoprecipitation.  IgG represents light chain. (B): CHO 
cells were transfected with Wt-MC2R, L55P, I130N, R137W and G226R mutants and 
MRAPα-Flag.  Cell lysates were immunoprecipitated with anti-HA and washed prior to 
immunoblotting.   
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Figure 3.10: Interaction between of the other missense mutations with MRAPα.  HA-
MC2R mutations and MRAP-Flag co-transfected into wild type CHO cells overnight.  
Proteins were immunoprecipitated using the anti-HA conjugated beads, and 
immunoblotted with anti-Flag antibody.   The arrowheads depict the MRAP protein 
(23kDa) and the light chain (IgG at 19kDa).   
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3.5 Discussion 
In this study, a systematic approach was taken to characterise the functional defect of 
twenty four naturally occurring missense mutations of the MC2R found in FGD type 1.  
It transpires that the majority of the mutations traffic poorly to the plasma membrane 
despite direct interaction with MRAP and that most of those that do traffic efficiently 
fail to signal after stimulation with ACTH.  This study provides a novel insight into the 
molecular mechanisms accounting for the MC2R functional defects, and confirms the 
problem of MC2R trafficking from the ER as that most likely to cause FGD type 1.   
Four out of six trafficking-competent mutations, D103N, D107N, R128C and H170L, 
failed to signal despite receptor cell surface expression.  Previous studies found that 
both D103N and D107N fail to bind ACTH (Naville et al. 1996b; Elias et al. 1999).   
The only receptor mutation which traffics successfully to the cell surface and is 
located intracellular region of the receptor is R128C.  This is an interesting mutation 
as it lies in the Asp-Arg-Tyr (DRY) region in the second intracellular loop, which is the 
most conserved region of all GPCRs (Oliveira et al. 1994).  Indeed, the arginine 
residue in this motif is the only amino acid conserved among all subclass 1 receptors 
(Probst et al. 1992). Substitution of the arginine residue within the highly conserved 
DRY motif will abolish or drastically reduce G protein coupling (Zhu et al. 1994; Jones 
et al. 1995) and is proposed to represent the primary trigger for the release of GDP 
from the receptor-G protein complex (Acharya & Karnik 1996).  Interestingly, 
substitution of the next amino acid in the DRY motif - the Y129C mutant caused 
significant intracellular retention.  Tyrosine is the least conserved of the triad 
sequence, and in other GPCRs this tyrosine mutation often only marginally affects 
receptor function, if at all (Rovati et al. 2007).  
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Both D20N and I44M were found to have efficient cell surface expression and cell 
signalling.  I44M was described in a Finnish girl by Weber et al (Weber et al. 1995), as 
a compound heterozygous mutation in combination with L192fs.  This frame shift 
results in a nonsense sequence of 54 residues followed by a premature stop codon.  It 
is not clear how the I44M mutation alters receptor function, if at all, as this isoleucine 
in the first transmembrane domain is not a conserved residue and is substituted by 
the relatively hydrophobic methionine in the bovine ACTH receptor.  No novel splice 
site was created by either mutation as predicted by analysis using 
http://www.fruitfly.org/seq_tools/splice.html.  A further possibility is that both D20N and 
I44M are in linkage disequilibrium with a more functionally significant mutation 
elsewhere in the gene and outside the coding region such as the previously reported -
2 substitution in the MC2R promoter initiator element (Slawik et al. 2004; Tsiotra et al. 
2006).  This is a relatively common polymorphism which is found in 6.5% of a healthy 
population (Tsiotra et al. 2006) and normal subjects homozygous for the rarer C allele 
displayed higher ACTH/cortisol ratios in response to CRH testing (Slawik et al. 2004).  
This variant has been proposed as a cause of FGD when combined as a compound 
heterozygote with a frameshift mutation on the other allele (Tsiotra et al. 2006).   
The majority of the mutant receptors trafficked inefficiently to the plasma membrane. 
Notably, the most severely affected mutations are located towards the C-terminus of 
the receptor.  Previous functional studies performed for a variety of mutations such as 
G116V (Collares et al. 2008), R137W (Fluck et al. 2002), R146H (Weber et al. 1995; 
Elias et al. 1999), T159K (Elias et al. 1999), C251F (Naville et al. 1996b) and Y254C 
(Fluck et al. 2002) all found that there was impaired receptor signalling when 
stimulated with ACTH and low affinity for ACTH binding.  It is now apparent that this 
was because of impaired cell surface expression of the receptors.  We investigated 
the hypothesis that mutations that affect trafficking do so by interfering with the 
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interaction between MRAP and MC2R, as the latter plays an important role in 
facilitating trafficking of the receptor to the cell surface.  No mutation was found to 
block this interaction using co-immunoprecipitation, implying that this may not be the 
mechanism underlying trafficking failure.  However, in a system with over-expression 
of MC2R and MRAP, it is possible this technique would not be sensitive enough to 
detect any differences in MRAP interaction at all.   
This finding has also been shown for other melanocortin receptors.  Similar studies 
have been performed in MC1R mutants (Sanchez-Laorden et al. 2009) with 
phenotypes which result in poor photoprotective phenomelanins and increased risk of 
skin cancer.  They concluded the naturally occurring mutations in MC1R such as 
R151C, R160W and D294H demonstrated loss of function and altered cell surface 
expression.  In parallel with mutants in the equivalent position found in MC2R, R151C 
and R160W were retained within the ER and the proximal Golgi respectively, whilst 
good cell surface expression was seen in D294H.  Similar results are also seen in 
monogenic obesity.  About 130 naturally occurring MC4R gene mutations have been 
identified, in patients with this condition and intracellular retention of mutated MC4Rs 
is a common obesity associated defect (Ho & MacKenzie 1999). 
Several inherited diseases are now found to result from GPCR trafficking defects.  
These include, rhodpsin mutations in retinitis pigmentosa (Mendes et al. 2005), 
vasopressin 2 receptor mutations causing nephrogenic diabetes insipudus (Bernier et 
al. 2004) and GnRHR  mutations causing hypogonadotrophic hypogonadism 
(Janovick et al. 2002).  The strict quality control mechanisms within cells ensures that 
improperly folded proteins are targeted for degradation via the proteosome or other 
pathways (Sitia & Braakman 2003).  At least two types of quality control systems have 
been described.  A general system involving ER-resident chaperones tests for broad 
conformational features such as correct disulfide bonding (Ellgaard & Helenius 2003; 
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Anelli & Sitia 2008). A more specific quality control system, is thought to be able to 
distinguish the specific motifs interacting with proteins that assist correct folding or 
escort the correctly folded proteins through the ER and the Golgi (Duvernay et al. 
2005; Michelsen et al. 2005).  Only a limited number of these motifs have been 
identified.  The trafficking defective mutants identified in this study which were 
localised in the ER are likely to be under the scrutiny of the general system where the 
folding or conformational structure is incorrect.     
It has been suggested that some low molecular weight compounds have been shown 
to inhibit aggregation and/or enable mutant proteins to escape the quality control 
system and, theoretically, this will result in the “rescue” of their function.  These small 
molecules, named chemical chaperones, are thought to non-selectively stabilise 
mutant proteins and facilitate their folding (Welch & Brown 1996).  Receptor ligands or 
enzyme inhibitors, which selectively recognise the mutant proteins and rescue 
conformational mutants, are referred to as pharmacological chaperones, and these 
present promising therapeutic avenues (Conn et al. 2002; Cohen & Kelly 2003).  In 
principle this approach could also be applied for rescuing MC2R mutations with 
trafficking defects, but this therapy is not likely to be practical, as there already exists 
a simple and effective treatment in the form of replacement with hydrocortisone.   
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Variation of phenotype and genotype in FGD 1 and 2 
Chapter 4  Variation of phenotype and genotype in 
FGD 1 and 2 
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4.1 Introduction 
In FGD type 1, multiple mutations have been identified throughout the MC2R 
receptor, the majority of which are homozygous or compound heterozygous missense 
mutations.  FGD resulting from MC2R mutations accounts for ~25% of all FGD and is 
now known as FGD type 1 (OMIM#202200).  FGD type 2 (OMIM*609196) describes a 
group of patients with normal MC2R but with mutations in MRAP which is required for 
MC2R trafficking and function (Metherell et al. 2005) and this accounts for ~20% of 
FGD and is now known as FGD type 2 (Clark et al. 2005). 
There are at least twenty-five missense mutations of MC2R identified in FGD 
type 1.  In vitro functional studies in Chapter 3 have shown that the majority of MC2R 
mutants have impaired trafficking from the endoplasmic reticulum (ER) to the cell 
surface resulting in reduced receptor expression and ACTH signalling.  Consequently 
there is often some protein with residual function.  There are also mutations which 
traffic effectively but fail to signal.  It would therefore be of interest to compare the in 
vitro findings with the clinical data of the patients.   
Nine mutations of MRAP in FGD type 2 have been reported to date, all of 
which are splice site or nonsense mutations and are predicted to produce proteins 
lacking the transmembrane domain essential for interaction with MC2R (Metherell et 
al. 2005; Modan-Moses et al. 2006; Rumie et al. 2007).  MRAP is expressed more 
widely than MC2R and there is evidence that it may interact with other melanocortin 
receptors (Chan et al. 2009a).  For this reason, the phenotype of FGD type 2 may 
differ from that of FGD type 1, perhaps reflecting a broader spectrum of activity than 
that of the MC2R.  Of particular relevance is the report that a patient with FGD type 2 
was significantly obese from childhood, which prompted the speculation that MRAP 
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may have a role in the activity of the appetite regulator MC4R in the hypothalamus 
(Rumie et al. 2007) 
 
4.2 Aims 
The aim of this study was to define the relationship between genotype and 
phenotype in patients with FGD, by analysing auxological, biochemical and genetic 
data from all known patients with FGD type 1.  Moreover, this project also aimed to 
compare the phenotypic differences between FGD type 1, caused by MC2R mutations 
and FGD type 2, caused by MRAP mutations.   
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4.3 Patients and Methods 
4.3.1 Patients 
164 DNA samples collected between 1993 to 2008 from patients with a clinical 
diagnosis of FGD characterised by elevated plasma ACTH, and low or undetectable 
cortisol in the absence of overt mineralocorticoid deficiency were available for genetic 
screening.  Other causes of adrenal insufficiency such as autoimmune adrenalitis, 
adrenoleukodystrophy or secondary adrenal failure and others were excluded. From 
this cohort, 26 patients with FGD type 1 and 19 with FGD type 2 were identified 
among these. All clinical details and information given by the referring physician were 
included in the analysis.  All mutation analyses of MC2R and MRAP have previously 
been performed by others in the lab.   
In addition, a PubMed search was performed for all genetically identified FGD 
type 1 and 2 cases reported until September 2009 and this resulted in a further 19 
patients being included in this study.  This included seventeen patients with FGD 1 
and two patients with FGD 2.   
 
4.3.2 Statistical evaluation 
Data were tested for normality on SPSS software Version 16.  For normally 
distributed data, the two groups were compared using independent t-test.  Values are 
stated as the mean ± SD unless otherwise stated. Significance was defined as P < 
0.05.   
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4.4 Results 
In the analysis, forty-three FGD type 1 patients with eighteen different 
homozygous and compound heterozygous MC2R mutations and twenty-one FGD 
type 2 patients with 9 different mutations within MRAP were included (Table 4.1 and 
4.2).  The majority of the MC2R mutations have been previously reported (Weber et 
al. 1995; Naville et al. 1996b; Wu et al. 1998; Slavotinek et al. 1998; Elias et al. 1999; 
Elias et al. 2000; Ishii et al. 2000; Fluck et al. 2002; Penhoat et al. 2002; Collares et 
al. 2008; Artigas et al. 2008; Mazur et al. 2008; Chan et al. 2009a; Chan et al. 2009c), 
and of these the S74I mutation was present in 20 patients.  All nine mutations have 
previously been reported for FGD type 2 (Metherell et al. 2005; Modan-Moses et al. 
2006; Chan et al. 2006; Rumie et al. 2007).  
Auxological data included in the comparisons were the age of presentation, 
height (in standard deviation score, SDS) of subjects at presentation, biochemical 
parameters including ACTH and cortisol levels and response to short synacthen 
testing (where available).  Table 4.1 summaries all published and unpublished MC2R 
and Table 4.2 MRAP mutations and the clinical data.   
The phenotypic presentation of FGD type 1 has been summarised in Table 
4.1. There appears to be no pattern of clinical correlation with respect to the 
genotyping.  Even within the same mutation such as homozygous S74I, there is a 
diverse range of age at presentation (Table 4.1).   
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Mutations 
 
Age at diagnosis 
Basal ACTH 
(ng/L)  
[NR: 10-80] 
Basal Cortisol 
(nmol/L) 
[NR >200] 
 
SST  
[Norm > 580] 
 
Height  
(SDS) 
 
Weight  
(SDS) 
 
Source 
I44M comp hete; I44M and L192fs  1yrs >1500 undect NS 4.6 NS (Weber et al. 1995) 
S74I homozygote 6yrs 2700 undect NS NS NS (Wu et al. 1998) 
 homozygote 7yrs 648 190 550 1 1.5 (Elias et al. 1999) 
 homozygote 3yrs 1850 90 NS 0.9 2 (Elias et al. 1999) 
 homozygote 3.5yrs NS undect NS 2 2 (Elias et al. 1999) 
 homozygote 4.6yrs NS 133 NS 2 NS (Elias et al. 1999) 
 homozygote 1.33yrs NS undect 12 NS NS (Elias et al. 1999) 
 homozygote 3 mths high 49 194 NS NS (Elias et al. 1999) 
 homozygote 6.5yrs >1000 30 <20 2.9 NS (Elias et al. 1999) 
 homozygote 3 mths NS 502 461 0.9 NS (Elias et al. 1999) 
  homozygote  2yrs 2690 449 613 1 NS Clark Lab 
 homozygote 16yrs NS undect 8.9 -1 NS Clark Lab 
 homozygote 14 weeks 2080 undect <30 0.9 3.1 Clark Lab 
 homozygote 18mths 4050 163 F 2 2 (Thistlethwaite et al. 1975) 
 homozygote 4.6yrs 6888 132 F 2 2 (Thistlethwaite et al. 1975) 
 homozygote neonatal 546 106 149 NS NS Clark Lab 
 homozygote 6.5yrs, 324 undect F 0.2 7.6 Clark Lab 
 homozygote 9mths 900 NS NS 0.3 NS Clark Lab 
 homozygote 5.66yrs high NS NS 2 2 Clark Lab 
 homozygote 10yrs  NS NS NS NS NS Clark Lab 
 comp hete; S74I and  I118fs 3yrs 4310 <30 <30 4 2 (Elias et al. 1999) 
D103N homozygote 1.5yrs 277 207 NS NS NS (Penhoat et al. 2002) 
 homozygote 2mths 1800 <30 F 1.3 1.3 (Kim et al. 2009) 
 comp hete; T159K and D103N 2 yrs; 4320 undect 29 2 2 (Elias et al. 1999; Elias et 
al. 2000) 
D107N homozygote 4 hours old 2520 undect F NS NS (Naville et al. 1996b) 
G116V homozygote 4yrs 940 20 F 2 NS (Collares et al. 2008) 
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S120R premature stop R201stop and 
S120R 
1yrs 426 undect NS NS NS (Tsiotra et al. 2006) 
A126S comp hete; G217fs and A126S 2yrs 1047 <27 30.35 3.5 NS (Artigas et al. 2008) 
R128C comp hete; S74I and R128C 8.5yrs 820n  170-190 300/452 4.5 4.5 (Weber et al. 1995) 
Y129C comp hete; Y129C and F278C 8mth >1250 low low -1.5 -1.5 (Chan et al. 2009a) 
R137W comp hete; D103N and R137W 3mths 396 70 65 0.9 0.9 (Ishii et al. 2000) 
 homozygote 2.25yrs 1134 <27 F 2 3.7 (Fluck et al. 2002) 
R146H homozygote 4.7yrs 790 37 50 4 NS (Weber et al. 1995) 
 homozygote 2.25yrs 3240 undect F 1.2 NS (Weber et al. 1995) 
 homozygote 5.75yrs 1409 undect F 2 2 (Slavotinek et al. 1998) 
T152K homozygote 4yrs >1250 undect F 2.4 2.4 Clark Lab 
T159K homozygote 8 days; 1000 undect 83 2.2 NS (Elias et al. 1999; Elias et 
al. 2000) 
 homozygote 3mths 5160 undect F -1.5 NS (Elias et al. 1999; Elias et 
al. 2000) 
H170L comp hete; S74I and H170L neonate extremely high extremely low NS NS NS Clark Lab 
A233P homozygote 10 day old 4652 <30 NS NS NS (Penhoat et al. 2002) 
C251F comp hete; C251F and G217fs 2yrs 250 undect <28 NS NS (Naville et al. 1996a) 
Y254C comp hete; Y254C and S74I 1.58yrs 1485 37 & 55 NS 2 1.5 (Fluck et al. 2002) 
P273H comp hete; S74I and P273H 12 mth  545 undect NS NS NS (Wu et al. 1998) 
 
Table 4.1: Summary table of all published and unpublished mutations of MC2R.  The clinical data including age of onset; cortisol and ACTH at 
presentation; cortisol response to synacthen testing (SST); weight and height at presentation.  NS = not specified; undect = undetectable level; F= 
failed. 
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Mutations 
 
Patient 
 
Age at diagnosis  
(yrs) 
Basal ACTH  
(ng/L)  
[NR:10-80] 
Basal Cortisol 
(nmol/L)  
[NR > 200] 
 
SST 
[Norm >580] 
 
Height  
(SSD) 
 
Weight  
(SDS) 
 
BMI 
 
Source 
IVS3ds+1delG 1 0.25 108.5 <50 F 1.8 -1.5 12.5 (Metherell et al. 2005) 
 2 0.25 increased low NS NS NS NS (Metherell et al. 2005) 
IVS3ds+3insT 3 neonate >1500 47 NS 1.24 0.9 14.2 (Metherell et al. 2005) 
 4 NS NS NS NS NS NS NS (Metherell et al. 2005) 
 5 birth 1400 undetect  F -1.3 0.7 18.5 (Metherell et al. 2005) 
 6 birth 3705 31 NS -2.3 -0.3 19.7 (Metherell et al. 2005) 
 7 birth 1703 24 NS NS NS NS (Metherell et al. 2005) 
IVS3ds+1G→C 8 neonate increased <50 NS NS NS NS (Metherell et al. 2005) 
 9 neonate 697 <50 F -0.5 1 24.7 (Metherell et al. 2005) 
M1I 10 1.16 4500 200 F 0.9 3.7 36.9 (Metherell et al. 2005) 
 11 neonate >1500 <50 UD 0.1 2.6 30.7 (Metherell et al. 2005) 
 12 NS 273 276 NS 0.3 0.6 16.2 (Metherell et al. 2005) 
 13 NS 248 469 NS 0.4 0.2 17.8 (Metherell et al. 2005) 
 14 1.08 NS NS F -1.6 -0.9 23.4 (Metherell et al. 2005) 
 15 0.11 288 <50 NS -0.1 NS NS (Metherell et al. 2005) 
compound het M1I, ds+1G→ A 16 neonate extremely elevated <50 NS NS NS NS (Metherell et al. 2005) 
compound het M1I, IVSds+3 insT 17 1.08 1250 undetect F 1.4 2.2 19.7 (Metherell et al. 2005) 
Y11X 18 0.125 1200 33 NS -1.6 -2.1 15.8 Clark Lab 
 19 birth 3275 NS NS 0.9 0.6 16.5 Clark Lab 
V44X   20 0.125 >730 <50 F 1.2 2.5 28 (Rumie et al. 2007) 
Del 17-23 stop codon L31X 21 1.58 1250 <50 NS NS NS NS (Modan-Moses et al. 
2006) 
 
Table 4.2: Clinical summary table of all published and unpublished MRAP mutations. F=failed; NS = not specified.
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4.4.1 Age at presentation 
FGD type 1 presents with a variable age of onset, mean (± SD) 3.11 ± 3.40 yrs 
(range 0-16yrs), whilst FGD type 2 presents at an earlier age with mean onset at 0.31 ± 
0.51 yrs (range 0-1.6yrs), p < 0.01 (Figure 4.1A).  Interestingly, the most common MC2R 
mutation, homozygous for S74I (n=20), appears to display a wide spectrum in age of 
presentation, with the mean age of onset 3.82 ± 3.81yrs (range 0-16) which does not differ 
from that of other patients with FGD type 1 (Figure 4.1A).     
 
4.4.2 Height and weight at presentation 
The height of patients with FGD type 1 has previously been noted to be unusually 
tall (Clark & Weber 1998; Elias et al. 2000; Imamine et al. 2005).   In FGD type 1 height 
SDS at presentation was + 1.76 ± 1.52 (mean ± SD) and in FGD type 2 height SDS at 
presentation was + 0.12 ± 1.35, p < 0.001 (Figure 4.1B).  Not all weight measurements 
were available for FGD 1.  Often weight was only available in SDS rather than in metric 
units.  Where data was present, the mean weight SDS for FGD type 1 (n=19) at 
presentation was + 1.7 ± 1.46 and in FGD type 2 (n=14) the mean weight SDS at 
presentation was + 0.718 ± 1.62, (NS).  (Figure 4.1C).  There is no concordance between 
height variations in relation to the age of presentation in FGD 1, the relationship did not 
reach statistical significance (Figure 4.1D).   
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 4.4.3 ACTH / cortisol at presentation  
The basal cortisol at presentation is shown in Figure 4.1E, with FGD type 1 mean 
cortisol 78.9 ± 115.9 nmol/L and FGD type 2 mean cortisol 79.0 ± 106.5 nmol/L, (NS).  
Where tested, the majority of the FGD type 1 and 2 patients failed short synacthen testing.  
Similarly, the mean plasma ACTH (± SD) at presentation for FGD type 1 was 1920 ± 
1685.78 ng/L and 1454 ± 1195.07 ng/L for FGD type 2, (NS) (Figure 4.1F).   
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Figure 4.1: Plotted graphs of all auxological and biochemical data for FGD patients at 
presentation. (A) Age (years) of all patients with FGD type 1, those patients with the S74I 
mutation, and FGD type 2 are shown.  The horizontal line represents the mean. (B) Height (in 
SDS) of all patients with FGD type 1 and FGD type 2 are shown.  The horizontal line 
represents the mean. ** = p< 0.01; *** = p<0.001.  Weight of FGD patients at presentation is 
seen in C.  The weight (in SDS) of all patients with FGD type 1 and 2 are shown.  The 
horizontal line presents the mean.  There was no statistical significance detected.  (D): 
Relationship between height SDS at diagnosis and age of presentation in FGD type 1 
patients.  Plasma ACTH and cortisol at presentation.  (E) cortisol (nmol/L) and (F) ACTH 
(ng/L) and for all patients with FGD type 1 and 2 are shown.  The horizontal line represents 
the mean.  No statistical significance was detected in the two groups.   
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4.5 Discussion 
The diagnosis of FGD is based on clinical findings and patients usually present 
with hypoglycaemia, seizure, jaundice, hyper-pigmentation, failure to thrive and frequent or 
severe infections.  The biochemical findings are a markedly elevated plasma ACTH in the 
presence of low cortisol but with a preserved mineralocorticoid production and are 
characteristic of ACTH insensitivity.  There are three genetically identified causes in FGD, 
mutations in the MC2R, MRAP and STAR known as FGD 1, 2 and 3 respectively.  This is 
the first phenotype-genotype comparison between FGD types 1 and 2.   
 
4.5.1 Age at presentation  
The auxological data in FGD type 1 demonstrated a wide variation in disease 
presentation associated with different mutations for MC2R.  Even for the same mutation, 
such as S74I, which is the most common FGD mutation, the age of presentation ranged 
from neonate to 16 years old (Table 4.1).  This variability was also observed for basal 
cortisol at presentation (from undetectable cortisol to 502nmol/L), responsiveness to short 
synacthen testing and height (SDS) at presentation.  The in vitro data from Chapter 3 
(Figure 3.5) suggested that mutations near the C terminus appeared to have a greater 
effect on trafficking, however this was inconsistent with the clinical data.  For example, 
T159K is functionally less defective than C251F in the cell surface assay (Figure 3.5), 
nevertheless the age of presentation appear to contradict the in vitro data.  Therefore, no 
correlation between genotype and phenotype features in FGD type 1 was found.  The 
results in Chapter 3 has shown in in vitro studies that missense mutations in the MC2R 
have varying degrees of impaired trafficking from the ER to the cell surface resulting in 
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reduced receptor expression (20-100% when compared with wild-type) and ACTH 
signalling.  Consequently there is often some protein with residual function.  Contrasting 
this to an animal model in the MC2R knockout (KO) mice, approximately three-quarters of 
MC2R KO pups died within the first 48 hour after birth (Chida et al. 2007).  Only five out of 
70 MC2R KO survived until 12 weeks, this demonstrates that the phenotypic presentation 
of MC2R KO mice do not represent human equivalent of FGD 1 missense mutations.  The 
homozygous nonsense and frameshift MC2R mutations in FGD may represent a more 
appropriate comparsion with the MC2R KO model, although such patients are extremely 
rare.  All six children previously reported (Chan et al. 2009b) presented during neonatal 
period or in infancy with severe illness.  Some of these patients had some degree of 
disturbance of the renin-angiotensin-aldosterone axis, but no patient was frankly 
mineralocorticoid deficient to require fludrocortisone replacement.   
FGD 2 had a much earlier age of presentation when compared with FGD 1 and 
therefore a more severe phenotype.  This is in agreement with the view that MC2R 
mutations have residual protein function and hence later age of presentation.   
 
4.5.2 Weight of FGD patients 
There was no statistical difference between weight SDS in FGD 1 and 2 at 
presentation.  If there is a difference in weight then perhaps a better comparison should be 
body mass index, since FGD 1 patients are comparatively taller.  However, due to lack of 
clinical data including the missing paired weight and height this calculation was not 
possible.  In the plotted data for weight (Figure 4.1C), it could be appreciated in FGD 2 that 
majority of the weight SDS at presentation were below 1 SDS.  FGD 2 patients appear to 
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show a more severe phenotype with earlier age of presentation and perhaps the more 
reduced body weight could be the result of failure to thrive in a more severe phenotype.   
In vitro study has shown that MRAP and MRAP2 can interact with MC4R (Chan et 
al. 2009c), and this interaction reduced the cell surface expression of MC4R and also 
caused reduction in signalling.  MC4R negatively regulates appetite and food intake in 
response to agonist, such that there is an increase in energy expenditure and a decreased 
food intake (Yeo et al. 1998; Farooqi et al. 2003).  MC4R knockout mice displayed 
hyperphagia and increased adiposity (Huszar et al. 1997).  Theoretically, interaction of 
MC4R with MRAP in the hypothalamus would impair the ability of MC4R to regulate 
appetite and hence it is possible that the loss of function mutations in MRAP seen in FGD 
type 2, would relieve this negative regulation of MC4R activity resulting in the leaner FGD 
2 phenotype.   
Rumie et al (2007) reported that a patient with an MRAP mutation was markedly 
obese, and hypothesised that MRAP may play a positive role in MC4R function, given its 
expression in the brain.  The data presented here show that MRAP patients are more 
commonly underweight and data from Chan et al (2009) show that MRAP has a negative 
effect on MC4R function, indication that the obesity seen in this patient is unlikely to result 
from the MRAP mutation.  These observations assume that MRAP is present in the 
hypothalamus, but its expression is yet to be determined.   
 
4.5.3 Height of FGD patients 
When the clinical features of FGD types 1 and 2 were compared, striking 
distinctions were discovered in the age of presentation and height, but not in other aspects 
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of endocrinology or body weight.  Due to the incompleteness of the data, such as ethnicity 
SDS and mid parental height could not be considered. The correlation between the 
estimated severity of the receptor defect in vitro and the degree of clinical severity remains 
poor.  Plotting height versus age was not suggestive of a relationship between length of 
exposure to high ACTH / low glucocorticoid and tall stature (Figure 4.1D).  These data 
were transformed in various ways including log transformation for age in years and months 
or charting data divided into quartile age groups (not shown).  However, there was no 
statistically significant relationship between age of presentation and height in FGD type 1.   
Unusually tall stature has been described in many FGD type 1 cases in the 
literature (Shepard et al. 1959; Migeon et al. 1968; Thistlethwaite et al. 1975; Soltesz et al. 
1985), the cause of which is not known.  In vitro, ACTH increases the development of a 
chondrogenic phenotype with an increase in proliferation and differentiation of chondrocyte 
precursors (Evans et al. 2004).  Consequently it is a reasonable hypothesis that ACTH at 
high concentrations could activate melanocortin receptors expressed in bone and the 
cartilaginous growth plate and stimulate growth (Yeh et al. 2006).  Alternatively, 
glucocorticoid inhibits the synthesis of IGF binding protein 5 (IGFBP-5) in the osteoblast 
(Gabbitas et al. 1996).  Bone growth is stimulated by IGFBP-5, and thus conceivably 
cortisol deficiency results in a lack of negative inhibition and the consequent growth spurt 
seen in FGD type 1.  No abnormality in the GH-IGF-I axis has been reported in FGD 
patients to date.  It is interesting to note that MC2R KO mice do not exhibit any significant 
difference in body length when compared with wild-type (Chida et al. 2007).   
Clinical observations suggest that replacement of glucocorticoid normalises the 
advanced growth rate in FGD (Elias et al. 2000; Imamine et al. 2005).  This can be seen 
when the growth rate is documented in growth charts (Figure 4.2).  Two patients presented 
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with heights at the 97th centile at the time of diagnosis, and the growth rate declined after 
replacement with hydrocortisone. In the reported cases, despite adequate hydrocortisone 
replacement ACTH often remains elevated both in FGD 1 and 2, for reason which remain 
unclear (Elias et al. 2000).  It is conceivable that the treating clinicians may attempt to 
normalise the ACTH.  Therefore, it is also very difficult to exclude the possibility that 
overtreatment with glucocorticoids may be responsible for this deceleration in growth.  The 
discordance of the plasma ACTH and bone growth suggest exposure to cortisol could play 
a role in this.  However, if height is partly ACTH driven then the question remains as to 
why this phenomenon is not observed in FGD type 2.  A probable explanation may be that 
FGD 2 patients present at and are treated at an earlier age.   
 
 
Figure 4.2: Growth chart of two patients with FGD type 1.  Both patients were diagnosed with 
S74I mutations.  The vertical arrow indicates the commencement of hydrocortisone 
treatment (12mg/m
2 
and 15mg/m
2
).  The growth rate slows down after treatment.  Adapted 
from Clinical Endocrinology (Elias et al. 2000).   
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4.5.4 Limitation 
A limitation of this study is that the available clinical data is far from complete.  The 
majority of the patients were only referred to us for genotyping by the treating clinicians, 
both locally and internationally.  Even though the biochemical data were available for most 
patients, they were in different units and sometimes different normal ranges (especially for 
ACTH).  This adds to the challenges of comparing different data.  Furthermore, the 
different ethnic origin of the patients was not accounted for in the analysis, for example, 
comparing the height of an Irish Caucasian with a Turkish patient.  Growth chart of each 
ethnic origin should be used for more accurate comparison.   
Although the results suggest no difference in weight between FGD 1 and 2, the 
possibility cannot be excluded that there may be weight over-estimation for some taller 
patients in FGD type 1, since taller patients are heavier.  As mentioned before, 
assessment of SDS for body mass index may provide further information for the true 
weight comparison.   
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4.6 Conclusion 
In conclusion, the MC2R mutations are associated with a wide range of FGD 
phenotypes.  Even though rare, it should still be considered in young patients who suffer 
from recurrent infections, seizure and hypoglycaemia when other causes have been 
excluded.  Patients with FGD type 1 present later and have tall stature when compared to 
FGD type 2.  This is consistent with the suggestion that prolonged ACTH excess or 
glucocorticoid deficiency increases linear growth.  FGD type 2, in contrast, presents earlier 
and appropriate treatment may be sufficient to prevent the enhanced growth rate seen in 
FGD type 1.  Currently, there was no evidence that MRAP deficiency had any influence on 
any other physiological functions beyond that seen with a defective MC2R.  More clinical 
data is needed in order to compare the body weight differences between FGD type 1 and 
2.   
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Melanocortin 2 receptor dimerisation 
Chapter 5  Melanocortin 2 receptor dimerisation 
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5.1 Introduction 
 The idea that GPCRs might dimerise was first proposed in 1982 (Agnati et al. 
1982), this idea did not gain much interest until a decade later.  This idea came from the 
unexplained observation that larger than expected estimates of the size of receptor 
complexes were seen on gel filtration columns (Angers et al. 2002).  Subsequently,  many 
studies support the view that GPCRs can exist as dimers or higher-ordered oligomers 
(Terrillon & Bouvier 2004; Milligan & Bouvier 2005), however their functional importance 
remains controversial.  There is a large body of evidence, with functional data to support 
homodimerisation and heterodimerisation of GPCRs such as chemokine receptors 
(Mellado et al. 2001), angiotensin receptors (Szidonya et al. 2007) and others.  It would 
therefore be of interest to investigate if MC2R can homo or heterodimerise and if there is 
any functional consequence.   
 The first evidence of melanocortin receptor dimerisation was reported for MC4R.  It 
was proposed that the dimerisation of MC4R may play a role in severe early-onset  
monogenic obesity (Biebermann et al. 2003).  Inactivating mutations of the MC4R were 
found to be inherited in an autosomal-dominant manner.  It was demonstrated that a 
heterozygous mutation D90N-MC4R mutant results in a nearly complete loss of function.  
Both the mutant and wild type MC4R (Wt-MC4R) demonstrated high expression at the cell 
surface but there was a poor signalling response in D90N.  The co-expression of Wt-
MC4R and D90N together gave rise to a defective signaling response.  Using both ELISA 
and FRET, it was confirmed that MC4R forms homodimers and that Wt-MC4R and D90N 
heterodimerised, indicating that this protein-protein interaction resulted in a dominant-
negative effect (Biebermann et al. 2003).   
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 Similar findings were evident in MC1R mutants which exerted dominant-negative 
effects on the wild-type MC1R (Sanchez-Laorden et al. 2006).  This group found that 
MC1R undergoes constitutive dimerisation in heterologus cells overexpressing the 
receptor and that MC1R dimerisation occurs in the ER.  The mutant MC1R exerts a 
dominant-negative effect by trapping wild type MC1R intracellularly and results in loss in 
function (Sanchez-Laorden et al. 2006).   
In contrast to MC1R and MC4R, there is no clinical data to suggest dominant 
negative effect of MC2R.  The reason remains unclear.  One possibility is that MC2Rs do 
not dimerise, or that they dimerise without functional consequences, hence the need for 
this study.  In the phenotype-genotype characterisation for FGD type 1 (in Chapter 4), 
compound heterozygous patients were examined, whose individual mutations were both 
trafficking-defective.  So far there has not been a report of a compound heterozygote with 
the combination of a ligand-binding defective (eg D103N) MC2R and a signalling defective 
(for example, R128C) MC2R, which are both trafficking-competent.  It could be speculated 
that if there is cross talk by the receptors, such that a dimer between a ligand binding 
mutant and a signaling mutant created a functional receptor, this heterozygote may be a 
silent phenotype and hence un-diagnosed.  If there is “transactivation” of the receptor, then 
when these two mutations are co-expressed, their function could theoretically be rescued.  
However, it may be such that a combination is merely a rare phenomenon.  In principle the 
functional consequence of such a compound heterozygous mutation would be of interest.  
There is evidence from RT-PCR that MC3R and MC4R are expressed in rat 
adrenal glands (Dhillo et al. 2003).  It has been reported that α-MSH stimulates 
corticosterone release in rat adrenal cells (Oliver et al. 1994; Dhillo et al. 2005) and γ-MSH 
may be involve in the regulation of adrenal steroidogenesis (Harmer & Bicknell 2005).  The 
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reason for this observation remains unclear, maybe MC3R and 4R expression result in 
heterodimerisation with MC2R in the adrenal and subsequently contribute in 
steroidogenesis.     
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5.2 Aims 
The aim of this series of experiments was to: a) investigate if MC2R could homodimerise 
in the presence of MRAP; b) determine whether dimerisation is promoted or inhibited by 
MRAP or ACTH stimulation; c) investigate if there is any novel functional consequence of 
dimerisation which may rescue MC2R mutations; d) investigate if MC2R could 
heterodimerise with other melanocortin receptors (MCRs).   
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5.3 Materials and Methods 
In order to conduct receptor co-immunoprecipitation, a different epitope tagged hMC2R is 
required.  From chapter 3, 3XHA-hMC2R had been used and will also be used for the 
investigation of dimerisation.  The 3XFlag-hMC2R was cloned to create a second epitope 
tagged hMC2R.   
5.3.1 Cloning of 3XFlag-hMC2R 
Materials: 
Vector: p3XFLAG-CMV-10 expression vector (Sigma) 
Untagged hMC2R (pcDNA3.1) (Missouri S&T cDNA Resource Center) 
  
5.3.1.1 Identification of common cloning site for restriction digestion 
For the insertion of untagged hMC2R into 3XFLAG-CMV vector, their common cloning 
sites were identified using vector maps.  Vector maps from hMC2R vector identified EcoR1 
and Xba1 to be common to the p3XFLAG expression vector (as seen in Figure 5.1 and 
5.2).   
 
Figure 5.1: Vector map of human MC2R from cDNA.org. This illustrates the multiple cloning 
sites. 
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Figure 5.2: vector map of p3XFlag vector.  MCS: multiple cloning sites are illustrated. 
 
5.3.1.2 Restriction digestion 
This has been described in section 2.4.3 under materials and methods. 
EcoR1 and Xba1 (New England Biolabs, NEB or Promega, UK) were used for double 
digests.  The double enzyme digestion mixtures were prepared and incubated at 37ºC for 
2 hours.    
The digested DNAs were purified via agrose gel electrophoresis.  This is followed by 
ligation of the insert and vector performed at 1:2, 1:3 and 1:4 ratios.  The ligated mixtures 
were then transformed and colonies selected and sent for sequencing. 
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5.3.1.3 Site directed mutagenesis 
The cloned 3XFLAG-hMC2R was confirmed to be out of frame after sequencing.  
Therefore site directed mutagenesis had to be performed for the insertion of an extra 
nucleotide. 
The predicted out of frame sequence:   
↓ Start of 3XFlag 
ATG GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAC ATC GAT TAC AAG GAT 
GAC GAT GAC AAG CTT GCG GCC GCG AAT TC ACC ATG AAG CAC ATT ATC 
                                                                                               ↑ Start of MC2R 
With the insertion of C (grey) this put the sequence back into frame.   
 
In frame sequence: 
↓Start of 3XFlag 
ATG GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAC ATC GAT TAC AAG GAT 
GAC GAT GAC AAG CTT GCG GCC GCG AAT TCC ACC ATG AAG CAC ATT ATC 
                   ↑Start of MC2R  
 
 
The forward primer used:  TGCGGCCGCGAATTCCACCATGAAGCACA 
The reverse primer used:   TGTGCTTCATGGTGGAATTCGCGGCCGCA 
PCR was performed with an annealing temperature of 65ºC for 12 cycles.   
The new sequence was confirmed to be in frame via sequencing.   
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5.3.2 Co-immunoprecipitation (Co-IP) 
 To demonstrate MC2R dimerisation, HEK293 cells were transfected with 3XFlag-
hMC2R and 3XHA-hMC2R.  Immunoprecipitation of GPCRs was performed with anti-HA 
agarose (Sigma) and IB with anti-Flag M2 antibody (Sigma).  Reciprocal Co-IP was 
performed with anti-Flag agarose (Sigma) and anti-HA antibody (Sigma).   
 To demonstrate heterodimerisation of the MC2R, Co-IP was performed on lysates 
from HEK293 cells co-transfected with all other HA-hMCRs (Missouri S&T cDNA Resource 
Centre) and 3XFlag-hMC2R.   
 The protocol was followed as described in section 2.5.7 (Materials and Methods), 
the only difference was that after the addition of β-mercaptoethanol, the samples were not 
denatured at 99ºC.  The glycosylated MC2R can produce artificial aggregates during the 
boiling step, which makes the samples extremely difficult to load and give erroneous 
bands on SDS-PAGE.  Instead, the samples were left to incubate at room temperature for 
1 hour prior to loading.  This step was extremely important for loading GPCRs.    
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5.4 Results 
5.4.1 MC2R homodimerisation 
HEK293 cells were transisently transfected with MRAP, 3XFlag-hMC2R and 3XHA-
hMC2R.  Co-IP showed that MC2R forms homodimers (Figure 5.3).  The presence of 
MRAP does not seem to affect homodimerisation.  Mock transfection and transfection of 
3XFlag-hMC2R and 3XHA-hMC2R alone acted as controls.   
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Figure 5.3: MC2R undergoes homodimerisation.  Identical sample loading in individual lane 
for each of the blots and their common labels are indicated above.  A: Immunoblot with anti-
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Flag antibody in transfected HEK295 cells reveals equal protein expression of the Flag-
MC2R.  A protein at ~30kDa in size, indicated by the asterisk is suggestive of Flag-MC2R 
expression.  B: Immunblot of same gel using anti-GAPDH antibody.  C: Co-
immunoprecipitation with anti-Flag agarose beads and immunoblotted with anti-HA, showing 
MC2R homodimerisation with or without MRAP.  IgG light chain is indicated by the arrow.   
 
The reciprocal experiment (ie immunoprecipitate with anti-HA and immunoblot with 
anti-Flag) was performed without MRAP (Figure 5.4).  This confirmed that MC2R 
constitutively homodimerises.  There were two bands, one at 30kDa and the other at 
27kDa present in the Co-IPs (Figure 5.4B).  To demonstrate that the lighter band is the 
light chain IgG, a repeat of the experiment with and without β-mercaptoethanol was 
performed.  β-mercaptoethanol reduces disulphide-bonds and causes the dissociation of 
the antibody into light and heavy chains.  In the absence of β-mercaptoethanol, the 
undissociated antibody runs at approximately 150kDa and is not seen in the image (Figure 
5.4E).   
hMRAP2-Flag (Chan et al. 2009c) was used in this experiment as a positive control 
for the Flag antibody.  Human MRAP2 has a predicted molecular mass of 23.5kDa, 
MRAP2-Flag is seen in Figure 5.4A.  Human MC2R is approximately 33.9kDa and when in 
association with 3XFlag this is predicted to be 36kDa.  The band seen at 30kDa in Figure 
5.4A and B indicates Flag-MC2R.  The markers used are likely to be inaccurate, which 
would explain the difference in size.   
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Figure 5.4: Immunoblot and co-immunoprecipitation assay showing MC2R homodimerisat-
ion.  A: Immunoblot with anti-Flag in transfected HEK293 cells.  Expression of Flag-MC2R or 
MRAP2-Flag is seen.  B: Co-IP with anti-HA agarose beads and immunoblotted with anti-Flag 
showing dimerisation of MRAP2 with MC2R and MC2R homodimerisation.  C: Immunoblot of 
the repeat experiment transfecting Flag-MC2R and HA-MC2R with or without β-
mercaptoethanol.  D: Blotting using anti-GAPDH antibody.  E: Co-IP demonstrating the 
absence of heavy and light chain when β-mercaptoethanol is not used.   
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5.4.2 Homodimerisation in the presence of ACTH 
 The above data indicate that MC2R can homodimerise.  An unanswered question 
is whether receptor activation by ACTH can promote or inhibit dimerisation.  To investigate 
this, HEK cells were transiently transfected with epitope-tagged MC2Rs and untagged 
MRAP for 24 hours.  Cells were then treated with ACTH 10-6M for 20mins.  Figure 5.5 
demonstrates that homodimerisation of MC2R in the presence of ACTH remains 
unaltered.   
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Figure 5.5: The effect of ACTH on MC2R dimerisation.  Flag-MC2R, HA-MC2R and MRAP 
were co-expressed in HEK293 cells with and without 20 minutes of ACTH treatment.  A: 
Immunoblot with anti-Flag demonstrating expression of Flag-MC2R (indicated by asterisk).  
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B: blotted with anti-GAPDH antibody showing equal loading.  C: Co-IP with anti-HA agarose 
beads and immunoblotted with anti-flag.   
 
5.4.3 Homodimerisation and MC2R signalling in trafficking-competent    
mutants 
 Although GPCRs have been demonstrated to signal as monomeric units (Ernst et 
al. 2007), there is evidence that dimerisation of GPCRs could be of functional importance, 
with respect to ligand binding and receptor activation (Hansen & Sheikh 2004; Szidonya et 
al. 2008).  Receptor cross-talk has been demonstrated in AT1R receptors, supporting the 
concept of dimerisation (Szidonya et al. 2007), and therefore this phenomenon was tested 
in MC2R mutations.  Two trafficking-competent MC2R mutations (already characterised in 
Chapter 3) and MRAP were cotransfected in HEK293 cells and then stimulated with 
ACTH.  A cAMP responsive luciferase construct was used to detect cell signalling.  D103N 
which is defective in ligand binding and R128C which is known to be defective in signalling 
were co-expressed.  If receptor cross-talk takes place with the MC2R, then in theory 
dimerisation may allow ACTH to bind to R128C and signal through D103N and hence lead 
to the functional rescue of this mutant receptor combination.   
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Figure 5.6: ACTH responsiveness in MC2R mutations.  A: Schematic diagrams of D103N and 
R128C.  B: Luciferase activity after stimulation with ACTH 10 
-7 
M for 5 hours.    Wild type 
MC2R stimulated and un-stimulated were used as controls.  The experiments were 
independently repeated at least three times.   
 
Wild type MC2R and MRAP were co-transfected into HEK293 cells as controls.  
Unstimulated cells showed a low basal luciferase activity, however, after stimulation with 
ACTH (10-7 M) the luciferase activity was significantly enhanced.  When the signal 
defective mutation, R128C was stimulated after transfection, luciferase activity was 
detectable but at reduced levels compared to wild type.  The signal in D103N after 
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stimulation with ACTH was markedly reduced.  This is consistent with the data obtained in 
Chapter 3 (Figure 3.8).  However, when the two mutations were co-expressed in the 
presence of MRAP, the luciferase response to ACTH stimulation was unchanged (Figure 
5.6).  This experiment suggests that there was no receptor cross-talk between these two 
mutations.   
Even though there is evidence that MC2Rs could homodimerise on co-
immunoprecipitation studies, the dimerisation of the two mutations did not enhance their 
function, suggesting that there is no transactivation of the receptors. 
 
5.4.4 MC2R heterodimerises with other MCRs 
 In order to investigate whether MC2R heterodimerises with other MCRs, HEK293 
cells were transfected with Flag-MC2R and HA-epitope tagged MC1R to 5Rs followed by 
Co-IP. HA-calcitonin receptor (Class B GPCR) was transfected to investigate the 
specificity of heterodimerisation.  There is convincing evidence from Co-IP that MC2R 
appeared to heterodimerise with MC1R, MC3R and to a lesser extent MC4R and 5R 
(Figure 5.7).  There is a 30kDa band seen in the IP (Figure 5.7C) for calcitonin receptor 
(last lane), however, the specific pattern of Flag-MC2R (as seen in other lanes) was not 
present.  Therefore it is unclear if MC2R heterodimerises with calcitonin receptor or 
whether heterodimerisation with other MCRs is specific or not.  
Chapter 5 – MC2R Dimerisation 
     
163 
 
Flag-MC2R
__ + ++++++
HA-MCR
_ _2R 1R CALR5R4R3R2R
__________________________
IB: Anti-Flag
30kDa>
}Flag MC2R
HA-MCR
_ _2R 1R CALR5R4R3R2R
IB: Anti-Flag
IP: Anti-HA
30kDa> *
___________________________
< IgG
}Flag MC2R
46kDa>
__________________________
IB: GAPDH
46kDa>
46kDa>
80kDa>
A
B
C
 
Figure 5.7: Heterodimerisation of MC2R with other MCRs.  A: Immunoblotting by anti-Flag 
showing expression of Flag-MC2R.  B: Immunoblotting with anti-GAPDH.  C: 
Immunoprecipitation with anti-HA agarose beads and blotted with anti-Flag.  IgG light chain 
is shown.  The asterisk indicates the 30kDa band which indicates Flag-MC2R.  The images 
shown are representative of two independent experiments.   
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5.5         Discussion 
5.5.1      MC2R homodimerisation 
          The data shown in this chapter indicate that MC2R can homodimerise when 
overexpressed in HEK293 cells.  The dimerisation does not seem to be affected by the 
presence of MRAP or ACTH.   
Co-immunoprecipitation is the most frequently used method to detect the 
oligomerisation of GPCRs (Szidonya et al. 2008).  This system uses the differentially 
epitope-tagged molecules coexpressed in heterologous cells.  The receptor complex is 
electrophoresed, blotted and visualised using an antibody against the receptor of choice 
(Szidonya et al. 2008).  Immunoprecipitation with the second antibody and immunoblotting 
with the first is performed to ensure specificity of the interaction.   
The results of this chapter consistently showed that MC2R is seen as a particular 
molecular weight (approximately 30kDa) in either immunoblotting or immunoprecipitation.  
In addition, the presence of weaker bands at higher molecular weights is seen through out 
all the blots.  This may be due to the various glycosylated forms of the receptor or just the 
nature of GPCRs (membrane soluble protein) which runs badly on SDS-PAGE.  Flag-
MC2R is represented as a 30kDa band.  The 3XFlag epitope is only 22 amino acids long 
(approximately 2.2kDa).  The naked MC2R is approximately 33.9kDa, therefore the 
approximate molecular weight of unglycoslyated 3XFlag-MC2R is 36kDa.  The difference 
in molecular weight observed on the blots (ie 30kDa rather than 36kDa) suggests that the 
molecular weight marker used may be inaccurate.  The different glycosylated form of HA-
MC2R could also be seen in Figure 5.3c.   
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            MC2R forms homodimers which were not affected by the presence of MRAP.  This 
result is consistent with the theory that dimerisation occurs the ER.  In systems without 
MRAP, MC2R are trapped inside the ER (Metherell et al. 2005; Cooray et al. 2008).  
MRAP interacts with MC2R and assists trafficking of the receptor.  Furthermore, once at 
the cell surface, MC2R dimerisation was not influenced by ACTH.  This indicates that 
ACTH binds to pre-existing MC2R dimers and induces subsequent conformational change 
and signal transduction without any change in dimerisation.  Constitutive dimerisation has 
been shown to occur with other MCRs, for example, MC1R and MC3R have been shown 
to form homodimers and MC1R/MC3R heterodimers (Mandrika et al. 2005).  It was found 
that there was no modulation of the constitutively formed dimers with either agonists or 
antagonists.  The relevance of melanocortin receptor heterodimerisation remains unclear.   
           Studies on MC1R showed that dimerisation occurs early in the biosynthesis 
pathway  (Sanchez-Laorden et al. 2006).  This was evident by the finding of dimers of the 
deglycosylated “de novo” form of MC1R, when on immunoblotting the mobility of dimers 
was not affected by deglycosylation with endoglycosidase H.  Dimerisation in intracellularly 
retained, loss of function mutants was also observed.  Therefore the authors proposed that 
there are other factors apart from dimerisation which enables the receptor to traffic to the 
cell surface.   
             Biosynthesis of dimers in the ER have been reported in GPCRs such as β1-
adrenergic (Hebert et al. 1996) and vasopressin receptors V1a and V2 (Terrillon et al. 
2003), which form constitutive dimers (Hansen & Sheikh 2004).  As discussed in Chapter 
3, the ER quality-control system will only allow the correctly folded receptors to exit the ER 
and the misfolded or incompletely folded receptors will eventually degrade (Petaja-Repo et 
al. 2000).  Studies using fluorescence or bioluminescence resonance energy transfer 
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(FRET and BRET respectively) have also shown that dimerisation takes place in the ER 
(Issafras et al. 2002; Overton & Blumer 2002; Floyd et al. 2003).  The effect of dimerisation 
on some GPCRs such as rhodopsin mutants (Colley et al. 1995) and truncated 
vasopressin V2R (Zhu & Wess 1998) demonstrate that dimerisation enables dominant 
negative behaviour.  The interaction of truncated mutants and wild type receptors 
prevented cell surface expression and subsequent retention of the receptor dimers in the 
ER.  This dominant negative phenomenon does not exist in MC2R, as is evident by the 
observation that parents of FGD patients who have one normal allele and one mutant have 
normal adrenal function.   
There is no consensus on the influence of ligand binding on dimerisation.  Many 
studies are based on co-immunoprecipitation and resonance energy transfer techniques.  
Co-immunoprecipitation is semi-quantitative at best, and any change in the 
immunoreactivity could result from agonist-induced conformational changes that alter 
epitope recognition or may reflect a change in receptor dimers.  Similarly, in BRET or 
FRET studies, the ligand-induced changes in energy transfer from donor to acceptor 
fluorophores could reflect conformational change of pre-existing dimers or change in 
receptor dimers.  Therefore, a more defined experimental model is required to address the 
question whether ligand affects dimerisation.  In co-immunoprecipitation of MC2R, ACTH 
did not promote or inhibit dimerisation.  This data is in agreement with the BRET studies 
performed by another investigator in the lab.  The BRET data (unpublished) showed that 
MC2R dimerises constitutively and that ACTH did not affect the dimerisation.   
It has been seen in some GPCRs, such as MC1R, that dimerisation will allow the 
swapping of helices from each monomer and restores the function of two defective 
mutations (Sanchez-Laorden et al. 2006).  This could only occur if the mutations on MC1R 
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are located in different domains.  The authors managed to restore the function of 
mutations in the transmembrane fragments when co-expressed with a mutant deleted of 
five C-terminal amino acids.   
A similar mechanism was investigated in MC2R mutations, with the analysis of the 
transactivation of the receptor complex formed by the potential dimerisation of two different 
mutations which traffic to the cell surface.  The co-expression of R128C (signalling 
defective) and D103N (ligand binding defective) did not produce any signalling 
enhancement after stimulation with ACTH.  The co-immunoprecipitations of MC2R were 
performed on wild type receptors only.  Co-immunoprecipitation was not performed for 
these mutations, therefore raising the question of whether these mutants were capable of 
dimerisation.  The alternative explanation is that there is no cross-talk between the 
receptors.   
Most of the FGD 1 patients presenting with compound heterozygous mutations 
(see Section 4.4 and Table 4.1) are usually two separate trafficking-defective mutants.  
The exceptions are S74I/H170L and D103N/R137W, which is a combination of trafficking-
defective (S74I and R137W) and trafficking-competent (D103N and H170L) mutations.  
D103N and H170H are thought to be ligand binding defective. These patients presented 
typically with ACTH insensitivity and phenotypic features of FGD.  This implies that there is 
a loss of function and that there is no transactivation of receptors in S74I/H170L or 
D103N/R137W or, alternatively that the trafficking defective receptors are trapped inside 
the ER.  However, if transactivation took place in a compound heterozygote with, for 
example, R128C and D103N, it would result in normal MC2R functions and therefore be a 
silent mutant for which the patient will not present with FGD.   
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5.5.2 MC2R Heterodimerises with other MCRs 
MC2R appears to heterodimerise with MC1R, MC3R and to a lesser extent MC4R 
and 5R.   It is unclear if these interactions are specific, as there is some evidence that 
MC2R dimerised with calcitonin receptor when receptors are overexpressed.  Even though 
there is the presence of Flag-MC2R (indicated by asterisk in Figure 5.7), the lane does not 
display the broad range of glycosylated forms of MC2R as seen in the other lanes.  
Deglycosylation and proteolysis studies would better define this and additional 
experiments performed on dimerisation with other Class A GPCRs would also differentiate 
if these interactions with other melanocortin receptor are specific.   
 The biological significance of MC2R heterodimerisation could only be applied to 
receptors which are present in the same cells.  MC5R (Chhajlani 1996) are present in the 
human adrenal cortex.  There is also evidence from RT-PCR that MC3R and MC4R are 
present in rat adrenals (Dhillo et al. 2002).  MC2R is present in the skin (Slominski et al. 
1996), possibly in the same location as MC1R.  Therefore, it would be of interest to 
investigate if the heterodimerisation of these receptors has any functional consequences.  
One way to test the transactivation theory is by stimulation with α-MSH.  All MCRs except 
MC2R are responsive to α-MSH.  Therefore, if a mutation at the highly conserved DRY 
sequence was created for all four MCRs, thereby creating signalling defective mutants and 
these were co-expressed with MC2R, cAMP responsive following stimulation with α-MSH 
would indicate cross-talk between the MC2R and other MCRs.  If transactivation between 
MC2R and other MCRs occurred in vivo then further studies could explore if there is any 
physiological application.   
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A similar experimental approach was recently performed in AT1 angiotensin 
receptors (AT1R) by Szidonya et al (2007).  They demonstrated that AT1Rs can “cross-
inhibit” the G protein signalling.  They created two AT1R mutants, firstly, AT1R-S109Y 
which is insensitive to binding of the AT1R-antagonist, candesartan, but has normal 
binding and signalling properties to angiotensin II (Ang II) which was co-expressed with a 
second mutant, the AT1R-DRY which is defective in G-protein activation yet preserved 
internalisation and ligand binding properties.  They found that candesartan can inhibit Ang 
II induced G-protein activation, even though candesartan could only bind to the signalling 
deficient AT1R-DRY mutant.  Therefore it was suggested that there is cross-inactivation of 
homo-oligomerised AT1Rs with candesartan (Szidonya et al. 2007; Karip et al. 2007).   
Even more interesting is the therapeutic approach exploiting heterodimerisation 
which has been developed for treating pituitary tumours.  It is known that somatostatin 
receptors (SSR) and D2 dopamine (DR) receptors are significantly expressed in pituitary 
tumours (Stefaneanu et al. 2001; Moller et al. 2003; Saveanu et al. 2008).  It has been 
shown that SSR does not just act as a monomer but can display a differential tendency to 
homo- and heterodimerise, depending on the subtype of receptor involved (Duran-Prado 
et al. 2008).  The association of SSRs and DR in the majority of the pituitary tumours 
suggested the possibility of synthesising chimeric molecules containing the structural 
elements of both somatostatin and dopamine as a novel pharmacological approach 
(Figure 5.8), thereby targeting two families of GPCRs (Ferone et al. 2007; Saveanu et al. 
2008).  In vitro studies in somatotroph adenomas demonstrated that adenomas, which are 
partially responsive to a somatostatin analogue such as octreotide were found to have 
good response with this chimeric compound (Saveanu et al. 2006).  This is another 
demonstration which highlights the possible biological significance of heterodimerisation.   
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Somatostatin analogue __ __dopamine agonist
SSR DR
 
Figure 5.8: Somatostatin/dopamine chimera compound.  This compound induces additive 
cytotoxicity via SSR and DR in neuroendocrine tumour cells.  Diagram adapted from 
Regulatory Peptides (Kidd et al. 2007).   
 
5.5.3 Conclusion 
In the HEK293 cells, co-immunopreicipitation of MC2R demonstrates the existence 
of homodimers which are independent of MRAP or ACTH.  When a signalling defective 
mutant is co-expressed with a ligand binding mutant, there appears to be no 
transactivation of the receptors after stimulation with ACTH.  MC2R can heterodimerise 
with other melanocortin receptors, and further investigation of this phenomenon would be 
required to define the specificity of the interaction and whether there were any functional 
consequences.  
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6.1 Summary of findings   
 The autosomal recessive disease of adrenal insufficiency known as Familial 
Glucocorticoid Deficiency (FGD) is characterised by isolated glucocorticoid deficiency.  
The resistance to the action of ACTH is due to genetic defects discovered so far, in the 
MC2R, MRAP and STAR genes, classified as FGD type 1, 2 or 3 respectively.  These 
mutations account for approximately 50% of FGD patients (Metherell et al. 2009).  The 
focus of this thesis is the mechanism of disease caused by MC2R mutations.  Significant 
effort has previously been made to study this smallest member of the melanocortin 
receptor but this was previously hindered by difficulties in the functional expression in a 
system that is free of any endogenous MCR expression (Naville et al. 1996b; Noon et al. 
2002; Rached et al. 2005).  The characterisation of MC2R mutations in heterologuous 
expression systems is now possible with the discovery of the MRAP gene.  This is the first 
comprehensive functional characterisation of MC2R using MRAP as a tool in a non-
adrenal cell lines.  In the presence of MRAP, MC2R is readily expressed and allows 
characterisation of mutant function and explore the existence and relevance of receptor 
dimerisation.   
 A total of twenty-four MC2R naturally occurring missense mutations found in FGD 
were characterised in the non-adrenal cell lines HEK 293 and CHO stably expressing 
MRAPα.  The results of the cell surface assay and confocal studies in Chapter 3 
concluded that majority of the MC2R mutants were non-functional as they failed to traffic 
and were trapped in the ER.  The majority of the trafficking defective mutations were 
located in either the transmembrane domains or the intracellular loops, suggesting that 
their interaction with MRAP may be defective.  Protein misfolding is the most common 
cause of defective GPCRs, for example in rhodopsin causing retinitis pigmentosa (Mendes 
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et al. 2005), vasopressin 2 receptor (V2R) in nephrogenic diabetes insipidus (Bernier et al. 
2004) and others .  Since MRAP has been identified to be an essential element for MC2R 
trafficking and ligand binding of ACTH (Metherell et al. 2005; Cooray et al. 2008; Sebag & 
Hinkle 2009b), the interaction with MRAPα was investigated with co-immunoprecipitation.  
Although all mutations interacted with the MRAP protein, this suggested that there may be 
multiple sites of interaction with MRAP and that a single point mutation was not enough to 
interfere with MRAP interaction but effectively disrupted folding of the receptor.  But it is 
conceivable that the position of the mutations were not at the right site to disrupt the 
interaction with MRAP.  It is also possible that the overexpression system used here may 
be too insensitive to pick up any defective interaction.  Alternatively, there may be another 
closely associated protein yet to be defined, which assists in quality control and the correct 
folding of the receptor.   
 The trafficking competent mutations, all of which interacted with MRAP, failed to 
signal after stimulation with ACTH.  Multiple attempts were made to investigate ligand 
binding but failed to provide adequate data to contribute to these findings.  If binding 
results were available then it would be of interest to perform theoretical modelling to map 
out the possible ACTH binding site on the MC2R.  Remarkably, the mutation R128C, 
which located within the highly conserved DRY sequence, trafficked efficiently to the cell 
surface and did not have complete loss of function as expected.  In contrast, to this, the 
next mutation in Y129C, also part of the DRY sequence, failed to traffick to the cell 
surface, implying that the trafficking property of MC2R could be easily disrupted.     
 After the missense mutations were characterised, the genotype-phenotype 
correlation was analysed in Chapter 4.  There were no phenotypic characteristics which 
could be related to the severity of the functional defect in vitro.  Even with the most 
Chapter 6 – Final Discussion 
     
174 
 
common FGD mutation, S74I, there was a wide spectrum of presentation with respect to 
age of onset (Figure 4.1).  This may be due to a variation of residual receptor functions, or 
that the normal adrenal function deteriorates with age.  It is unclear why adrenal failure 
occurs later in life in some patients, it could be speculated that the misfolded receptor 
accumulates in the ER over a period of time overwhelms the degradation system and 
eventually kills off the zona fasciculata cells.  In FGD type 2, in which patients had MRAP 
mutations, the age of onset of disease was earlier, indicating a more severe phenotype.  
Functional studies of these MRAP mutations would of interest.  As previously reported 
(Elias et al. 2000), the FGD type 1 patients were significantly taller at presentation.  The 
reason for this is yet to be determined but one hypothesis is that prolonged exposure to 
circulating high levels of plasma ACTH in the presence of defective MC2R could activate 
melanocortin receptors expressed in bone and growth plates, leading to accelerated 
growth.   
 The result of Chapter 4 found no weight differences between FGD 1 and 2, and the 
shortcomings of the study have been previously discussed.  The BMI SDS of the patients 
would be a better marker for comparison.  Given that MRAP has a negative effect on 
MC4R (Chan et al. 2009c), it would be logical to hypothesise that FGD type 2 patients 
would be underweight instead.  However, it is yet to be determined whether MRAP is 
present in the hypothalamus in the same cell as the MC4R.  MRAP appears to regulate 
other MCRs and in a recent study suggested mouse MRAP impaired MC5R dimer-
oligomer formation, and that consequently MC5R was trapped in the ER and failed to 
reach the cell surface (Sebag & Hinkle 2009a).  This interesting phenomenon raises the 
possibility of MRAP causing inhibition of dimerisation on other MCRs with potential 
functional consequence.   
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 The lack of dominant negative effect seen in MC2R in FGD led to question if MC2R 
homodimerise or if dimerisation occurred if there is any physiological relevance.  Therefore 
the final aim of the thesis was to investigate the dimerisation property of MC2R in the 
presence and absence of MRAP.  Like other GPCRs, MC2R appears to homodimerise 
constitutively.  This was not influenced by the presence of MRAP or ACTH stimulation.  
This suggests that dimerisation may be important in the formation of a functional receptor 
which occurs in the ER before interaction with MRAP.  The pre-existing MC2R dimer 
traffics to the cell surface for ligand binding with ACTH, which induces conformational 
change or signal transduction without any change in dimerisation.  The dimerisation of 
D103N and R128C did not influence the signalling property of the receptor after stimulation 
and therefore, at least in this instance, there does not appear to be transactivation 
between the receptors within the dimer formation.  The functional relevance of MC2R 
dimerisation therefore remains unclear.  Inhibition of MC2R homodimerisation by site 
directed mutagensis and studying receptor functionality may be one way to investigate this 
question.   
MC2R appears to heterodimerise with other MCRs, especially with MC1R and 
MC5R and to a lesser extend MC3R and MC4R.  The dimerisation may be specific but 
more experiments are needed with other classes of GPCR in order to further determine 
this and whether it has any physiological significance.  If the MC2R heterodimerisation with 
other MCRs is specific then further investigation into whether there is any transactivation 
of the receptors would be of great interest.   
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6.2 Future Prospects 
This is the first demonstration of the functional effect of MC2R mutations in the presence 
of MRAP.  This work has provided a molecular explanation for the adrenal failure observed 
in FGD type 1 and also potentially highlights other areas for future investigation.   
6.2.1 Identify the interaction site between MC2R and MRAP 
Point mutations spread across the MC2R did not inhibit the interaction with MRAP.  
This suggests that there may be multiple sites of interaction between MC2R and MRAP.  A 
systematic approach using a chimeric receptor, based, for example, on the β-adrenergic 
receptor, which does not interact with MRAP, and swapping domains with those from 
MC2R (Figure 6.1), thereby creating constructs with either transmembrane domains (TMD) 
(1-7), the intracellular loops (I to III), or the C-terminus, may allow mapping of the MRAP 
interaction domains in MC2R. A similar technique has previously been employed in the 
identification of the MRAP interaction site with the MC2R (Webb et al. 2009).   
N terminus
Plasma 
Membrane
Intracellular loops
Extracellular loops
1 2 3 4 5 6 7
III
III
1 2 3 4 5 6 7
III
III
A B
 
Figure 6.1: Schematic diagram of the possible chimeric receptor.  A: insertion of the TMD 3 
or B: intracellular loop III of the MC2R.   
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6.2.2 Rescue of the trafficking defective mutations 
 Multiple missense mutations of the MC2R led to failure to traffic and trapping in the 
ER probably due to misfolding of the receptor.  It would be very interesting if small 
molecules could rescue the function of the misfolded receptor.  This concept has been 
tested in other GPCRs such as V2 vasopressin receptor mutants found in diabetes 
inspidus (Morello et al. 2000), when the function of a trafficking defective mutant was 
restored after 16 hours of treatment with a cell permeant V2R antagonist.  A similar 
advance has also been made by rescuing the activity of defective MC4R mutants with 
small molecule ligands in vitro (Fan & Tao 2009), which probably bind to stabilize the 
MC4R structure.  Pharmacological rescue of naturally occurring GnRH mutations is also 
seen in patients with hypogonadotrophic hypogonadism (Janovick et al. 2002).  Through 
this approach may offer some more insight into the basic biology of the receptor and may 
open up therapeutic advantage in the treatment of FGD.   
 
6.2.3 Functional studies on MRAP mutations 
FGD 2 patients with MRAP mutations had a more severe onset of disease.  In vitro 
studies on the function of these MRAP mutations would be relevant.  This work is currently 
been carried out by another researcher in the laboratory.   
There has been much work on MRAP in vitro using heterologus expressing cells 
(Sebag & Hinkle 2007; Cooray et al. 2008; Sebag & Hinkle 2009b; Chan et al. 2009c). 
MRAP has been shown to modulate the expression and function of other MCRs (Chan et 
al. 2009c), MRAP interacted with other MCRs and significantly attenuated signalling in 
both MC4R and MC5R.  Creation of MRAP knockout (MRAP-KO) mice may be informative 
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allowing the opportunity to further investigate whether MRAP has any influence on food 
intake, energy expenditure, or weight.   
 
6.2.4 MC2R heterdimerisation with other MCRs and other GPCRs 
 As already discussed in Chapter 5, MC2R heterodimerised with other MCRs but it 
is unclear if this observation is specific.  Therefore, it would be important to repeat these 
studies attempting to coimmunoprecipitate with other GPCRs of a similar class.  If the 
interaction is specific then further exploration into the possible functional aspect would be 
exciting.   
 If there is MC2R heterodimerisation with other MCRs, one possibility is the study of 
transactivation of the receptors.  By mutating the highly conserved DRY sequence for the 
four other MCRs and co-expressing each with Wt-MC2R, cAMP responsiveness following 
α-MSH stimulation would reveal whether cross-talk between receptors is possible.  If there 
is indeed cross-talk then co-localisation of MC2R with the relevant MCRs in the same cells 
using in situ hybridization or co-immunohistochemical analysis would be desirable.  
However, the latter technique would depend on good quality MCRs antibodies being 
available.  The relevance of any functional work is dependent on co-localisation of the 
receptors involved.   
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6.3 Conclusion 
 This thesis focused on identifying and characterising the molecular defects 
underlying FGD type 1.  The functional defect of MC2R mutations have been examined in 
the presence of MRAP.  The majority of MC2R mutations are due to trafficking defects, 
with the cause presumed to be the misfolding of the receptor and consequent retention in 
the ER.  The degree of retention is variable such that there are some proteins with residual 
function and slow deterioration of adrenal cortex, perhaps explaining the later age of 
presentation compared to FGD type 2.  MC2R was further found to constitutively 
homodimerise in a MRAP and ACTH independent manner, the functional importance of 
which is yet to be explored.   
 This thesis represents the first steps of MC2R characterisation enabled by the 
relatively recent discovery of MRAP.  Further research into MC2R and MRAP interaction, 
ACTH induced conformational change of MC2R and homodimerisation and 
heterodimerisation with other MCRs could provide further insight into this important GPCR.   
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Appendix 8.1: Laboratory Equipment 
Equipment Manufacturer 
Balances  
Mettler PM 300 Gallenkamp, London, UK 
Can 28 automatic electrovalence WT Avery Ltd, W. Mids, UK 
  
Camera  
Kodak ID and ID Image Analysis Software Kodak Ltd, Hemel Hempstead, Herts, UK 
  
Centrifuges  
Sorvall OTD-55B Ultracentrifuge Du Pont (UK) Ltd, Stevenage, Herts, UK 
Sorvall RT 6000B Du Pont Ltd, Herts, UK 
Beckman J-6B Beckman Instruments, CA, USA 
Falcon 6/300 Sanyo Gallenkamp PLC, Leicester, UK 
Microcentaur microfuge MSC, UK 
  
Electrophoresis tank  
BRL H5, H6, S2, V16.2 BRL, Paisley, UK 
  
Liquid Nitrogen Storage  
Cryostat Jencons, Bedfordshire, UK 
Cryolab25 Statebourne Cryogenics, Tyne & Wear, UK 
  
Microplate reader  
Lumistar Omega BMG Labtech.   BMG Labtech, Germany 
  
Microscope  
Lieca DMIL 
Leica Microsystem (UK) Ltd, Milton Keynes, 
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UK 
Fluorescence microscope  
Zeiss LSM 510 laser scanning focal 
microscope Carl Zeiss Microimaging, NY, USA 
  
PCR machines  
Hybaid Omnigene thermal cycler Hybaid, Life Science Int., UK  
GeneAmp PCR system 2400 PE Biosystems, Cheshire, UK 
GeneAmp PCR system 9700 PE Biosystems, Cheshire, UK 
  
Membrane and Plate Reader  
LI-COR® Odyssey plate reader LI-COR® Odyssey, USA 
  
pH meter  
EDT GP 353 Pentacourt Ltd, Haltead, Essex, UK 
  
Power supply units  
LKB Bromma 2197 LKB Instruments Ltd, Croydon, Sussex, UK 
GIBCO BRL 400L Life Technologies Ltd, Paisley, UK 
Atto AE3105 Genetic Research Instruments,  
 Bishops Stortford, Herts, UK 
  
Temperature controlled incubators  
Leec MK II Luckhams, Sussex, UK 
Orbital incubator: Innova 4300 New Brunswick Scientific, UK 
  
Spectrophotometers  
GeneQuant RNA/DNA  Pharmacia Biotech,  Cambridge, UK 
Calculator spectrophotometer   
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NanoDrop ND 1000 NanoDrop Technologies, USA 
  
Semi Dry Blotter  
Transblot SD semi dry transfer cell Biorad, Hemel Hempstead, Hertfordshire, UK 
  
Ultraviolet Transilluminator  
UVP 20 Genetic Research Instruments, Herts, UK 
  
Water baths  
Grant JB1 and SE 10 Chemlab Instruments, Hornchurch, Essex, UK 
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Appendix 8.2: Laboratory Chemicals and antibodies 
Chemicals Supplier 
Deoxyribonucleotide Promega, Southhampton, UK 
  
Restriction and modifying enzymes Promega, Southhampton, UK 
Dpn 1 restriction enzyme  New England Biolabs, UK 
  
Polymerase enzymes Promega, Southhampton, UK 
Advantage® HD Polymerase Mix Clontech, CA, USA 
  
Cell surface assay Blocking Buffer LI-COR® Bioscience 
  
S.O.C medium  
Invitrogen, Renfrew Renfrewshire, 
UK 
  
RNAsin Promega, Southhampton, UK 
  
DNA ladders MBI, Fermentas 
  
Loading dye MBI, Fermentas 
  
Kaleidoscope Prestained protein marker 
Bio-rad laboratories, Hemel 
Hempstead, 
 Hertfordshirem, UK 
  
n-Dodecyl-β-D-maltoside  Sigma-Aldrich, Dorset, UK 
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16% Formaldehyde  TAAB, Bershire, UK 
  
Oligonucleotides Sigma-Genosys, Cambridge, UK 
  
Protease inhibitor cocktail  Roche, cOmplete 
  
MES or MOP SDS Running buffer  Invitrogen NuPAGE®, UK 
  
10-12% Bis-Tri Gel  Invitrogen NuPAGE®, UK 
  
Luciferase assay kit Promega, Southhampton, UK 
  
(
125
I-iodotryosyl
23
)ACTH (1-39 Perkin Elmer, UK 
  
Truncated ACTH Bachem AGK, Switzerland 
  
Plasmid vectors  
pcDNA 3.1 
Invitrogen, Renfrew Renfrewshire, 
UK 
pGEM T-Easy Promega, Southhampton, UK 
  
Bacterial strains  
JM109 Promega, Southhampton, UK 
  
Tissue Culture reagents  
DMEM, DMEM+F12, F12 Sigma Reagents Ltd, Dorset, UK 
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Foetal calf serum Sigma Reagents Ltd, Dorset, UK 
Penicillin/Streptomycin Gibco BRL, Paisley, UK 
G418 Sigma Reagents Ltd, Dorset, UK 
Trysin/EDTA Gibco BRL, Paisley, UK 
  
Transfection reagents  
Lipofectamine 2000 
Invitrogen, Renfrew Renfrewshire, 
UK 
Opti-MEM® I reduced serum medium 
Invitrogen, Renfrew Renfrewshire, 
UK 
  
Primary Antibodies  
Anti-Flag M2 mouse monolonial antibody (F1365) Sigma-Aldrich, Dorset, UK 
Anti-HA, mouse monoclonal, clonal HA-7 antibody Sigma-Aldrich, Dorset, UK 
(H9658)  
Anti-GAPDH antibody (sc-32233) Santa Cruz biotechnology, USA 
  
Secondary Antibodies  
Cy2-conjugated donkey anti-rabbit (#711225-152) Jackson ImmunoResearch, USA 
Cy3-conjugated donkey anti-rabbit (#711165-152) Jackson ImmunoResearch, USA 
Cy2-conjugated donkey anti-mouse (#711225-150) Jackson ImmunoResearch, USA 
Cy3-conjugated donkey anti-rabbit (#711165-150) Jackson ImmunoResearch, USA 
  
IRDye®680CW Conjugated Goat Anti-Mouse IgG   LI-COR® Bioscience, USA 
IRDye®800CW Conjugated Goat Anti-Mouse IgG   LI-COR® Bioscience, USA 
IRDye®680CW Conjugated Goat Anti-Mouse IgG   LI-COR® Bioscience, USA 
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Plasmid Kits  
QIAGEN RNeasy® mini kit QIAGEN, Crawley, UK 
QIAGEN RNeasy® midi kit QIAGEN, Crawley, UK 
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Appendix 8.3: List of 24 primers used for  FGD type 1 mutations 
 
 
 
Mutation aa from Change aa to Primer sequencing forword Reverse primer 
D20N aspartic asparagine AAGAAATAATTCCAACTGTCCTCGTGT ACACGAGGACAGTTGGAATTATTTCTT 
I44M isoleucine methionine GGAGAATCTGATGGTCCTGCTGGCT AGCCAGCAGGACCATCAGATTCTCC 
L55P leucine proline AGAATAAGAATCCCCAGGCACCCAT ATGGGTGCCTGGGGATTCTTATTCT 
S74I serine isoleucine ATATGCTGGGCATCCTATATAAGAT ATCTTATATAGGATGCCCAGCATAT 
D103N aspartic asparagine GAAACCACAGCCAATGACATCATCG CGATGATGTCATTGGCTGTGGTTTC 
D107N aspartic asparagine GATGACATCATCAACTCCCTGTTTG CAAACAGGGAGTTGATGATGTCATC 
G116V glycine valine TCTCCCTGCTTGTCTCCATCTTCAG CTGAAGATGGAGACAAGCAGGGAGA 
S120R serine arginine GGCTCCATCTTCCGCCTGTCTGTGA TCACAGACAGGCGGAAGATGGAGCC 
R128C arginine cysteine ATTGCTGCGGACTGCTACATCACCA  TGGTGATGTAGCAGTCCGCAGCAAT 
Y129C tyrosine cysteine CTGCGGACCGCTGCATCACCATCTT AAGATGGTGATGCAGCGGTCCGCAG 
I130N isoleucine asparagine CGGACCGCTACAACACCATCTTCCA  TGGAAGATGGTGTTGTAGCGGTCCG  
R137W arginine tryptophan TTCCACGCACTGTGGTACCACAGCA TGCTGTGGTACCACAGTGCGTGGAA 
H139Y histidine tryosine GCACTGCGGTACTACAGCATCGTGA  TCACGATGCTGTAGTACCGCAGTGC  
R146H arginine histidine TGACCATGCGCCACACTGTGGTGGT ACCACCACAGTGTGGCGCATGGTCA 
T152K threonine lysine TGGTGGTGCTTAAGGTCATCTGGAC GTCCAGATGACCTTAAGCACCACCA 
T159K threonine lysine GGACGTTCTGCAAGGGGACTGGCAT ATGCCAGTCCCCTTGCAGAACGTCC 
H170L histidine leucine TGATCTTCTCCCTTCATGTGCCCAC GTGGGCACATGAAGGGAGAAGATCA 
L198P leucine proline TGCACATGTTCCCGCTGGCTCGATC  GATCGAGCCAGCGGGAACATGTGCA 
G226R glycine arginine ACCATCCTGCTCAGGGTCTTCATCT  AGATGAAGACCCTGAGCAGGATGGT 
A233P alanine proline ATCTTCTGCTGGCCCCCCTTTGTGC GCACAAAGGGGGGCCAGCAGAAGAT 
C251F cysteine phenylalanine GTAACCCCTACTTCGCCTGCTACAT  ATGTAGCAGGCGAAGTAGGGGTTAC 
Y254C tyrosine cysteine ACTGCGCCTGCTGCATGTCTCTCTT AAGAGAGACATGCAGCAGGCGCAGT 
S256F serine phenylalanine CCTGCTACATGTTTCTCTTCCAGGT ACCTGGAAGAGAAACATGTAGCAGG 
P273H proline histidine CCGTCATTGACCACTTCATATATGC GCATATATGAAGTGGTCAATGACGG 
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Appendix 8.4:  Vector map of pGEM®T-easy and pcDNA3.1 (+/-).     
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Appendix 8.5A: Confocal microscopy of MC2R mutations. 
The scale bar represents 10 µm.   
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Appendix 8.5B: Confocal microscopy of MC2R mutations. 
The scale bar represents 10 µm. 
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